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Tissue engineering strategies represent exciting potential therapies to repair 
cartilage injuries; however, difficulty regenerating the complex extracellular matrix 
(ECM) organization of native cartilage remains a significant challenge. Cartilaginous 
ECM molecules, specifically chondroitin sulfate (CS) glycosaminoglycan, may possess 
the ability to promote and direct MSC differentiation down a chondrogenic lineage. CS 
may interact with the stem cell microenvironment through its highly negative charge, 
generation of osmotic pressure, and sequestration of growth factors; however, the role of 
CS in directing differentiation down a chondrogenic lineage remains unclear. The overall 
goal of this dissertation was to develop versatile biomaterial platforms to control CS 
presentation to mesenchymal stem cells (MSCs) in order to improve understanding of the 
interactions with CS that promote chondrogenic differentiation. 
To investigate chondrogenic response to a diverse set of CS materials, progenitor 
cells were cultured in the presence of CS proteoglycans and CS chains in a variety of 2D 
and 3D material systems. Surfaces were coated with aggrecan proteoglycan to alter cell 
morphology, CS-based nano- and microspheres were developed as small particle carriers 
for growth factor delivery, and desulfated chondroitin hydrogels were synthesized to 
examine electrostatic interactions with growth factors and the role of sulfation in the 
chondrogenic differentiation of MSCs. Together these studies provided valuable insight 
into the unique ability of CS-based materials to control cellular microenvironments via 
morphological and material cues to promote chondrogenic differentiation in the 







Cartilaginous tissues play important structural and mechanical roles throughout 
the body. Particularly in the articular joints, hyaline cartilage distributes loads across the 
ends of long bones and facilitates motion with low-friction gliding along its surfaces. 
Unfortunately, cartilage tissue possesses a low capacity for healing, largely because it is a 
poorly vascularized tissue [1]. As a load bearing tissue, damage to articular cartilage by 
arthritis and physical trauma can be both debilitating and extremely painful. Of nearly 
995,000 arthroscopic procedures performed on the knee in the United States in 2006, 
466,000 (47%) of those performed in an ambulatory (outpatient) setting were diagnosed 
with a tear of the medial or lateral cartilage or menisci. An additional 56,500 (6%) were 
diagnosed with osteoarthritis of the knee [2]. In 2005, an estimated 27 million adults in 
the US had clinical osteoarthritis with indirect costs totaling approximately $89 billion 
per year [3-4]. To address this growing need, novel tissue engineering therapies seek to 
promote repair of cartilaginous tissue and restore long-term joint function.  
Tissue engineering seeks to promote regeneration of tissue replacements through 
the combination of cells, scaffold materials, and various soluble, physical, or mechanical 
differentiation stimuli. While cartilage appears to be a relatively simple tissue that lacks 
vascularization and nerves and primarily contains only one cell type, challenges to 
cartilage regeneration include maintaining the phenotype of chondrocytes in vitro and 
recapitulating the complex extracellular matrix (ECM) organization of cartilaginous 
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tissues [5]. Mesenchymal stem cells (MSCs) are multipotent progenitor cells, found in 
adult bone marrow, that are capable of differentiating into cartilaginous tissues [6], and 
recent research has investigated the ability of cartilaginous ECM molecules to direct 
differentiation of MSCs down a chondrogenic lineage [7-11]. Chondroitin sulfate (CS) is 
a glycosaminoglycan (GAG) that is prevalent in cartilage, primarily linked with aggrecan 
proteoglycan. While is it well established that the high negative charge density of CS 
contributes to cartilage’s compressive strength by osmotically retaining water within the 
tissue matrix [12-13], its role in promoting the development, maintenance, and repair of 
cartilage tissue is not as well understood.  
CS-containing proteoglycans versican and perlecan regulate mesenchymal 
condensation during cartilage development [14-15], and several enzymes involved in CS 
initiation, elongation, and sulfation are required for proper skeletal development and 
patterning [16-18], indicating that CS glycosaminoglycans (GAGs) play an important 
role in chondrogenesis in vivo. Recent studies have investigated the ability of CS-
modified biomaterials to promote the production of cartilaginous ECM in vitro as well. 
Aggrecan-coated surfaces promoted the aggregation and production of GAG and collagen 
II in dermal fibroblasts [10], and culture in CS-containing hydrogels upregulated 
expression and production of cartilaginous ECM by encapsulated goat and mouse MSCs 
[8-9]. Sulfated GAGs may alter the extracellular microenvironment via altered osmotic 
swelling pressure, streaming potential under dynamic loading, and sequestration of 
growth factors [19-22]. Additionally, downstream effects of cell clustering in CS-
modified materials may play a role in differentiation, including increased cell-cell contact 
[8, 10, 23]. While some of the effects of CS materials on ECM production have been 
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broadly characterized, an improved understanding of the role of GAGs in stem cell 
differentiation is a vital step in developing tissue engineering therapies to regenerate 
cartilage. 
 
1.2 Research Objectives 
The objective of the research presented is this dissertation was to develop CS-
based materials as platforms to control CS presentation to MSCs in order to study the role 
of CS in chondrogenic differentiation. To investigate the chondrogenic response to CS, 
MSCs were cultured in the presence of CS proteoglycan and CS GAG chains on 2D 
surfaces, with nano- and microparticles, and in 3D hydrogels. MSC response on 2D 
aggrecan-coated surfaces was explored for cell morphology, including aggregation and 
cell contact, and expression and production of ECM. CS-based materials were also 
developed, over numerous size scales, to study their role in electrostatic complexation 
with positively charged growth factors. CS particles were developed for controlled 
delivery of growth factors within micromass culture, and particles were characterized for 
size, charge, cytocompatibility, and ability to bind and release growth factor. Given the 
role of sulfation in the high negative charge density characteristic of sulfated GAGs, a 
biomaterial platform was developed to explore the role of sulfate moieties in growth 
factor sequestration through the desulfation of CS. These materials were then used to 
examine the role of sulfation in electrostatic sequestration of the chondrogenic growth 
factor transforming growth factor-β1 (TGF-β1) and in subsequent chondrogenic 
differentiation of MSCs. The goal of these studies was to provide additional insight 
regarding the interactions with CS that alter stem cell microenvironments to drive 
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chondrogenic differentiation of MSCs. The central hypothesis of this research was that 
engineering of GAG-based materials to control presentation of CS matrix within a variety 
of 2D and 3D systems would enhance production of chondrocytic ECM in MSCs. The 
presence of CS matrix would drive chondrogenic differentiation of MSCs by regulating 
cellular response through morphological cues and through sequestration of chondrogenic 
TGF-β1 from the culture medium. The role of CS in chondrogenic differentiation of 
MSCs was explored in the following three specific aims:  
 
Hypothesis I: 2D surfaces modified with cartilaginous GAGs will promote aggregation 
of bovine MSCs and differentiation toward a cartilaginous phenotype.  
Specific Aim I: Determine the effect of sulfated GAGs on cellular aggregation and 
chondrogenic differentiation of bovine MSCs when cultured on 2D surfaces, in the 
absence of chondrogenic growth factors.  
The cartilaginous chondroitin sulfate proteoglycan aggrecan was previously 
shown to promote cell aggregation and upregulation of GAG production by rabbit dermal 
fibroblasts [10]; therefore, aggrecan-coated surfaces were investigated as a potential pre-
culture technique to promote the production of chondrogenic ECM prior to cell 
implantation. The morphology of bovine MSC aggregates was observed on 2D aggrecan-
coated surfaces, in the absence of chondrogenic growth factors, and anterior cruciate 
ligament (ACL) fibroblasts were also cultured on aggrecan to examine their potential for 
the formation of a more fibrochondrocytic phenotype for regeneration of a 
fibrocartilaginous ligament-bone insertion. Aggregation promotes high density culture 
and cell-cell contact, similar to that seen in pre-cartilaginous condensations during 
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cartilage development, suggesting that aggregation may facilitate increased production of 
cartilaginous ECM by MSCs and ACL fibroblasts [24]. Gene expression and production 
of ECM were examined over the course of 2 weeks in MSCs and ACL fibroblasts 
isolated from 3 different bovine donors, compared to nonadhesive surfaces that promoted 
cell aggregation in the absence of aggrecan and MSC monolayers on unmodified tissue 
culture-treated polystyrene surfaces.  
 
Hypothesis II: Chondroitin sulfate-based nanoparticles and microparticles will 
electrostatically sequester positively charged growth factors. 
Specific Aim II: Develop CS-based nanoparticles and microparticles for growth factor 
delivery and characterize their ability to sequester positively charged growth factors, as a 
means to direct stem cell differentiation. 
Micromass culture is a functional technique in the culture of embryonic stem cell 
embryoid bodies and chondrogenic MSC pellets; however, dense, multicellular spheroids 
possess numerous boundaries to diffusion, and growth factor supplementation from the 
culture medium may result in insufficient or heterogeneous stem cell differentiation. 
Small particle carriers are valuable tools for controlled delivery to a variety of tissues, 
and controlled size scale allows for tailored release kinetics, including diffusion rate and 
degradation properties; therefore, nanospheres and microspheres were fabricated over a 
range of different size scales from CS materials. CS particles were synthesized and 
characterized for size, morphology, surface charge, and cytocompatibility. To explore the 
ability of negatively charged GAGs to electrostatically sequester positively charged 
proteins, CS microparticles were loaded with the positively charged growth factor TGF-
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β1, and release was observed over 5 days, compared to the negatively charged cytokine 
tumor necrosis factor-α (TNF-α).  
 
Hypothesis III: Desulfation of CS will diminish its affinity to electrostatically sequester 
TGF-β1, and desulfated chondroitin hydrogels will promote a weaker chondrogenic 
differentiation response in MSCs, compared to CS.  
 
Hypothesis IIIA: Desulfated chondroitin materials will have a weaker affinity for 
sequestration of TGF-β1, compared to CS, due to decreased negative charge density.  
Specific Aim IIIA: Chemically desulfate CS to produce desulfated chondroitin materials, 
and determine the effect of sulfation on sequestration and release of TGF-β1. 
While previous studies have explored the role of increased GAG sulfation on 
sequestration of positively charged growth factors [25-26], development of a nonsulfated 
variant would permit investigation on the role of decreased sulfation, and therefore 
decreased negative charge density, without modification of the remaining GAG structure. 
CS was chemically desulfated, and desulfated chondroitin materials were characterized to 
determine that sulfates were removed from CS without modification of the remaining CS 
chemical structure. Chondroitin and CS chains were then methacrylated to permit the 
formation of GAG-containing hydrogels, and modified materials were also examined to 
determine if chemical modification prevented enzymatic degradation by chondroitinase 
ABC enzyme. Finally, release of TGF-β1 from CS and chondroitin hydrogels over 7 days 
and sequestration of soluble TGF-β1 out of solution were measured by enzyme-linked 
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immunosorbent assay (ELISA) to determine the role of sulfation on interactions with 
TGF-β1. 
 
Hypothesis IIIB: Sulfation of CS plays an essential role in CS-mediated chondrogenic 
differentiation, and desulfated chondroitin hydrogels will promote a weaker chondrogenic 
response in encapsulated human MSCs cultured in the presence of TGF-β1, compared to 
CS.  
Specific Aim IIIB: Determine the effect of sulfation of chondroitin on the chondrogenic 
differentiation of human MSCs when encapsulated in CS and desulfated chondroitin 
hydrogels.  
While CS-containing hydrogels have been shown to promote the production of 
chondrogenic ECM in the presence of chondrogenic media [8-9], the role of sulfation and 
negative charge density in directing chondrogenic differentiation is not currently well 
understood. The high degree of sulfation of CS carries a highly negative fixed charge 
density that facilitates a variety of interactions with cartilaginous ECM, signaling 
molecules, and interstitial fluid; therefore, sulfation is expected to play an essential role 
in CS-mediated chondrogenic differentiation. To independently examine the roles of 
TGF-β1 and sulfation of CS, human MSCs were encapsulated in PEG-based hydrogels 
containing 50% CS or 50% chondroitin by mass or in PEG-only controls and were 
cultured for 6 weeks in the presence of medium with or without 10 ng/mL TGF-β1. 
Encapsulated MSCs were analyzed over 42 days for viability, total DNA, gene 
expression by quantitative reverse transcription polymerase chain reaction (RT-PCR), 




1.3 Significance and Scientific Contributions 
The studies in this dissertation provide significant insights into the role of sulfated 
GAGs in altering stem cell microenvironments to control differentiation. A variety of CS-
based materials, including 2D surfaces, nano- and microparticles, and bulk hydrogels 
with varying degrees of sulfation, were developed, and these novel tools provided 
information on the diverse interactions of sulfated GAGs that may influence 
differentiation. Culture on 2D aggrecan surfaces provided insight on the (non)adhesive 
properties of cartilage proteoglycans and the role of cell-cell contact in the production of 
cartilaginous ECM. GAG-based particles were fabricated over a range of size scales that 
improve understanding of the electrostatic interactions between sulfated GAGs and 
positively charged growth factors. Desulfation of CS materials facilitated well-controlled 
study of the role of sulfation in growth factor sequestration by CS and provided new 
information on the role of sulfation and growth factor interactions in directing 
differentiation of MSCs. Controlled presentation of CS through diverse GAG-based 
biomaterial platforms improved understanding of the various interactions with GAGs that 
influence stem cell microenvironments, and these principles may be applied to direct 
differentiation of various multipotent and pluripotent progenitor cells down other non-
cartilaginous lineages. The knowledge garnered from these studies, in turn, may advance 
understanding of the role of GAG matrix during development, maintenance, and repair of 
cartilaginous tissues.  
In addition to advancing the current understanding of stem cell differentiation, 
development of GAG-based materials to control CS presentation has important 
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implications for tissue engineering and regenerative medicine. Materials that facilitate 
careful control of cell-cell and cell-matrix interactions could be developed as pre-culture 
techniques to “prime” stem cell fate prior to implantation. Novel CS-based particles have 
potential as delivery vehicles to promote improved growth factor transport and more 
homogeneous differentiation within a variety of tissue and stem cell environments, and 
careful control over GAG sulfation could contribute to the development of chemically 
and spatially controlled constructs for tissue regeneration. This research provides 
additional insight into the contributions of local chemical and biomolecular environments 
on many broader applications within the fields of cellular differentiation, tissue 
engineering, and treatment of orthopaedic injuries. Together these findings provide a 
framework for future investigations into the use of GAG-based biomaterials for cartilage 
repair and regeneration, and this research will aid in the development of design principles 







2.1.1 Articular Cartilage Composition and Function 
Cartilage is connective tissue that is found throughout the body to perform a 
variety of mechanical and structural functions [27-28]. Cartilage can be classified as 
elastic cartilage, hyaline cartilage, or fibrocartilage [27-29]. Elastic cartilage contains 
high elastin content and is found in the ears and nose, while fibrocartilage has collagen 
type I and appears in the menisci, annulus fibrosis of intervertebral discs, 
temporomandibular joint, as well as the insertions of tendon/ligament into bone [27-29]. 
Hyaline cartilage includes articular cartilage which covers the ends of long bones and 
facilitates joint loading and motion [27-28]. The structure of articular cartilage facilitates 
function by providing compressive strength and allowing distribution of load across the 
joint [13, 30]. Cartilage also facilitates joint motion by providing a low friction surface 
for gliding [13, 30]. 65-80% of the total weight of hyaline cartilage is composed of water 
[13]. This fluid interacts with the extracellular matrix (ECM) to absorb loads, minimize 
peak pressures on the subchondral bone, and lubricate the joint [13]. In articular cartilage, 
nutrition and elimination of waste is primarily dependent on diffusion to and from the 
synovial fluid, so the high water content also facilitates the delivery of nutrients and 
removal of waste products in the largely avascular, aneural, and alymphatic tissue [28].  
ECM plays critical roles in cartilage function and maintenance, including 
protection of chondrocytes from loading forces, storage of cytokines and growth factors, 
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regulation of mass transport throughout the tissue, and transduction of extracellular 
signals to the cells [31-32]. Cartilaginous ECM is primarily composed of collagen (60-
70% dry weight), proteoglycans (20-35%), and glycoprotein (5-15%), while 
chondrocytes (1-5% total volume) are responsible for maintaining and remodeling the 
ECM network [12-13, 28, 31]. Collagen type II is the predominant collagen (90-95% of 
total collagen) in hyaline cartilage, and collagen II fibers form the primary fibrillar 
network that provides the tissue with tensile strength [31]. In lesser amounts, collagen IX 
forms inter-fibrillar connections, and collagen XI promotes nucleation of fibrils to form a 
fibrillar mesh with collagen II [13]. Collagen type VI is also present in the pericellular 
matrix to support chondrocyte attachment and link chondrocytes to the matrix [31]. 
Collagen type X is only expressed by hypertrophic chondrocytes in the mineralized zone 
of cartilage to support mineralization and provide structural support [13, 30-31]. 
Aggrecan is the most prevalent proteoglycan (90% of proteoglycan) found in 
adult cartilage tissue [31]. Aggrecan is a large 1-3 million Da molecule composed of a 
core protein with hundreds of sulfated glycosaminoglycan (GAG) side chains [12, 28, 
33]. These aggrecan proteoglycans become trapped within the ECM network by 
aggregating along hyaluronan chains via link proteins to form massive 100-200 million 
Da structures [12, 28]. The sulfated GAGs in aggrecan, chondroitin sulfate and keratan 
sulfate, possess negatively charged sulfates and carboxylates, resulting in a highly 
negative fixed charge density [12-13]. This negative charge density attracts high 
concentrations of positively charged molecules, while repelling negatively charged 
molecules, thus increasing the osmolarity of cartilage and creating a Donnan effect [13]. 
The resulting osmotic pressure causes the tissue to swell and retain water, which is then 
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constrained from expansion by tension of the collagen network. This fluid-ECM 
interaction allows the tissue to support high compressive loads while also lubricating 
joint motion [12, 28]. Compressive loading of the joint causes the internal hydrostatic 
pressure of the cartilage to increase, and once it exceeds the osmotic pressure of the 
cartilage, water is pushed out of the ECM, resulting in “weeping” lubrication of the joint 
[28]. The natural fluid flow that occurs with loading and unloading of the joint also plays 
an important role to stimulate transport of nutrients and waste within the tissue [28]. In 
addition to aggrecan proteoglycan, biglycan, decorin, and fibromodulin are small leucine-
rich proteoglycans (SLRPs) with shorter protein cores and fewer GAG chains that are 
found in cartilage tissue. These SLRPs interact with the collagen network to influence 
fibrillogenesis [31, 34], and have also been shown to bind TGF-β to influence cell 
signaling and function [34-35]. 
Glycoproteins, on the other hand, consist primarily of protein with only a few 
attached monosaccharides or oligosaccharides. Structural glycoproteins in cartilage 
interact with cellular receptors and regulate adhesion, migration, proliferation, and 
differentiation of chondrocytes [28]. Annexin V and cartilage oligomeric matrix protein 
(COMP) anchor chondrocytes to the surrounding matrix [31]. Fibronectin and tenascin 
have important roles in matrix organization and cell-matrix interactions. Fibronectin 
possesses binding affinity for fibrin, collagen, and heparin, and cell binding is mediated 
by integrins [28], while tenascin may bind and inhibit cell attachment to fibronectin [36]. 
Laminin is also present in cartilage and binds integrins to link chondrocytes to the 
surrounding ECM [37].  
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Chondrocytes are the cells that are responsible for synthesizing, degrading, and 
maintaining the complex ECM network of cartilage through normal ECM turnover. Their 
intracellular components are directly linked to the ECM through receptors on the cell 
surface [28]. While individual chondrocytes have high individual metabolic activity, due 
to their low total volume in cartilage the total metabolic activity of chondrocytes is 
relative low, allowing chondrocytes to function in low oxygen conditions [13, 27]. 
Chondrocytes, however, are quite sensitive to toxic influences, and even slight 
fluctuations in pH from physiological 7.4 can disrupt the highly specialized matrix 
infrastructure [13, 28]. Chondrocytes have also been shown to alter their expression to 
respond to differences in loading, including the different forces and mechanics 
experienced throughout the various zones in cartilage [31].  
2.1.2 Cartilage Structure and Organization 
In addition to the many diverse ECM components, cartilage contains four depth-
dependent zones with different ECM composition and organization in each: the 
superficial zone, transitional zone, middle (radial) zone, and calcified cartilage zone. 
These zones act to facilitate load-dependent deformation in each zone [31]. The 
superficial zone, found at the surface of cartilage, is the thinnest zone and begins at the 
surface with a thin sheet of fibrils and film of synovial fluid called lamina splendens [13, 
31]. Beneath this sheet, flattened ellipsoid cells lie parallel to the joint surface, within a 
matrix characterized by high collagen production, low proteoglycan content, and the 
highest water content of the zones [13, 31]. The collagen in the superficial zone is aligned 
parallel to the surface to provide tensile and shear strength [13, 31]. The transitional zone 
provides a spatial and structural intermediate between the superficial and middle zones. 
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In the transitional zone, spheroid shaped cells are present at a lower cell density than the 
superficial zone; however, larger diameter collagen fibers are randomly oriented and 
proteoglycan content is higher than the superficial zone [13, 31]. In the middle (radial) 
zone, spheroidal cells are arranged in a columnar fashion perpendicular to surface, and 
this zone has the largest diameter collagen fibrils, aligned perpendicular to the joint 
surface, as well as the highest proteoglycan concentration and lowest water content and 
cell density [13, 31]. A tidemark divides the middle and calcified zones, which provides a 
transition from cartilage to the subchondral bone. In the calcified cartilage zone, a small 
volume of hypertrophic chondrocytes are embedded in calcified matrix. These 
hypertrophic cells have very low metabolic activity and synthesize collagen X, which 
helps to provide structural integrity and shock absorbance with subchondral bone [13, 
31].  
The matrix can also be classified into three compartments, based on their cellular 
interactions, including the pericellular, territorial, and interterritorial matrix regions. The 
pericellular matrix (PCM) encompasses a thin rim of matrix in close contact with the cell 
membrane (~2 μm wide) [13]. The cartilaginous PCM is rich in proteoglycan and non-
collagenous proteins, as well as non-fibrillar collagen VI, and links the cell surface to the 
matrix [13, 31]. The territorial matrix surrounds the pericellular region of individual or 
clusters of chondrocytes. In this region, collagen fibrils are arranged in a crisscrossing 
manner, forming a fibrillar basket around the chondrocytes and protecting them from 
mechanical impact [13, 31]. The interterritorial matrix forms most of the volume of the 
cartilage matrix, and contains large diameter collagen fibrils, oriented differently by zone, 
as well as proteoglycan aggregates [13, 31].  
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2.1.3 Cartilage Development 
To form the complex ECM structure of cartilage, the development of cartilage 
and long bones in vivo are uniquely linked. The developmental process begins with 
migration of undifferentiated mesenchymal cells to areas of bone formation, followed by 
cellular condensation [24]. As the cells condense, they increase their cell packing and cell 
density, without an increase in proliferation, resulting in an increase in cell-cell contacts, 
cell-cell adhesion molecules, and gap junctions [24]. Undifferentiated mesenchymal cells 
begin the process by producing collagen I, hyaluronan, tenascin, and fibronectin; 
however, condensation and differentiation prompts a shift in ECM production to produce 
large quantities of collagen II, IX, XI, Gla protein, aggrecan, and link protein [24]. ECM 
deposition eventually pushes the cells apart to form chondrocytes that are encased in 
ECM with a characteristic rounded morphology [13, 27]. 
Cartilaginous condensation and differentiation appear to be directed by a variety 
of cell-cell and cell-matrix interactions. Prior to condensation, mesenchymal cells 
increase their production of hyaluronidase, remodeling the hyaluronan-rich matrix to 
permit increased cell-cell interaction [24]. Fibronectin is also increased in condensations 
and may facilitate matrix-driven translocation, while tenascin may act to inhibit cell 
attachment to fibronectin [24]. Within the condensing mesenchyme, neural-cadherin (N-
cadherin) and neural cell adhesion molecule (N-CAM) are highly expressed, forming 
cell-cell contacts that play a critical role in directing differentiation of the cells toward a 
chondrocytic phenotype [24]. Additionally, hyaluronan receptor CD44 appears to anchor 
cells to the aggrecan-rich PCM and direct assembly of the chondrocyte PCM during 
differentiation [24]. Proteoglycans and GAGs may also act as molecular tethers of 
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soluble factors that play a role in condensation and differentiation, possibly through 
modulation of the Wnt signaling pathway [24].  
During terminal differentiation, chondrocytes undergo hypertrophy, express 
collagen X and alkaline phosphatase, decrease expression of collagen II, and begin to 
mineralize the ECM. During endochondral ossification, hypertrophic cartilage is 
vascularized by the invasion of blood vessels from the perichondrium. Osteoblasts are 
transported into the tissue through the blood vessels, and begin replacing cartilage with 
mineralized bone [5, 24]. Indian hedgehog (Ihh) and parathyroid hormone-related protein 
(PTHrP) signaling may interact to regulate chondrocyte maturation and hypertrophy. It 
has been proposed that hypertrophic chondrocytes produce Ihh, which acts on Patched 
(Ptc) and Gli expressing cells in the perichondrium, adjacent to the pre-hypertrophic 
zone, inducing the expression of PTHrP. PTHrP then signals back to chondrocytes 
expressing PTHrP receptor and prevents them from proceeding down the hypertrophic 
pathway in a negative feedback loop that regulates maturation and hypertrophy [38]. 
Additional Ihh signaling pathways that are independent of PTHrP have also been 
identified to examine the role of Ihh signaling in promoting chondrocyte hypertrophy 
[38-40].  
 
2.2 Cartilage Injury and Repair 
2.2.1 Cartilage Pathology and Healing 
Cartilage injury may occur from direct blunt trauma, indirect impact loading, or 
torsional loading of a joint [41]; however, due to the low proliferative ability and 
metabolic activity of chondrocytes, cartilage has a low potential for natural healing. 
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Additionally, cartilage does not have direct access to progenitor cells, the dense ECM 
may impede cell migration, and proteoglycans tend to resist cell adhesion, further 
undermining the healing process [1, 42-43]. If severe damage is allowed to persist, the 
tissue may degenerate further and progress into development of osteoarthritis, which is a 
chronic disease characterized by wear and tear of the cartilage surface [44]. Cartilage 
damage can generally be classified into three types of injury, depending on the depth of 
the defect: matrix disruption, partial thickness defects, and full thickness defects. During 
matrix disruption, the damage to the ECM is relatively mild, and viable chondrocytes are 
capable of repairing the tissue by increasing their natural synthetic ability [41, 45]. Partial 
thickness defects describe more severe injuries that disrupt the cartilage surface but do 
not extend to the subchondral bone. In partial thickness injuries, the surrounding 
chondrocytes respond by increasing their proliferation, but cellular attempts to naturally 
repair the tissue cease before the defect is fully healed [41, 45]. Full thickness defects, on 
the other hand, transverse the entire cartilage thickness and penetrate the subchondral 
bone. In this case, subchondral blood vessels are disrupted, defects are filled with a fibrin 
clot, and the classic wound healing response ensues [41, 45]. Unlike partial thickness 
defects, access to the subchondral bone permits access to a population of progenitor cells 
from the bone marrow, which can migrate to fill the defect. At the end of the healing 
process, the fibrin clot is replaced with an intermediate tissue with properties between 
those of hyaline cartilage and fibrocartilage that is typically less stiff and more permeable 
than healthy cartilage [27, 41-42].  
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2.2.2 Clinical Interventions for Cartilage Repair 
While a total knee arthroplasty, in which the joint is replaced with artificial 
surfaces, is the most common treatment for end stage osteoarthritis, the surgery is 
extremely invasive, requires replacement every 10-15 years, and is not ideal for young 
patients with active lifestyles [13, 46]. Osteotomy can also relieve severe joint pain by 
removing part of the bone in order to redistribute load within the joint surface and correct 
misalignment of the joint [47-48]; however, these techniques are invasive and are 
typically only employed after less invasion interventions have failed [13, 27, 49].  
To encourage the natural healing response, one strategy to treat cartilage defects 
involves intentionally penetrating the subchondral bone in order to stimulate the bone 
marrow and promote the formation of a fibrin clot. The impetus for this technique is to 
disrupt subchondral blood vessels, similar to full thickness defects, to form a fibrin clot 
and induce bone marrow-derived chondroprogenitors to migrate into the lesion, 
proliferate, and differentiate. [50-51]. Bone marrow stimulation may also enhance 
expression of cytokines to promote repair [52]. Techniques include subchondral drilling, 
abrasion, and microfracture, and are commonly used in conjugation with debridement to 
remove necrotic tissue from the joint surfaces [53-56]. Marrow stimulation techniques are 
fairly easy to perform and relatively low cost; however, similar to full thickness healing, 
the tissue is often replaced with fibrous or fibrocartilaginous tissue, that is more prone to 
future degeneration [50-51, 56].  
In another approach, autografts are taken from non-load bearing regions to replace 
the injured cartilage tissue. In a mosaicplasty, cylindrical osteochondral plugs are 
harvested from non-weight bearing regions of the knee and transplanted into the defects. 
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While this approach replaces the damaged tissue with hyaline cartilage, the gaps between 
the plugs are often replaced with fibrocartilage, resulting in a lack of integration with the 
native tissue, as well as increased permeability [57-58]. As with all autografts, donor site 
morbidity and limited availability of autologous tissue limits this approach, especially for 
repair of large lesions [51, 59]. Perichondrium and periosteum have also been used as 
sources for autologous grafts, due to their chondrogenic and osteogenic potential; 
however, despite some promising results, they are still unable to consistently replace 
healthy cartilage tissue [13, 60-62].  
More recently, autologous chondrocytes have been cultured in vitro and 
reimplanted to promote healing. Autologous chondrocyte implantation (ACI) involves 
taking a tissue biopsy from a non-weight bearing region of cartilage, enzymatically 
isolating chondrocytes from the tissue, and expanding the excised chondrocytes for 2-3 
weeks in vitro [13]. After expansion, the defect is covered with an autologous periosteal 
flap, and a suspension of expanded chondrocytes is injected underneath the patch into the 
defect [13]. This approach has yielded some promising results; however, limitations 
include occasional leakage of transplanted cells, an invasive surgical method, 
hypertrophy of the periosteum, and the loss of chondrocytic phenotype associated with 
expansion of chondrocytes in culture [51, 63-65]. In addition, the regenerated cartilage is 
often more fibrous in nature, possibly due to the low proliferation potential of 
chondrocytes [66-67]. Overall, there has been large variation and contrasting degrees of 
success when comparing the current intervention techniques for cartilage repair. Jakobsen 
et al. evaluated sixty-one clinical cartilage repair studies including a total of 3,987 
surgical procedures using microfracture, autologous osteochondral transplantation 
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(mosaicplasty), autologous periosteal transplantation, and ACI [68]. Large variation was 
observed between each treatment modality, and no significant differences were found 
across techniques, suggesting that an improved clinical approach is necessary to properly 
repair cartilage after injury [51].  
 
2.3 Tissue Engineering and Regenerative Medicine 
2.3.1 Tissue Engineering of Cartilage 
The limited ability of cartilage to heal and the limitations of surgical repair have 
introduced the need for tissue engineering strategies for cartilage regeneration. Tissue 
engineering typically applies a combination of biological, chemical, and engineering 
principles to regenerate functional tissue. The typical tissue engineering approach uses a 
3D scaffold to promote tissue formation, cells that can be expanded and maintained in 
vitro, and the use of differentiation factors to drive tissue development [69]. Bioreactor 
systems have also been developed to apply mechanical or physical stimulation to the 
tissue and to facilitate precise control of the extracellular culture environment [70]. 
Cartilaginous tissues appear to be a strong fit for tissue engineering strategies, because of 
their relative simplicity as a tissue. Cartilage is largely avascular, lacks nerves, and 
contains primarily only one cell type; however, barriers to cartilage regeneration include 
maintaining the phenotype of chondrocytes in vitro and recapitulating the complex ECM 




2.3.2 Current Tissue Engineering Approaches 
2.3.2.1 Cell Sources 
An obvious choice of cell type for cartilage tissue engineering is chondrocytes, 
since chondrocytes are the predominant cell type in cartilaginous tissue and are 
responsible for maintaining the ECM. Unfortunately, chondrocytes have a limited 
proliferative capacity in vitro and tend to de-differentiate in extended culture, especially 
in monolayer, becoming increasingly fibrous in nature [71-72]. 3D encapsulation in a 
variety of materials improves maintenance of chondrocyte phenotype; however, culture 
in these materials also slows cell growth. Therefore a number of bioreactors, including 
spinner flasks, microcarrier suspensions, perfusion systems, and rotating-wall bioreactors 
have been developed for mass culture of chondrocytes to maintain mature phenotype [73-
76]. 
Mesenchymal stem cells (MSCs) are adult stem cells present in the bone marrow 
that can selectively differentiate into any mesenchymal cell type, including osteoblasts, 
chondrocytes, adipocytes, myoblasts, and ligament fibroblasts [77-79]. Marrow cells can 
be noninvasively collected from adult bone marrow by needle biopsy, and MSCs can be 
expanded in vitro, making them a promising cell source for cartilage tissue engineering. 
MSCs are mostly commonly differentiated in micromass/pellet culture to promote 
chondrogenesis [6]. High cell density and close cell-cell contact mimics mesenchymal 
condensation observed during cartilage development [24]. Common markers for 
chondrogenic differentiation include ECM markers collagen II, aggrecan, and cartilage 
oligomeric matrix protein (COMP), as well as SOX-9 transcription factor [80-82]. MSC-
like progenitor cells, with similar colony forming ability and multilineage potential, have 
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also been isolated from adipose tissue, periosteum, synovium, skeletal muscle, tendon, 
trabecular bone, and umbilical cord blood [83-89]; however, the differentiation potential 
of each population varies. MSC-like cells have also been derived from embryonic stem 
cells, which are pluripotent cells isolated from the inner cell mass of the blastocyst [90]. 
Embryonic-derived MSCs were capable of producing cartilage-like tissue in vitro and in 
vivo [91].  
2.3.2.2 Differentiation Factors 
A variety of soluble biochemical factors have been shown to influence MSC 
differentiation toward a cartilaginous phenotype. Most commonly medium containing 
transforming growth factor-β (TGF-β) and dexamethasone is established to drive MSCs 
toward a chondrogenic phenotype [6]. A number of TGF-β superfamily proteins are 
known play a crucial role in cartilage formation. In particular, TGF-β1, -β2, and -β3 are 
highly expressed in pre-cartilaginous condensations of the developing mesenchyme [24, 
92-93], and all three isoforms possess chondrogenic potential [94-97]. Bone 
morphogenetic proteins (BMPs) including BMP-2, -4, and -6 have also been shown to 
enhance chondrogenic differentiation of MSCs [98-99]. BMP-2, especially, has been 
demonstrated to exhibit an additive differentiation response in MSC pellet cultures when 
supplemented in combination with TGF-β [99]. Similarly, insulin-like growth factor-1 
(IGF-1) has been shown to upregulate expression of chondrocytic markers in MSCs [100-
102]. IGF-1 has independent signaling pathways to TGF-β and is capable of promoting a 
comparable chondrogenic response; however, IGF-1 has also been shown to promote an 




Unfortunately, chondrogenic MSCs cultured under these conditions tend to 
undergo hypertrophy, as the cells produce collagen X and alkaline phosphatase and 
undergo terminal differentiation [97, 103-104]. Chondrogenic MSCs also do not entirely 
suppress expression of collagen I, often resulting in a more fibrous tissue [105]. Basic 
fibroblast growth factor (bFGF) and PTHrP have been investigated for their ability to 
delay hypertrophy and maintain chondrocytic phenotype in vitro [106-109]. Recently, 
Gawlitta et al. published that oxygen tension may also play a role in chondrogenic 
differentiation and hypertrophy. In this study, hypoxic conditions (5% O2) were capable 
of delaying hypertrophy of chondrogenic MSC pellets [110].  
2.3.2.3 Scaffold Materials 
Various natural and synthetic materials have been investigated as scaffolds to 
support cartilage regeneration. Various synthetic hydrophobic polymers can be extruded 
or electrospun into micro- or nanofibers, and these fibers can be layered to form porous 
sponges. The resulting fibrous meshes are mechanically stiff, and MSCs can be seeded on 
and between the fibers [111]. Hydrolytically degradable materials, including poly(lactic 
acid) (PLA), poly(glycolic acid) (PGA), their copolymer poly(lactic-co-glycolic acid) 
(PLGA), and poly(ε-caprolactone) (PCL) have been shown to support chondrogenic 
differentiation and production of cartilaginous ECM by MSCs [112-116]. As these 
hydrolytically labile materials degrade, the scaffold can be replaced with ECM deposited 
by the embedded cells. These materials and their copolymers can also be chemically 
modified to control degradation rate [117] and modified with bioactive proteins, peptides, 
and molecules to support bioactivity [118-121].  
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Due to the high water content of native cartilage, hydrogel materials are popular 
scaffolds for 3D culture and chondrogenic differentiation of MSCs. Through the 
crosslinking of polymer chains, hydrogel scaffolds can be swelled in aqueous solution to 
create highly hydrated network structures [122-123]. Cells can be homogenously 
encapsulated within polymer networks and cultured for extended periods of time [124]. 
Encapsulation of MSCs reconstructs a 3D tissue environment in which the cells are 
immobilized within matrix with a rounded morphology, characteristic of chondrocytes, 
without the need for cell adhesion [71]. Prior to crosslinking, macromer solution can also 
be injected to a site of injury and crosslinked in situ for minimally invasive surgical 
techniques and cell delivery [124].  
Naturally-derived hydrogels for cartilaginous tissue engineering include collagen 
types I and II, fibrin, gelatin, and hyaluronan [11, 81, 125-129]. Along with the inherent 
biocompatibility of natural materials, encapsulated cells and bioactive molecules can 
actively interact with these materials and remodel the matrix over time. While alginate 
and agarose are naturally-occurring polysaccharides with application in chondrogenic 
culture, they are derived from marine algae and are cannot be produced or degraded by 
mammalian cells [81, 129-133]; therefore, they can be utilized to limit cellular 
remodeling when desirable. Unfortunately, the inherent complexity of natural scaffolds, 
along with batch-to-batch variability and limitations on chemical modification, are 
significant limitations for cartilage regeneration [134].  
While synthetic hydrogels do not possess inherent bioactivity, these materials can 
be precisely engineered to exhibit specific chemical and mechanical properties, and 
bioactive functionality must be expressly designed into the system [135]. Poly(ethylene 
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glycol) (PEG) is a common synthetic polymer used to support chondrogenic 
differentiation of MSCs [136-137]. By engineering bioactive moieties into the polymer 
network in a functionally, spatially, and temporally tailored fashion, one can study 
specific cell stimuli and responses in a discrete and controlled way. Design of PEG-based 
hydrogels for chondrogenic differentiation of MSC will be discussed in further detail in 
Section 2.3.3.  
2.3.2.4 Physical Stimuli 
Due to the established importance of mechanical forces in the development, 
maintenance, and remodeling of orthopaedic tissues, mechanical loading has been 
investigated as a technique to stimulate cartilage tissue formation. Cyclic, compressive 
loading has been shown to increase production of cartilage specific ECM, including 
collagen II and aggrecan, in MSCs encapsulated in a variety of hydrogel materials [125, 
138-141]. Similarly, application of cyclic, hydrostatic pressure increased collagen and 
proteoglycan production in encapsulated chondrogenic MSCs [142], as well as in 
scaffold-free MSC aggregates [143]. Huang et al. found that cyclic compression 
improved the matrix distribution and increased mechanical stiffness of chondrogenic 
MSC-laden agarose scaffolds after long-term culture for 42 days [144]. In studies by 
Kisiday et al., proteoglycan content was found to increase in agarose gels in response to 
loading after 15 days, even in the absence of chondrogenic cytokines [145].  
Other physical stimuli, including cell shape and the stiffness of the surrounding 
matrix, interact with chemical, molecular, and genetic factors to regulate stem cell fate 
[146]. McBeath et al. demonstrated that cell shape and area regulated osteogenic and 
adipogenic differentiation in MSCs [147]. Small cell areas and rounded shape dictated a 
 
26 
more adipogenic fate, while large areas and spreading promoted an osteogenic phenotype 
in identical mixed media, via RhoA/Rho kinase (ROCK) regulation of cytoskeletal 
tension. Kilian et al. followed up this finding by showing that cell shapes that enabled 
higher acto-myosin contractility, even under identical cell areas, promoted osteogenic 
differentiation over adipogenic differentiation [148]. These studies implicated a 
relationship between cytoskeletal organization and differentiation lineage. 
In chondrocyte culture or chondrogenic differentiation of MSCs, it has been well 
established that micromass culture and encapsulation, which maintain a rounded cell 
shape, are beneficial to maintaining or promoting a chondrocytic phenotype, compared to 
monolayer culture, suggesting that cell shape, cytoskeletal tension, and matrix 
interactions may also play important roles in chondrogenesis [149]. Gao et al. 
demonstrated that in the presence of TGF-β3 a rounded cell shape promoted 
chondrogenic differentiation of MSCs on 2D surfaces, while spreading promoted a 
myogenic smooth muscle cell phenotype [150]. In addition, while RhoA exhibited little 
change in activity, another GTPase Rac1 inhibited chondrogenesis, upregulated 
expression of N-cadherin, and induced smooth muscle differentiation. In an examination 
of nucleus shape, McBride and Knothe Tate also demonstrated that rounder nuclei were 
associated with greater expression of chondrogenic markers by C3H/10T1/2 stem cells on 
2D surfaces [151-152]. A series of studies on 2D surfaces demonstrated that chemical 
disruption of cytoskeletal tension and inhibition of RhoA/ROCK signaling promoted 
expression of chondrogenic markers by stem cells [153-157]; however, RhoA/ROCK and 
Rac1 signaling has been found to be vastly different in 3D micromass culture. Woods and 
Beier observed that in 3D micromass cultures of primary mouse mesenchymal limb bud 
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cells, RhoA/ROCK inhibition instead decreased expression of chondrogenic markers 
[158]. Furthermore, Woods et al. showed that Rac1 promoted chondrogenic 
differentiation in micromass culture through enhanced N-cadherin expression [159]. 
These studies suggest that while cytoskeletal tension and RhoA-ROCK and Rac1 
signaling may play important roles in chondrogenic differentiation, significant 
differences occur between 2D and 3D culture, possibly due to inherent differences in cell-
cell interactions, cell-matrix interactions, and cell shape.  
Along with geometry, matrix stiffness also influences stem cell lineage. In a 
seminal paper by Engler et al., stiff poly(acrylamide) substrates (Young’s modulus 25-40 
kPa) directed MSCs toward a more osteogenic phenotype, compared to moderate 
stiffness (8-17 kPa) for myogenic, and soft (0.1-1 kPa) for neurogenic differentiation. As 
formation of focal adhesions increased on stiffer substrates, nonmuscle myosin II was 
required for matrix stiffness-based direction of MSC lineage [160]. For culture of 
chondrocytes, it appears that relatively soft substrates which limit cytoskeletal tension 
encourage chondrogenic phenotype. Schuh et al. observed that softer poly(acrylamide) 
substrates (Young’s modulus 4 kPa) promoted greater production of collagen II and 
aggrecan by chondrocytes, along with decreased proliferation and actin organization, 
compared to stiffer substrates in 2D culture [161]. In addition, Park et al. determined that 
stiffness regulated MSC response to TGF-β1, promoting expression of chondrogenic 
markers on soft collagen I and poly(acrylamide) substrates and myogenic phenotype on 
stiffer substrates [162]. Overall, these studies have established that cell shape and matrix 
stiffness appear to regulate cell phenotype through cell-matrix interactions and 
cytoskeletal organization and tension in 2D. In 3D culture, however, these effects are 
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more difficult to discern, because cell shape and matrix stiffness are also highly 
dependent on the material properties of the scaffold, including crosslinking density, 
porosity, and resulting transport properties. In 3D, local ECM organization also regulates 
cellular interactions with the matrix. While Schuh et al. found that softer agarose 
constructs supported greater GAG production by encapsulated chondrocytes, softer 
constructs also supported formation of larger cell clusters and a different local ECM 
environment than stiffer gels [163].  
2.3.3 PEG-Based Hydrogels for Cartilage Tissue Engineering 
Poly(ethylene glycol) (PEG) is a nonadhesive synthetic material that is highly 
resistant to protein adsorption, making it an attractive material for cartilage tissue 
engineering [164-166]. These non-fouling properties enable PEG-based materials to act 
as a “blank slate” upon which additional bioactive functionality can be specifically 
tailored into the hydrogel formulation. PEG hydrogels have been extensively investigated 
for bone, cartilage, vascular, and neural engineering [136, 167-173]. To crosslink and 
form PEG-based hydrogels, PEG is most often chemically modified to include acrylate 
groups. The resulting PEG-diacrylate (PEG-DA) or -dimethacrylate (PEG-DMA) can be 
crosslinked via free radical initiation, where polymerization occurs through a chain-
growth mechanism that involves chain transfer of the radical to a free double bond on 
another acrylate group [174]. Radical initiators include the thermally responsive tandem 
ammonium persulfate (APS) and tetramethylethylenediamine (TEMED), as well as the 
photosensitive Irgacure 2959 [175-178]. Alternative step-growth crosslinking 
mechanisms, including Michael-type addition and “click” chemistry, have been utilized 
for crosslinking of PEG-based materials, and these techniques can also be used together 
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with chain-growth initiators for sequential or mixed-mode crosslinking reactions [174, 
179-182].  
PEG’s mechanical and biochemical properties can be easily modified for a variety 
of tissue engineering applications [167, 183-184]. Hydrolytically labile components have 
been added into PEG networks to control degradation [169, 185], and enzymatically 
degradable peptides have also been incorporated within PEG hydrogels for cell-mediated 
degradation [186-187]. More recently, novel photodegradable groups have been 
investigated as a means to degrade PEG networks on demand in the presence of 
ultraviolet (UV) light [188]. Functional peptides like the adhesive peptide arginine-
glycine-aspartic acid (RGD) and growth factors including TGF-β, bFGF, and vascular 
endothelial growth factor (VEGF) have been tethered into PEG networks to modulate cell 
response [171, 189-191]. Additionally, PEG hydrogels are capable of micropatterning to 
create well-defined physical and biochemical features via photolithography [192-197].  
Oligo(poly(ethylene glycol) fumarate) (OPF) is a PEG-based, hydrolytically 
degradable hydrogel material that supports various in vivo and in vitro tissue engineering 
applications, including chondrogenic and osteogenic differentiation of MSCs [175, 198-
202]. OPF’s swelling, degradation, and mechanical properties can be easily controlled by 
altering the molecular weight of its initial PEG chains [45, 202]. Using PEG-DA as a 
crosslinker, OPF/PEG-DA scaffolds have been modified with functional peptides, 
including RGD [201], and OPF hydrogels have also been utilized as a delivery vehicle 
for a variety of growth factors [203-205]. OPF is a versatile and biocompatible hydrogel 
biomaterial with potential for use in the regeneration of a variety of tissues.  
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For these reasons, PEG and OPF-based materials have been used in controlling 
chondrogenic differentiation of MSCs [136, 199, 206-208]. PEG-DA hydrogels 
encourage increased production of cartilaginous matrix, over monolayer culture, in 
chondrogenic media [136], and the network structure and mesh size can be precisely 
controlled to influence differentiation [207, 209]. Many forms of biofunctionality have 
also been designed into the hydrogel system to promote enhanced bioactivity, including 
various ECM molecules and biological mimics. Most commonly the adhesive peptide 
RGD has been incorporated into PEG-based hydrogels to promote adhesion and MSC 
viability [210-211]. The role of RGD, an integrin binding peptide located in the III10 
repeat of fibronectin, in chondrogenic differentiation of MSCs has yet to be fully 
elucidated [212]. While fibronectin is expressed in pre-chondrogenic condensations 
during cartilage development, RGD incorporation into PEG hydrogels has been shown to 
increased differentiation of chondrogenic MSCs [211], while RGD inhibited 
chondrogenesis in agarose gels [213]. Hypothesizing that RGD may promote early 
chondrogenic differentiation of MSCs, Salinas et al. used a matrix metalloproteinase 
(MMP)-sensitive peptide to achieve temporal presentation of RGD to cells [137]. As the 
cells underwent early differentiation in the presence of RGD, the RGD was enzymatically 
cleaved and released from the network by cell-secreted MMP-13. After 21 days, 
chondrogenic MSCs encapsulated with cleavable RGD moieties exhibited significantly 
greater production of cartilaginous ECM than those with uncleaveable RGD, suggesting 
that both spatial and temporal presentation of biological cues may be necessary for 
regeneration. Additional work has incorporated collagen types I and II, collagen mimetic 
peptides GFOGER and (POG)7, decorin sequence KLER, and GAGs hyaluronan and 
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chondroitin sulfate to examine their roles in chondrogenic differentiation [7-9, 214-216]. 
Together, the research presented here strongly suggests that ECM interactions play a 
critical role in directing MSCs down a chondrogenic lineage for cartilage repair and 
regeneration. Specifically, chondroitin sulfate (CS) is a cartilaginous GAG that plays 
important structural and biological roles in cartilaginous tissues; however, the role of CS 
in chondrogenic differentiation and the interactions between CS and MSCs are not well 
understood.  
 
2.4 Chondroitin Sulfate Interactions to Promote Chondrogenic Differentiation 
2.4.1 Role of CS Proteoglycans in Chondrogenesis 
Perlecan and versican are proteoglycans that play important roles in tissue 
development. CS proteoglycan versican influences embryonic cell adhesion, migration, 
proliferation, and ECM assembly in a variety of tissues [217], and versican exhibits 
increased expression during mesenchymal condensation in early cartilage development 
[14, 218-219]. Versican may act as an anti-adhesion molecule during the initiation of 
matrix assembly, and versican expression ceases after deposition of aggrecan in the ECM 
[220]. Perlecan is also essential for proper cartilage development [221-223]. Perlecan is 
expressed within cartilaginous condensations after expression of collagen II and 
aggrecan, and remains in the adult pericellular matrix where it interacts with other ECM 
molecules including laminin and fibronectin [224]. Perlecan containing both heparan 
sulfate and CS has been implicated in bFGF signaling to regulate chondrocyte 
proliferation during endochondral ossification in the growth plate [15, 223, 225-226]. 
Heparan sulfate chains bind bFGF in perlecan, sequestering it from FGF receptors, while 
 
32 
CS chains on perlecan appear to block FGF receptor binding [15]. Additionally, aggrecan 
also plays a critical role in skeletal formation and patterning, ECM production, and 
collagen fibrillogenesis [33, 227]. The major influence of CS proteoglycans in 
chondrogenesis suggests that CS GAGs may play an important role in directing 
chondrogenic differentiation.  
Furthermore, chondroitin sulfate production and patterning play critical roles in 
the development of cartilage and the skeleton, as mutations affecting production and 
patterning of CS are largely not viable. A recent study by Wilson et al. demonstrated that 
chondroitin sulfate synthase 1 (Chsy1), which is one member of a family of enzymes 
responsible for extension of chondroitin sulfate chains, is required for proper bone 
development and joint/digit patterning in mice [16]. Chsy1 mutations resulted in 
chondrodysplasia, decreased bone density, and abnormal digit patterning, possibly 
resulting from abnormal sulfation of CS. Similarly, Watanabe et al. showed that 
chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGalNAcT1), another enzyme 
responsible for the initiation and elongation of CS chains, is required for normal cartilage 
development, as knockout in mice resulted in 50% decrease in chondroitin sulfate 
production and significantly thinner growth plate cartilage with disorganized arrangement 
of collagen fibers [17]. Kluppel et al. also showed that chondroitin-4-sulfotransferase 1 
(C4st1) expression, which is responsible for transfer of sulfate groups onto the 4-O 
position of chondroitin, was required for development and growth factor signaling during 
cartilage morphogenesis in mice [18]. C4st1 mutations demonstrated underexpression 
and mislocalization of CS in the growth plate, resulting in disorganized ECM and 
abnormal chondrocyte orientation. Defective CS balance in C4st1 mutants also resulted 
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in upregulation of TGF-β3 signaling, and downregulation of BMP, suggesting a role in 
growth factor signaling. Interestingly, while deletion of chondroitin-6-sulfotransferase 1 
(C6st1), which transfers sulfates onto the 6-O position, did not affect skeletal 
development in mice, mutations in C6st1 in humans are associated with chondrodysplasia 
[228].  
CS structure is regulated during cartilage differentiation and development, as 
sulfation patterns may regulate the affinity of CS to bind growth factors [229-230], and 
CS sulfation and structure continues to change through maturation and into adulthood. In 
human articular cartilage, CS is primarily monosulfated on either the 4- or 6-carbon of N-
acetylgalactoseamine; however, CS structure and patterning in cartilage continues to 
change through adulthood. As the tissue matures and growth cartilage is replaced by adult 
cartilage, the ratio of 6-sulfated CS to 4-sulfated CS increases from ~0.77 to ~23, 
indicating a shift in the sulfation balance by adulthood [20, 231]. Additionally, sulfation 
pattern varies by zone, as deeper zones of cartilage contain more 4-sulfated CS than 
superficial zones [20]. In addition to sulfation pattern, the average CS chain length also 
decreases over time. The average chain size decreases from ~32 kDa in fetal cartilage to 
~20 kDa in postnatal cartilage, then down to ~8 kDa by skeletal maturity [231]. The 
change in structure and sulfation pattern from fetal cartilage to adulthood suggests that 
CS may actively regulate its structure over time to facilitate specific interactions and 
signaling mechanisms within the maturing tissue.  
2.4.2 Chondroitin Sulfate Hydrogels for Tissue Engineering 
Recent work has investigated the ability of ECM molecules to direct stem cell 
differentiation down specific lineages, including GAGs for chondrogenic differentiation. 
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Culture on aggrecan-coated surfaces was shown to promote cell aggregation and 
production of GAG and collagen II in rabbit dermal fibroblasts, following pretreatment 
with IGF-1 [10]. Studies have also shown that encapsulation of chondrocytes and 
mesenchymal stem cells within hyaluronan-based hydrogels increased production of 
cartilaginous ECM [11, 232-236], suggesting that cells interact with GAGs and that CS 
hydrogels may be a useful tool in promoting chondrogenic differentiation of MSCs.  
Various research groups have developed CS-containing hydrogels as tool to study 
3D interactions with cells, most often in combination with PEG. The Elisseeff research 
group has developed several forms of crosslinkable CS-based tissue adhesives to promote 
repair and regeneration. By chemically modifying CS with methacrylates, aldehydes, or 
N-hydroxysuccinimde, CS adhesives were crosslinked to themselves, PEG-DA, or with 
the amine groups present in proteins. These adhesives have demonstrated the ability to 
bond articular cartilage and cornea tissue with good biocompatibility [237-241].  
CS proteoglycans also play important roles in directing growth in neural systems, 
so Conovaloff and Panitch used CS/PEG hydrogels to study neurite growth for neural 
regeneration applications [242]. Chondroitin-6-sulfate was shown to bind NGF, BDNF, 
and NT-3 cytokines with high affinity, compared to heparin, by capillary electrophoresis, 
while hyaluronan bound NGF with higher affinity than CS. Culture of E8 chick dorsal 
root ganglia in the presence of NGF demonstrated more robust neurite outgrowth in 2% 
CS/98% PEG-DA hydrogels, compared to 2% hyaluronan/98% PEG-DA after 3 days, 
suggesting CS acts as a better scaffold than hyaluronan despite weaker affinity for NGF, 
possibly due to inhibition of growth by HA. While this study suggested that CS/PEG 
hydrogels support neurite growth, this result contrasts other studies that have shown that 
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CS and various CS proteoglycans inhibited neurite growth in glial scar and that inhibition 
is dependent on the degree of sulfation [243-247]; however, differences in sulfation 
pattern, CS presentation without the proteoglycan core protein, and growth factor 
supplementation may account for these differences.  
As a prominent GAG in cartilaginous tissues, CS/PEG hydrogels have also been 
developed for 3D culture of chondrocytes. Bryant et al. crosslinked varying amounts of 
methacrylated chondroitin-4-sulfate into PEG hydrogels to alter the macroscopic 
properties of the hydrogels. 40% CS/60% PEG hydrogels were shown to promote greater 
production of cartilaginous ECM by chondrocytes, than CS-only gels, suggesting that the 
addition of PEG-DA was necessary to support ECM deposition in these CS-containing 
hydrogels [248]. To compare CS hydrogels to other ECM components, Hwang et al. 
showed that chondrocytes encapsulated in CS/PEG hydrogels supported greater 
accumulation of cartilaginous matrix by superficial and deep zone chondrocytes than gels 
with collagen type I or hyaluronan, suggesting that CS possesses tissue specific benefits 
for maintaining chondrocytic phenotype [249]. Furthermore, to investigate the role of 
mechanical loading in CS/PEG hydrogels, Villanueva et al. demonstrated that 20% 
CS/80% PEG hydrogels simulated greater production of GAG and collagen by bovine 
chondrocytes under dynamic compression, compared to loaded PEG gels [21]. These 
studies suggest that CS/PEG hydrogels interact with chondrocytes in 3D hydrogels and 
may support the production of cartilaginous ECM.  
Sulfated GAGs generate osmotic swelling pressure in cartilaginous tissues as a 
result of the associated high negative charge density [20]. Mobile positive ions in solution 
rush into the tissue to shield the negatively charged GAGs, and the resulting osmotic 
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pressure provides the tissue with enhanced ability to withstand compressive loads [20]. 
Osmotic swelling pressure also facilitates streaming potential during loading, in which 
the mobile positive ions are forced in and out of the matrix resulting in an electric 
potential [21, 250]. Sulfation, osmotic swelling, and streaming potential appear to 
influence ECM production in chondrocytes [21]; however, its role in differentiation of 
MSCs remains unclear.  
To examine the role of CS interactions in differentiation of MSCs, Varghese et al. 
examined the chondrogenic differentiation of MSCs in CS/PEG hydrogels. Goat bone 
marrow MSCs aggregated in 50% CS/50% PEG-DA hydrogels and upregulated 
production of chondrocytic markers in chondrogenic media, compared to PEG-only 
controls [8]. Cadherin11 expression was also temporally upregulated at early stages of 
aggregation, suggesting that increased cell-cell contact in CS materials may encourage a 
more chondrogenic phenotype. Additional analysis by Nguyen et al. suggested that 
controlled presentation of the CS matrix could direct differentiation toward the different 
cartilaginous zones [9]. 50% CS/50% PEG-DA hydrogels promoted production of high 
levels of collagen II and proteoglycan similar to that found in transitional zone of 
cartilage by D1 mouse bone marrow stem cells. Meanwhile, incorporation of MMP-
cleavable peptide sequences into the CS/PEG hydrogel promoted a more superficial 
zone-like ECM with low proteoglycan, and hyaluronan/PEG produced proteoglycan 
production with lower collagen II similar to the middle (radial) zone of cartilage. CS-only 
hydrogels, on the other hand, produced higher levels of collagen X, reminiscent of the 
calcified zone of cartilage. 
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Of these studies investigating CS hydrogels, few studies have investigated the 
effect of CS on human MSCs. Chen et al. observed that 2D surfaces with crosslinked 
chondroitin-6-sulfate supported greater differentiation of human MSCs than MSCs 
cultured with CS and CS oligosaccharide present in the culture medium [251]. Steinmetz 
and Bryant also examined the effect of cyclic compressive loading on the chondrogenic 
differentiation of human MSC in CS/PEG hydrogels [252]. While the effects of CS in 
20% CS/80% PEG-DA hydrogels were not as apparent after 14 days as previously 
reported in animal-derived MSCs with little ECM accumulation, the results suggested 
that CS may slow the terminal differentiation process in response to loading, as observed 
by downregulation of collagen X production and Runx2 expression.  
2.4.3 Growth Factor Sequestration by Chondroitin Sulfate 
Charged GAGs, primarily associated with proteoglycans in vivo, play a major role 
in sequestration of growth factors, stabilizing growth factors and preventing denaturation 
[22, 253-254]. Negatively charged GAGs, including heparin, heparan sulfate, and CS, 
bind positively charged growth factors, such as bFGF, IGF, VEGF, platelet-derived 
growth factor (PDGF), and TGF-β, by electrostatic interactions [255-264]. GAGs 
electrostatically complex with growth factors due to their highly negative charge density, 
and increased degree of sulfation appears to correlate with stronger electrostatic 
interaction. Heparin binds with bFGF, IGF, VEGF, and glial cell line-derived 
neurotrophic factor (GDNF) in a sulfation-dependent manner and with special importance 
of 2-O-sulfation for binding [265-272]. While a majority of studies have focused on 
heparin and heparan sulfate, due to their relatively higher charge densities, CS has also 
been shown to bind to various growth factors in vitro [22, 261-264], indicating that 
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sequestration of chondrogenic growth factors by CS hydrogels may be a promising 
strategy to enhance chondrogenic differentiation of MSCs.  
Deepa et al. found that CS-E, which is 4,6-disulfated, bound directly to a variety 
of heparin-binding growth factors including midkine (MK), pleiotrophin (PTN), heparin-
binding epidermal growth factor-like growth factor (HB-EGF), FGF-2, FGF-10, FGF-16, 
and FGF-18. [261]. Binding affinity to CS-E was greater than or comparable to that 
observed in heparin, and growth factors bound CS-E in a specific and concentration 
dependent manner. Additionally, Hintze et al. demonstrated that chemical sulfation of CS 
and hyaluronan enhanced affinity for TGF-β1 and BMP-4 [25, 273]. Electrostatic binding 
was enhanced as degree of sulfation was increased from 0 to 3 sulfates per disaccharide, 
and interaction was inhibited by increasing the salt concentration of the buffer and 
through competitive inhibition by soluble GAGs, indicating that CS possesses sulfate-
dependent affinity for chondrogenic growth factors of the TGF-β superfamily.  
In an examination to determine the binding mechanism of sulfated GAGS to 
TGF-β, Lyon et al. demonstrated that heparin and highly sulfated liver heparan sulfate 
electrostatically bound TGF-β1 and TGF-β2 by affinity chromatography, while TGF-β3 
isoform did not [274]. The bound fraction was eluted with ≥0.5 M NaCl. These highly 
sulfated GAGs also potentiated TGF-β1 activity in mink lung epithelial cells, while a low 
sulfated mucosal heparan sulfate did not. TGF-β1 and TGF-β2 are reported to have 
isoelectric points (pI) of approximately 9.5 and 8.5, respectively [275-276], while TGF-
β3 has a lower pI of 6.8, suggesting that it is actually negatively charged at physiological 
pH and unable to electrostatically complex with sulfated GAGs [275].  
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Based on analysis of the TGF-β1 crystal structure (Figure 2.1a) and amino acid 
differences with TGF-β3, Lyon et al. predicted that TGF-β1 interacts with heparin via 
basic arginine and lysine residues at positions 25, 26, 31, and 37 and a histidine at 34 at 
the tip of first β-strand loop in TGF-β1, along with Arg/Lys at position 94 on the adjacent 
tip of another β-strand loop [272, 274]. In TGF-β3, the basic amino acid at position 26 is 
replaced with a neutral amino acid, suggesting that position 26 is critical for binding. 
While the proposed binding sites form two distinct sites at opposite poles but on the same 
face in the TGF-β dimer, they could be potentially be engaged by a single heparin chain 
at two points approximately 60 Å (or ~7 disaccharides) apart, as well as by two separate 
heparin chains (Figure 2.1b). The proposed binding site is also in a similar location, at the 
tips of the β-strand loops, to where TGF-β binds its receptors; however, little competition 
has been reported and in many cases heparin appears to potentiate the effect [272].  
 
 
Figure 2.1. GAG binding site in TGF-β1. Crystal structure of TGF-β1 as determined 
by Hinck et al. [277] (b) Diagram of heparin/heparan sulfate binding sites as 
proposed by Lyon et al. [274] 
 
Sulfation-dependent GAG/TGF-β1 interactions may play important roles in TGF-
β1 signaling, feedback to subsequently regulate GAG sulfation, as well as disease. 
Merceron et al. reported that sulfated polysaccharides may potentiate TGF-β1 signaling 
for chondrogenic differentiation [278]. The oversulfated marine polysaccharide GY785 
DRS possessed greater binding affinity to TGF-β1 than its less sulfated counterpart 
 
40 
GY785 DR, as determined by surface plasmon resonance (SPR). Additionally, human 
adipose-derived MSCs produced greater GAG and collagen when cultured with GY785 
DRS in the medium, and ERK1/2 phosphorylation and MAPK signaling suggested that 
GY785 DRS potentiated TGF-β1 signaling to promote chondrogenesis and that this 
interaction was dependent on the sulfation of the polysaccharide. Additionally, Zanni et 
al. reported that TGF-β1 signaling in cartilage explants resulted in reduction in 
chondroitin-4-sulfation and an increase in nonsulfated disaccharides, suggesting that a 
potential feedback loop may exist between sulfate-dependent GAG/TGF-β signaling and 
subsequent CS sulfation patterning via altered activity or synthesis of sulfotransferases 
[279]. Kim et al. also demonstrated that abnormal balance of 4- or 6-sulfation pattern and 
subsequent growth factor affinity may play a role in disease [280]. Decorin from the 
tendons of horses with equine systemic proteoglycan accumulation (ESPA) possessed 
enhanced 6-sulfation, as well as a decrease in 4- to 6-sulfation ratio, and that ESPA 
decorin exhibited diminished TGF-β1 binding in vitro. These finding may have relation 
to Ehlers-Danlos syndrome, a genetic disorder characterized by abnormal collagen 
synthesis in connect tissue, which has been linked to a mutation in galactosyl transferase 
I gene.  
Electrostatic interactions between CS and growth factors have been exploited for 
delivery and controlled release. Park et al. developed a porous chitosan-CS sponge for 
controlled sequestration and release of PDGF-BB [262]. Release kinetics were dependent 
on CS content in the sponge composition, up to 40% CS, and PDGF-BB-loaded sponges 
were shown to promote migration and proliferation of rat osteoblasts in vitro, compared 
to chitosan-only scaffolds. Mullen et al. also designed collagen-CS materials for gradual, 
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sustained release of the chondrogenic growth factor IGF-1 over 14 days [264]. IGF-1 
adsorption was characterized over time and as a function of loading concentration, and 
binding also varied with buffer ionic strength, indicating electrostatic interaction. 
Released IGF-1 retained bioactivity and promoted proteoglycan production of seeded 
human osteoarthritic chondrocytes in vitro, compared to unloaded constructs.  
Collectively , these studies suggest that CS sequesters and regulates important 
interactions with growth factors, including the chondrogenic growth factor TGF-β1, and 
that the degree of sulfation may play a role in binding affinity. Further examination of the 
role of CS in TGF-β1 signaling and the cellular interactions that promote chondrogenic 
differentiation of MSCs may aid in the development of novel tissue engineering strategies 





AGGREGATION OF BOVINE MARROW STROMAL CELLS AND 






Several recent studies have demonstrated that adult dermal fibroblasts may 
possess multilineage potential and specifically the ability to produce cartilaginous 
extracellular matrix (ECM) in controlled culture conditions [10, 281-284]. Previous work 
has also investigated the ability of ECM molecules to direct cell differentiation and 
promote ECM production. Aggrecan is a cartilaginous ECM proteoglycan, and culture on 
aggrecan-coated surfaces has been shown to promote cell aggregation and production of 
glycosaminoglycan (GAG) and collagen II in RAB-9 adult rabbit dermal fibroblasts pre-
treated with insulin-like growth factor-1 (IGF-1) [10]. These results suggest that adult 
dermal fibroblasts maintain the ability to differentiate/transdifferentiate and produce 
cartilaginous ECM on aggrecan-coated surfaces, and that aggrecan-modified materials 
could potentially be used to promote production of chondrocytic ECM.  
Production of cartilaginous ECM by a fibroblastic cell type may possess 
particular application for regeneration of fibrocartilaginous tissues. Fibrocartilage appears 
in the menisci, annulus fibrosis of intervertebral discs, and temporomandibular joint, and 
                                                 
1
 Portions of this chapter were adapted from Lim JJ, Scott L, Jr., Temenoff JS. 
Aggregation of bovine anterior cruciate ligament fibroblasts or marrow stromal cells 
promotes aggrecan production. Biotechnol Bioeng. 2011;108(1):151-62. 
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contains a fibrous collagen I matrix along with cartilaginous ECM, including collagen II 
and aggrecan [27-29]. Fibrocartilaginous tissues also mediate direct insertions of 
tendon/ligament into bone [285-286], as fibrocartilaginous regions permit a gradual 
increase in stiffness from the fibrous tendon/ligament to the highly mineralized bone, 
thus preventing the formation of stress concentrations in the tissue and decreasing the risk 
of failure [287-288]. Production of chondrocytic ECM in fibroblastic cell types may 
possess unique application to tendon/ligament insertions, because fibroblasts are the 
predominant cell type in tendons and ligaments [69, 78, 289]; therefore the production of 
cartilaginous ECM in ligament fibroblasts may present a novel approach to regenerate 
fibrocartilaginous interfaces for ligament repair.  
The anterior cruciate ligament (ACL) of knee is one of the most commonly 
injured ligaments with 250,000 ACL ruptures each year in the United States, resulting in 
over 100,000 ACL reconstructions annually [290]. In ACL reconstruction surgery, graft 
tissue is drawn across the knee to replace the ligament, and the graft is commonly held in 
place within bone tunnels using interference screws [287, 291]. During healing, 
collagenous fibers and mineralized tissue formation in the bone tunnels help anchor the 
graft to the bone; however, these fixation methods are unable to physiologically replicate 
the native fibrocartilaginous insertion points that are present at many interfaces of 
ligament and bone [287]. In addition, secondary surgeries for harvest of autograft tissue 
often results in significant donor site morbidity [78, 291], and deficiencies in fixation 
strength and graft positioning may lead to secondary pathologies, such as osteoarthritis 
[287, 292].  
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The limitations of surgical repair have introduced a need for tissue engineering 
strategies for ligament regeneration. A potential approach would be to develop a tissue-
engineered bone-ligament-bone graft that possesses a fibrous ligament midsubstance with 
the mechanical strength to restore function to the injured joint, as well as 
fibrocartilaginous insertions and osseous tissue for improved fixation of the graft to bone. 
In order to function similarly to native ligaments, the fibrous ligament body would 
possess structurally organized collagen type I fibers aligned in parallel to maximize 
tensile strength, along with sparsely distributed fibroblasts to maintain the ECM [293-
294]. The fibrocartilaginous insertions, on the other hand, would contain chondrocyte-
like cells within a matrix of collagen I, collagen II, aggrecan, and some collagen X [287-
288, 295-296].  
To engineer such tissue interfaces, methods to produce zonally-varied ECM 
similar to that found in the ligament-bone insertion point are needed. In prior work, 
fibrous poly(lactic-co-glycolic acid) (PLGA) has been combined with bioactive glass in a 
composite scaffold to support both ligament and bone development [297-298], and these 
scaffolds have been used as a multiphasic co-culture system for ligament fibroblasts, 
chondrocytes, and osteoblasts [298-299]. Additionally, gradients of retroviral transfection 
with RUNX2/CBFA1 osteogenic transcription factor in fibroblasts have been utilized to 
produce graded distributions of mineral deposition for transitional tissue interfaces [300]. 
While the experiments detailed above have explored the culture of multiple cell types or 
biomaterial-based induction of phenotypic changes to produce the ECM gradient required 
for these applications, few studies have examined the possibility of altering pre-culture 
techniques to encourage one cell type to produce the range of phenotypes needed for this 
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complex tissue structure. Therefore, the focus of this set of experiments was to examine 
the potential for formation of cartilaginous ECM through altering cell pre-culture 
parameters for ACL fibroblasts. This was then compared with the response under the 
same culture conditions for bone marrow stromal cells (BMSCs), which are known to 
differentiate into various mesenchymal cell types, including osteoblasts, chondrocytes, 
adipocytes, myoblasts, and tendon/ligament fibroblasts [77-79].  
Specifically, the purpose of this study was to investigate the role of aggrecan in 
chondrogenic differentiation of bovine ACL fibroblasts and BMSCs. We hypothesized 
that cells would aggregate on aggrecan-coated surfaces, and that aggrecan-coated 
surfaces would promote the expression and production of cartilaginous ECM by both 
ACL fibroblasts and BMSCs. Because cells were found to aggregate on aggrecan-coated 
surfaces, another aggrecan-free surface treatment that induced aggregation was used as a 
control to determine whether the resulting phenotypic differences were aggrecan-
dependent. In particular, cell morphology, gene expression, and ECM production were 
examined over 14 days for bovine ACL fibroblasts and BMSCs cultured on uncoated 
tissue culture-treated polystyrene (TCPS), aggrecan-coated TCPS, and nonadhesive 
culture plates in order to determine how the culture surface affected phenotypic responses 
for both cell types. 
 
3.2 Materials and Methods 
3.2.1 Bovine ACL Fibroblast and BMSC Harvest 
Bovine ACL fibroblasts were harvested according to a previously described 
protocol [174]. The femur and tibia of an immature calf (Research 87, Marlborough, MA) 
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were isolated, and the ACL was sterilely removed and cut into ~1 mm
3
 pieces. Ligament 
tissue was then digested in 0.4% (w/v) collagenase type II (Invitrogen, Carlsbad, CA) 
solution in high-glucose DMEM (Mediatech, Manassas, VA), 1% 
penicillin/streptomycin/neomycin (Invitrogen), 1% kanamycin (Mediatech), 0.1% 
gentamicin (Mediatech), and 0.1% Fungizone (Invitrogen) for 24 hr. The digested cell 
solution was filtered through a cell strainer with 80 µm mesh (Small Parts, Miramar, FL), 
collagenase was removed by centrifugation, and cells were resuspended in “fibroblast 
medium” containing high-glucose DMEM, 10% fetal bovine serum (FBS; Thermo 
Scientific HyClone, Waltham, MA), 1% antibiotic/antimycotic (Mediatech), 1% 
nonessential amino acids (Mediatech), 1% HEPES buffer (Mediatech), and 50 µg/ml 
ascorbate (Sigma-Aldrich, St. Louis, MO) and cryopreserved until use.  
Bovine bone marrow stromal cells (BMSCs) were harvested according to a 
previously described protocol [213]. The femur and tibia of an immature calf were 
isolated, and marrow was placed into phosphate-buffered saline (PBS) with 1% 
antibiotic/antimycotic. The resulting mixture was physically disrupted by repeatedly 
pipetting through 50 and 10 mL pipettes, followed by 16, 18, and 20 gauge syringe 
needles. After centrifugation, the fatty layer was aspirated off, and the cell solution was 
plated for 30 minutes in “BMSC medium” containing low-glucose DMEM (Mediatech), 
10% FBS, 1% antibiotic/antimycotic, and 1 ng/mL basic fibroblast growth factor (bFGF, 
Peprotech, Rocky Hill, NJ) to allow rapidly adhering cells to attach to the tissue culture 
plastic. The remaining cells in solution were then plated in tissue culture flasks. After 24 
hours, nonadherent cells were aspirated off, culture medium was replaced, and BMSCs 
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were allowed to expand until confluency. Confluent cells were trypsinized in 0.05% 
trypsin/EDTA (Mediatech) and cryopreserved until use.  
For long-term storage, ACL fibroblasts and BMSCs were placed in medium 
supplemented with 20% FBS and 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) and 
stored in liquid nitrogen until further use. Before use, cells were replated at 1.0x10
6
 
cells/flask for at least 3 days in T-150 flasks to eliminate transitory effects from the 
thawing process. To examine the effects of interdonor variability, ACL fibroblasts and 
BMSCs were each isolated from 3 different animals (donors) for this study, including 1 
donor from which both ACL fibroblasts and BMSCs were isolate from a single leg 
(donor #3).  
3.2.2 Cell Culture on Aggrecan, Nonadhesive, and Control Surfaces 
Similar to [10], wells of a tissue culture-treated 24-well plate were coated with 5 
µg of bovine aggrecan (Sigma-Aldrich) by suspending aggrecan in PBS at a 
concentration of 50 µg/mL and allowing the PBS to evaporate overnight in a sterile 
environment at room temperature. After washing wells with PBS to remove residual 
unadsorbed aggrecan, wells were stained for 30 minutes with 16 µg/mL 
dimethylmethylene blue (DMMB; pH 3.0; Sigma-Aldrich) for sulfated GAGs to 
determine the distribution of aggrecan on the surfaces. For other samples, bovine ACL 
fibroblasts (P1) and BMSCs (P2) were plated at 8.8x10
4
 cells/well on aggrecan-coated 
surfaces and TCPS control surfaces in FBS-supplemented media. ACL fibroblasts were 
cultured in fibroblast medium as described above and including 1% nonessential amino 
acids, 1% HEPES buffer, and 50 µg/mL ascorbate. BMSCs were cultured in BMSC 
medium as described above and including 1 ng/mL bFGF. For all experiments in FBS-
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supplemented media, FBS from a single lot was used to prevent variability between 
serum lots. These two cell types were also cultured on nonadhesive surfaces that resist 
cell attachment (Ultra-Low Attachment surfaces, Corning, Lowell, MA). To examine the 
nature of the cellular interaction with aggrecan, ACL fibroblasts and BMSCs were 
cultured in FBS-free media on aggrecan-coated and control surfaces. 
Additionally, for specific experiments, aggrecan was added to the media of ACL 
fibroblasts and BMSCs cultured on control surfaces to examine the effect of aggrecan 
when suspended in the culture medium. 5 µg of aggrecan was added to the medium either 
at the time of seeding or 24 hours after seeding, instead of pre-treating the wells prior to 
seeding. For all experiments, culture medium was replaced every 2-3 days, and cell 
morphology was observed with a phase contrast microscope using a 10X objective 
(Nikon Eclipse TE2000-U, Tokyo, Japan).  
3.2.3 Reverse Transcription Polymerase Chain Reaction 
Gene expression of ACL fibroblasts and BMSCs on both aggrecan-coated 
surfaces and nonadhesive surfaces was analyzed after 3, 7, and 14 days by reverse 
transcription polymerase chain reaction (RT-PCR) for collagen I (fibroblastic marker), 
collagen II (chondrocytic marker), aggrecan (chondrocytic marker), and peroxisome 
proliferator-activated receptor γ2 (PPAR-γ2; adipocytic marker). ACL fibroblasts and 
BMSCs isolated from 3 different bovine donors, including 1 donor from which both ACL 
fibroblasts and BMSCs were isolated from a single leg (donor #3), were analyzed for 
interdonor variability. On aggrecan-coated surfaces, aggregates were separated from non-
aggregating cells for analysis using a 1000 µL pipette tip to isolate the samples. 
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Nonadherent aggregates on nonadhesive surfaces were simply resuspended in culture 
medium, and TCPS monolayers were trypsinized and resuspended.  
RNA was extracted from cell samples using a QIAshredder tissue homogenizer 
and RNeasy kit with DNase I digestion (Qiagen, Hilden, Germany). Reverse transcription 
was performed using SuperScript III Reverse Transcriptase (Invitrogen) with Oligo(dT)15 
primers (Promega, Madison, WI) and nucleotides (Promega). Custom primers 
(Invitrogen) specific to bovine mRNA for the target sequences are shown in Table 3.1, 
and quantitative PCR amplification was performed on a StepOnePlus System (Applied 
Biosystems, Carlsbad, CA) with SYBR Green master mix (Applied Biosystems). Fold 
regulation over control TCPS surfaces was calculated using the ΔΔCT method with 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an endogenous control [301].  
 
Table 3.1. Bovine primer sequences for quantitative polymerase chain reaction 
Target Primer Sequences (5’-3’) GenBank 





















3.2.4 Dimethylmethylene Blue (DMMB) and PicoGreen Assay 
ACL fibroblast and BMSC aggregates were also analyzed by DMMB assay for 
sulfated GAG production and by PicoGreen assay for DNA content. ACL fibroblast 
(donor #1) and BMSC (donor #3) aggregates cultured on aggrecan-coated and 
nonadhesive surfaces were isolated as described above and digested in 1 mg/mL 
proteinase K (Sigma-Aldrich) in tris(hydroxymethyl)aminomethane 
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(Tris)/ethylenediaminetetraacetic acid (EDTA) digestion buffer (pH 6.5) with 185 µg/mL 
iodacetamide (Sigma-Aldrich) and 10 µg/ml pepstatin A (Sigma-Aldrich) for 16 hours at 
56°C, and analyzed by DMMB assay, measuring absorbance at 520 nm (SpectraMax 
M2e; Molecular Devices, Sunnyvale, CA), compared to acellular blanks and a 
chondroitin sulfate standard curve [302]. Cells were then lysed through a series of 
freeze/thaw cycles and sonication, and PicoGreen assay (Invitrogen) was used to evaluate 
the total DNA content in each sample, according to established protocols [303]. 
Fluorescence was read at excitation 485 nm, emission 525 nm (SpectraMax M2e), and 
DNA content was determined using a standard curve of DNA and translated to cell 
number, compared to known numbers of bovine ACL fibroblasts and BMSCs. GAG 
content and cell number was normalized to the approximate number of aggregates per 
sample, and GAG content was also normalized to cell number.  
3.2.5 Histological Staining 
For this study, staining was only undertaken for proteins that were upregulated 
according to gene expression results (in this case, aggrecan only). Nonadherent ACL 
fibroblast and BMSC aggregates, from a single bovine donor (donor #3), cultured on 
nonadhesive surfaces were rinsed in PBS and fixed for 60 minutes in 10% buffered 
formalin after 3, 7, and 14 days. Fixed aggregates were encapsulated in Histogel 
(Richard-Allan, Waltham, MA), embedded in paraffin wax, and sectioned at 5 µm 
thickness. Sections were either stained with hematoxylin and eosin (H&E; Leica 
Autostainer XL, Wetzlar, Germany) or stained by immunohistochemistry (IHC) for 
aggrecan. For immunostaining, antigen retrieval was achieved with 20 µg/mL proteinase 
K for 10 minutes. Samples were deglycosylated with 10 µL of 0.75 U/mL chondroitinase 
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ABC (Sigma-Aldrich) for 1.5 hours to uncover the aggrecan core protein epitope. After 
blocking nonspecific binding with a solution of 2% goat serum, 1% bovine serum 
albumin (BSA), 0.1% gelatin, and 0.1% Triton-X in PBS and blocking endogenous 
peroxidases with 0.3% H2O2 in methanol, monoclonal mouse antibodies to bovine 
aggrecan (Abcam, Cambridge, UK) were allowed to bind overnight, and horseradish 
peroxidase-conjugated (HRP) secondary goat anti-mouse antibodies (Abcam) were 
allowed to incubate for 30 minutes, before diaminobenzidine (DAB) chromogen (Abcam) 
was used to develop the brown color that indicated positive immunostaining for 
aggrecan. Histological sections were imaged using a brightfield microscope at 10X and 
40X magnifications (Nikon Eclipse E600).  
3.2.6 Statistical Analysis 
All values were reported as mean ± standard deviation. Statistical significance of 
quantitative results was determined using a two-way (quantitative PCR, DMMB) or 
three-way (PicoGreen) analysis of variance (ANOVA) with Tukey’s multiple comparison 
test (p≤0.05). For quantitative PCR analysis, the two factors were surface and time. For 
DMMB analysis, the two factors were cell type and time. For PicoGreen analysis, the 
three factors were surface, cell type, and time. Statistical analysis was carried out using 




3.3.1 Aggregation of ACL fibroblasts and BMSCs on aggrecan-coated and 
nonadhesive surfaces 
Aggrecan-coated surfaces induced formation of dense cellular aggregates along 
the periphery of the wells within 24 hours of cell seeding (Figure 3.1a,e), compared to 
TCPS surfaces (Figure 3.1d,h). DMMB staining of aggrecan-coated surfaces verified that 
the majority of aggrecan adsorbed in a ring along the periphery of each well, aligning 
closely with where cell aggregation occurred. These aggregates were tethered to the 
surface, but some aggregates were still able to move when the medium surrounding them 
was agitated. Aggregation occurred in both ACL fibroblasts (Figure 3.1a) and BMSCs 
(Figure 3.1e). Aggregates were consistently less than 100 µm in diameter with most 
aggregates between 30 and 80 µm. Aggregate formation on aggrecan-coated surfaces was 
not dependent on the presence of serum proteins, with ACL fibroblast and BMSC 
aggregates forming in serum-free media (Figure 3.1b,f). When aggrecan was suspended 
in the culture medium, rather than pre-adhered on culture surfaces, the cells appeared 
morphologically similar to cells on control surfaces, indicating that aggrecan must be 
adsorbed to the surface prior to cell seeding to induce aggregation. Large cellular 
aggregates also formed on nonadhesive surfaces in the absence of aggrecan (Figure 
3.1c,g), and unlike aggrecan-coated surfaces, these aggregates were not adhered to the 
culture surface. Aggregate size for both ACL fibroblasts and BMSCs on nonadhesive 






Figure 3.1. ACL fibroblasts (a-d) and BMSCs (e-h) on aggrecan-coated, 
nonadhesive, and control tissue culture-treated polystyrene surfaces in serum-
supplemented and serum-free media after 3 days. Within 24 hours, aggregation 
(arrows) was observed on aggrecan-coated (a,e) and nonadhesive (c,g) surfaces, and 
aggregate morphology was maintained over 14 days. Aggregate formation on 
aggrecan-coated surfaces was not dependent on the presence of serum proteins (b,f). 
Scale bars in all images are 100 µm. 
 
PicoGreen DNA assay was used to estimate the number of cells in ACL fibroblast 
(donor #1) and BMSC (donor #3) aggregates cultured on aggrecan-coated and 
nonadhesive surfaces. On aggrecan-coated surfaces, ACL fibroblast aggregates were 
composed of approximately 150±34 cells, and BMSC aggregates contained 51±17 cells 
on day 3. Aggregates cultured on nonadhesive surfaces, however, demonstrated higher 
cell number than those on aggrecan-coated surfaces, regardless of cell type; ACL 
fibroblast aggregates possessed approximately 3,920±480 cells, and BMSC aggregates 
contained 600±95 cells on nonadhesive surfaces on day 3. From statistical analysis, ACL 
fibroblast aggregates had significantly higher cellularity than BMSC aggregates when 
cultured on nonadhesive surfaces, although aggregate cell number was not significantly 
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different between cell types on aggrecan-coated surfaces. PicoGreen results further 
indicated that aggregate cell number did not significantly change over time on either 
surface.  
3.3.2 Upregulation of aggrecan gene expression in ACL fibroblast and BMSC 
aggregates on aggrecan-coated and nonadhesive surfaces 
Overall, ACL fibroblast and BMSC aggregates on aggrecan-coated and 
nonadhesive surfaces showed significantly upregulated aggrecan gene expression. 
Though some interdonor variability was evident, in all donors (donors #1-3), ACL 
fibroblast aggregates on aggrecan-coated surfaces demonstrated significantly upregulated 
aggrecan expression at all time points, compared to cells on TCPS controls (Figure 3.2a-
c). On nonadhesive surfaces, ACL fibroblasts experienced significant upregulation of 
aggrecan expression on day 14 in all donors (Figure 3.2d-f), and donor #1 also showed 
upregulated aggrecan expression on days 3 and 7, compared to TCPS controls (Figure 
3.2d). In addition, collagen I expression was significantly downregulated in ACL 
fibroblasts on nonadhesive surfaces over all time points in all 3 donors. Collagen II and 
PPAR-γ2 were generally downregulated over most time points on nonadhesive surfaces 
in cells from donors #1 and #2. Minimal change in gene expression of collagen I, 






Figure 3.2. Gene expression of ACL fibroblasts from 3 different bovine donors on 
aggrecan-coated (a-c) and nonadhesive (d-f) surfaces over 14 days, relative to cells 
on untreated control surfaces. (Aggrecan expression is depicted on separate axes 
using a different vertical scale.) Some interdonor variability was evident; however, 
ACL aggregates significantly upregulated aggrecan gene expression on aggrecan-
coated and nonadhesive surfaces (n=3), particularly by day 14. * indicates 
significantly different from control samples (p≤0.05). 
 
Similar to ACL fibroblasts, BMSC aggregates on aggrecan-coated and 
nonadhesive surfaces also demonstrated an increase in aggrecan gene expression. Though 
some interdonor variability was evident, BMSC aggregates on aggrecan-coated surfaces 
showed significantly upregulated aggrecan expression on day 3, compared to TCPS 
controls, in all bovine donors (donors #3-5; Figure 3.3a-c); however, expression 
diminished to control levels on days 7 and 14. On nonadhesive surfaces, BMSCs from all 
3 donors experienced significant upregulation of aggrecan expression over TCPS controls 
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on all time points (Figure 3.3d-f). Collagen II was significantly downregulated on both 
surfaces over all times in cells from donor #5 and on nonadhesive surfaces over most 
time points with donor #3. Collagen I and PPAR-γ2 were significantly downregulated 
over most time points on nonadhesive surfaces in cells from donors #3 and #4. Minimal 
change in gene expression of collagen I and PPAR-γ2 was observed on aggrecan-coated 
surfaces.  
3.3.3 Production of sulfated GAG in ACL fibroblast and BMSC aggregates 
ACL fibroblast (donor #1) and BMSC (donor #3) aggregates on nonadhesive 
surfaces were analyzed by DMMB assay for production of sulfated GAG. ACL fibroblast 
aggregates produced 69±3 ng GAG per aggregate, while BMSC aggregates produced 
12±2 ng GAG per aggregate, suggesting that ACL aggregates contained significantly 
more GAG than BMSC aggregates; however, GAG production was not statistically 
significant across cell types when normalized to cell number. ACL aggregates contained 
18±1 pg GAG per cell, while BMSC aggregates contained 20±4 pg GAG per cell after 
day 3 (Table 3.2). GAG content in ACL and BMSC aggregates on nonadhesive surfaces 





Figure 3.3. Gene expression of BMSCs from 3 different bovine donors on aggrecan-
coated (a-c) and nonadhesive (d-f) surfaces over 14 days, relative to cells on 
untreated control surfaces. (Aggrecan expression is depicted on separate axes using 
a different vertical scale.) Some interdonor variability was evident; however, BMSC 
aggregates significantly upregulated aggrecan gene expression on aggrecan-coated 
and nonadhesive surfaces on day 3 (n=3). * indicates significantly different from 
control samples (p≤0.05). 
 
Table 3.2. Sulfated GAG content within cell aggregates cultured on nonadhesive 
surfaces as determined by DMMB assay, normalized by cell number (n=3) 
Cell Type 
Mass of GAG (pg per cell) 
Day 3 Day 7 Day 14 
ACL Fibroblasts 18±1 pg/cell 21±6 pg/cell 21±4 pg/cell 
BMSCs 20±4 pg/cell 24±2 pg/cell 16±14 pg/cell 
 
3.3.4 Production of aggrecan in ACL fibroblast and BMSC aggregates 
Immunostaining of ACL fibroblast and BMSC (both donor #3) aggregates 
cultured on nonadhesive surfaces verified the presence of aggrecan after 3, 7, and 14 days 
 
58 
(Figure 3.4b-d,f-h), compared to negative control samples stained without primary 
antibody for aggrecan (Figure 3.4a,e). Also, BMSCs formed noticeably better defined 
aggregates than ACL fibroblasts. While ACL aggregates showed some sectioning 
artifact, especially at early time points, in which cells dissociated from the aggregate 
body, BMSC aggregates appeared to possess a thin, smooth layer surrounding each 
aggregate and remained intact during sectioning. In immunostaining and hematoxylin and 
eosin staining, a distinct change in aggregate morphology was observed in BMSC 
aggregates from 3 to 14 days (Figures 3.4f-h, 3.5d-f). Starting at day 7 and increasing by 
day 14, small pocket-like spaces were present in BMSC aggregates with ECM 
organization appearing as a circular, interconnected network. ACL aggregates, however, 
did not observe this pocket-like ECM organization, and morphology did not appear to 






Figure 3.4. Presence of aggrecan within ACL fibroblast (a-d) and BMSC (e-h) 
aggregates as indicated by immunohistochemistry staining. ACL and BMSC 
aggregates stained strongly for aggrecan (b-d, f-h), compared to negative control 
samples stained without primary antibody for aggrecan (a,e). A noticeable change in 
ECM morphology is evident over 14 days in BMSC aggregates. Boxed regions are 
magnified in insets located in the lower left corner of each image. Scales bars in 





Figure 3.5. Hematoxylin and eosin (H&E) staining of ACL fibroblast (a-c) and 
BMSC (d-f) aggregates. A noticeable change in ECM morphology is evident over 14 
days in BMSC aggregates. Boxed regions are magnified in insets located in the lower 
left corner of each image. Scales bars in images are 100 µm, and insets are 25 µm. 
 
3.4 Discussion 
The results from this study demonstrated that aggrecan-coated surfaces can be 
used to alter the morphology of both bovine ACL fibroblasts and BMSCs. Modification 
of surfaces with aggrecan molecules promoted the formation of ACL fibroblast clusters 
and BMSC aggregates (Figure 3.1). DMMB staining verified that the localization of 
aggrecan on tissue culture surfaces aligned closely with areas of cell aggregation. 
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Aggregation required that aggrecan molecules be adsorbed to the surface prior to cell 
seeding, and the presence of aggrecan suspended in the culture medium did not induce 
aggregate formation, suggesting that the interaction between the aggrecan and the surface 
prior to cell seeding reduced cell adhesion to the culture dish and thus encouraged cell 
clustering. However, aggregation on aggrecan-coated surfaces was not dependent on the 
presence of serum proteins, with aggregates forming in FBS-free media (Figure 3.1). 
After formation, ACL fibroblast and BMSC aggregates on aggrecan-coated surfaces 
contained significantly fewer cells than aggregates on nonadhesive surfaces, and 
aggregate cellularity did not change with time.  
Aggregation of bovine ACL fibroblasts and BMSCs, even in the absence of 
aggrecan (as shown on nonadhesive surfaces), promoted gene expression and production 
of aggrecan, a key cartilaginous ECM proteoglycan (Figures 3.2-4, Table 3.2). In general, 
there was variability between the 3 bovine donors tested for gene expression, suggesting 
intrinsic differences in how these cells respond to culture conditions; however, the 
general trend of aggrecan upregulation was maintained regardless of cell source, which 
indicated that aggregation is a robust method to promote cartilaginous gene expression in 
these cells. Results from the DMMB assay and immunostaining verified that ACL 
fibroblast and BMSC aggregates cultured on nonadhesive surfaces also produced 
detectable amounts of sulfated GAG/aggrecan. However, direct comparison of aggrecan 
production between culture surfaces was not possible as cells on aggrecan-coated 
surfaces could not be isolated without releasing the original aggrecan coating as well, 
thus potentially contaminating the samples.  
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These data suggested that cells could potentially be pre-cultured as aggregates in 
order to promote the production of cartilaginous ECM within a cell population, prior to 
their incorporation into a portion (insertion points) of a 3D scaffold for ligament tissue 
engineering applications. Alternatively, biomaterial scaffolds may be designed with 
means to induce differing degrees of cellular aggregation along their length [174], 
thereby predisposing a certain population of cells to produce larger amounts of aggrecan 
in areas near the insertion point. RT-PCR results indicated that cells responded similarly 
in aggregates, regardless of the cell culture surface employed (Figures 3.2-3.3), 
suggesting aggregation itself was a major stimulus for the changes in gene expression 
observed. This leaves open the possibility of using a wide variety of pre-culture methods, 
including those tissue culture surfaces presented here, to encourage cells to form 
cartilaginous ECM for insertion point regeneration. 
Similar to culture of these cell aggregates on nonadhesive surfaces, pellet culture 
and micromass culture are established methods to prevent the dedifferentiation of 
chondrocytes or to promote chondrogenic differentiation of BMSCs [6, 98, 132, 304-
307]. High-density culture may mimic the cell environment of mesenchymal 
condensation that occurs during cartilage development prior to chondrogenesis, including 
cell-cell and cell-matrix interactions [24, 308]. However, to our knowledge, this is the 
first time aggregate culture has been investigated for chondrogenic differentiation of 
tendon/ligament fibroblasts. High-density culture of human tenocytes, including pellet 
formation by centrifugation or clustering in response to ultra-confluent monolayer 
culture, has been examined for maintenance of tenocyte phenotype [309-311], and one 
group reported accumulation of proteoglycan over 14 days with no change in collagen II 
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[309]; however, further implications for chondrogenic differentiation were not explored. 
In contrast, this study induced aggregate formation via culture on nonadherent 2D 
surfaces, both with or without aggrecan treatment, to investigate expression of 
cartilaginous ECM by ACL fibroblasts. Micromass culture has also been applied with 
lactic acid treatment to promote production of cartilaginous ECM by human dermal 
fibroblasts [281]. These results suggest that ligament fibroblasts retain the plasticity to 
alter their gene expression and possibly differentiate toward a chondrogenic phenotype 
under the appropriate conditions.  
While aggrecan was significantly upregulated in clustered cells, collagen type II, 
another chondrocytic ECM marker, was either significantly downregulated or remained 
unchanged in both ACL fibroblast and BMSC aggregates on both surfaces. This 
decoupled expression of aggrecan and collagen type II suggests that while aggrecan 
expression is upregulated in cell aggregates, the cells are not completely committed to a 
chondrocytic phenotype. For use as part of a tissue-engineered ligament replacement, 
cartilaginous ECM (aggrecan and collagen II) should be upregulated, while fibrous ECM 
(collagen I) expression should be either upregulated or maintained within ACL 
fibroblasts and BMSCs; however, this system may be useful to investigate the basic 
interactions of cells with aggrecan in the absence of a collagen II matrix. Also, it is 
important to note that gene expression of other markers such as PPAR-γ2 was either 
downregulated or unchanged over most time points, indicating that ACL fibroblasts and 
BMSCs are not differentiating down an alternate (adipogenic) lineage. Further work is 
required to determine the optimal culture conditions that would simultaneously 
upregulate collagen I, collagen II, and aggrecan expression for production of 
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fibrochondrogenic ECM. A combination of aggregate-inducing culture substrates with 
soluble factors or mechanical loading (not explored in this study) may be necessary to 
achieve an optimal cell phenotype for use in the insertion sites of future tissue-engineered 
ACL replacements.  
The ability of BMSCs and ACL fibroblasts to alter their gene expression and 
ECM production may be dependent on the presence of a subpopulation of multipotent 
progenitor cells in both cases. BMSCs and ACL fibroblasts in this study are 
heterogeneous populations of cells from the bone marrow and ACL, respectively. 
BMSCs likely include a subpopulation of multipotent mesenchymal stem cells [77], and 
while cells from the ACL are mostly ligament fibroblasts, they may include a small 
subpopulation of ligament progenitor cells, similar to progenitor/stem cells isolated from 
tendon and periodontal ligament [312-313]. Overall, BMSCs displayed greater and more 
consistent upregulation of aggrecan expression than ACL fibroblasts (Figures 3.2-3.3), 
suggesting that, even though ACL fibroblasts are capable of altering their gene 
expression profiles, BMSCs are more consistently responsive to cell aggregation and may 
possess are larger population of progenitor cells than ACL fibroblasts. Ligament 
fibroblasts, however, have been extensively explored as a cell source for ligament tissue 
engineering [69, 314-315], as an injured ACL could be surgically removed and the 
harvested fibroblasts used as an autologous cell source to populate a ligament graft [316]. 
The ability of ACL fibroblasts to alter their gene expression and produce cartilaginous 
ECM suggests that ACL fibroblasts may also be a promising cell type in the development 
of a tissue-engineered bone-ligament-bone graft including fibrocartilaginous insertions.  
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From histological sections, distinct differences were observed between the 
morphology of ACL fibroblast and BMSC aggregates cultured on nonadhesive surfaces 
(Figure 3.4-3.5). Most noticeably, in this study, small pocket-like spaces were observed 
in day 14 BMSC aggregates with ECM appearing as a circular, interconnected network. 
The matrix organization in day 14 BMSC aggregates may be an effect of nutrient 
transport into these large cell aggregates. It should be noted that this ECM network has 
not been reported by similar studies examining micromass culture of bovine BMSCs over 
similar time scales [132, 307]. However, in these other studies, aggregates were formed 
by centrifugation resulting in much larger cell pellets, which could account for 
differences in observed pellet morphology. Additionally, cells in this study were cultured 
with 10% FBS, while other studies replaced serum with insulin-transferrin-selenium 
(ITS) supplement with and without transforming growth factor-β1 or -β3 (TGF-β). 
Further work is needed to fully understand the timing and events involved in 
differentiation and matrix production that may lead to this unique ECM structure within 
these aggregates.  
Together the results of these studies present aggregate culture of ACL fibroblasts 
and BMSCs as a potential pre-culture technique to promote the regeneration of 
cartilaginous and fibrocartilaginous tissues.  
 
3.5 Conclusions 
These studies have shown that aggrecan-coated surfaces induce the aggregation of 
bovine ACL fibroblasts and BMSCs, and cell clusters (on aggrecan-coated surfaces and 
in the absence of aggrecan) demonstrated upregulated aggrecan gene expression, 
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regardless of cell type. Immunostaining also confirmed the presence of aggrecan in cell 
aggregates over 14 days. These findings suggest that both cell types could potentially be 
pre-cultured as aggregates to promote production of cartilaginous ECM, specifically 
aggrecan proteoglycan, prior to seeding on scaffolds, for orthopaedic tissue engineering 
applications requiring the presence of this molecule. This is particularly attractive as it 
suggests that altering pre-culture conditions like degree of clustering could produce a 
range of phenotypes from a single cell source, such as the ACL fibroblast. As such, these 
findings represent a first step which may inform future approaches to producing tissue-
engineered alternatives for current ACL grafting procedures through regeneration of 





DEVELOPMENT OF NANO- AND MICRO-SCALE CHONDROITIN 






Chondroitin sulfate (CS) is a sulfated glycosaminoglycan (GAG) that is 
covalently bound to a variety of protein cores to form proteoglycans that are found 
throughout the human body [317]. During development, one of the key roles of GAGs is 
to establish morphogen gradients that pattern tissue morphogenesis by sequestering 
secreted growth factors at the cell membrane [318]. Negatively charged GAGs, including 
heparin, heparan sulfate, and CS, are capable of electrostatically interacting with 
positively charged growth factors, including basic fibroblast growth factor (bFGF), 
insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), and transforming growth factor-β (TGF-β), to stabilize 
and prevent degradation of the growth factors in solution [206, 262, 319], indicating that 
CS biomaterials may be a promising vehicle for delivery of cationic growth factors, 
particularly to direct differentiation of stem cells.  
Size scale plays an important role in the release kinetics of a given delivery 
vehicle, including the diffusion rate of molecules out of the material and the degradation 
                                                 
2
 Portions of this chapter were adapted from Lim JJ, Hammoudi TM, Bratt-Leal AM, 
Hamilton SK, Kepple KL, Bloodworth NC, et al. Development of nano- and microscale 




properties of the material [320]; therefore, control of size enables one to tailor the release 
profile for a variety of applications. Nanospheres and microspheres possess a high 
surface area-to-volume ratio, accelerating the diffusion of molecules from the particles 
and potentially enhancing the hydrolytic or enzymatic degradation of the carrier and 
further accelerating release [320-321]. The small size of nano- and microspheres, relative 
to cells and tissues, make them especially advantageous carriers for delivery and 
sustained release within dense tissues, high-density cell pellets, or tissue engineering 
scaffolds with numerous barriers to diffusion [322], because these small particle carriers 
can be incorporated or locally injected within a tissue for controlled release of specific 
molecules to achieve a localized or more homogenous cell response [321].  
Additionally, nano-sized particles (< 500 nm diameter) are capable of being 
internalized by cells, permitting efficient transport across the cell membrane [321]. 
Generally, smaller particles are endocytosed more effectively than larger particles, 
though an optimal size range commonly exists around 100-200 nm [323]. Larger micro-
scale delivery vehicles, however, may be advantageous for preventing cell endocytosis if 
extracellular release is desired, and their larger size scales also possess potential for 
greater molecule loading and prolonged release due to their larger volumes.  
In this study, we explored the means to fabricate both micron-scale particles and 
nano-scale micelles from CS. Micelles are nanoscale, self-assembling particles composed 
of amphiphilic molecules. In an aqueous environment, micelles self-assemble into 
sphere-like structures with a hydrophilic shell surrounding a hydrophobic core, making 
them largely stable in the aqueous environment of the body [324]. Due to its negative 
charge density and hydrophilic nature, CS can be utilized as a hydrophilic segment of a 
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polymeric micelle. CS has been previously reported as the hydrophilic component with 
poly(L-lactic acid) (PLLA) and poly(lactic-co-glycolic acid) (PLGA) copolymers to form 
amphiphilic microspheres for use as drug and protein delivery carriers [324-326]. With 
its nanoscale size and high negative charge density, CS-derived micelles have promising 
potential for many drug and protein delivery applications.  
The long term goal of this research was to examine CS interactions with stem 
cells, particularly as a means to control growth factor release in order to direct 
differentiation. Therefore, the first set of experiments in this study were designed to 
develop facile means to control the size of CS-based particles over a broad range of size 
scales (at least two orders of magnitude) and characterize the resulting materials. 
Subsequently, the ability of these CS-based biomaterials to interact electrostatically with 
positively charged growth factors, as well as the cytocompatibility of these materials with 
both embryonic and mesenchymal stem cells was demonstrated, confirming the potential 
for these materials as naturally-derived carriers for growth factor delivery for a variety of 
stem cell-based tissue engineering and regenerative medicine applications.  
 
4.2 Materials and Methods 
4.2.1 Modification of Chondroitin Sulfate 
4.2.1.1 Chondroitin Sulfate Modification for Micelle and Hydrogel Fabrication 
To examine the effects of reaction stoichiometry on the resulting modification of 
CS, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) chemistry, which forms an 
amide bond between a primary amine and a carboxylic acid, was used to synthesize 
chondroitin sulfate methacrylamide (CSMAm; Figure 4.1a). N-(3-
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aminopropyl)methacrylamide (APMAm) was conjugated to chondroitin sulfate A, using 
EDC chemistry adapted from [327]. 2.5 mM CS (~48.7 kDa; Sigma-Aldrich, St. Louis, 
MO) [328] based on CS disaccharide molecular weight was reacted with APMAm 
(Polysciences, Warrington, PA), EDC (Sigma-Aldrich), and N-hydroxysulfosuccinimide 
(sulfo-NHS; Sigma-Aldrich) at various molar ratios depicted in Table 4.1. Since CS 
possesses 1 carboxyl moiety per disaccharide, this represented the molar ratio of reagent 
to each reactive carboxyl group. The reaction mixture was incubated at room temperature 
and pH 5.0 for 2 hours with stirring.  
Sulfo-NHS stabilizes the EDC reaction and was used to control the degree of 
substitution of the reaction; however, to reduce the degree of modification for micelle 
formation, the reaction with the highest molar ratio of 4:1 was repeated in the absence of 
sulfo-NHS. Initially a 2:1 ratio of APMAm and EDC to CS was used and allowed to react 
for 2 hours, and then a second round of APMAm and EDC was added to the solution for 
a total 4:1 molar ratio to CS. The reaction without sulfo-NHS was allowed to proceed for 
2 more hours at pH 5.0. All reaction mixtures were dialyzed in 1,000 Da molecular 
weight cutoff (MWCO) dialysis membrane (Spectrum Laboratories, Rancho Dominguez, 
CA) against distilled water (dH2O) for 3 days, and the product was then lyophilized 
(Labconco FreeZone 4.5, Kansas City, MO) for 4 days and stored at 4°C until use.  
4.2.1.2 Chondroitin Sulfate Modification for Microsphere Fabrication 
For microsphere formation, CS was reacted with methacrylic anhydride (Sigma-
Aldrich) to conjugate methacrylate groups to the existing hydroxyl groups in CS (Figure 
4.1b). Methacrylation of CS was carried out per established protocols [328]. After 
complete dissolution, 60 mL methacrylic anhydride was added dropwise into 60 mL of a 
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25% w/v chondroitin sulfate A solution (20.6:1 molar ratio of methacrylic anhydride to 
reactive hydroxyl) under basic conditions. The reaction solution was stirred at 60°C for 
24 hours, then precipitated and washed in cold methanol:isopropanol (10:1). The 
resulting chondroitin sulfate methacrylate (CSMA) precursor was subsequently dried 
under vacuum at room temperature. The resulting product was dialyzed (1,000 Da 
MWCO) against dH2O for 3 days, followed by lyophilization for 4 days.  
 
 
Figure 4.1. Modification reactions of chondroitin sulfate. (a) Chondroitin sulfate A 
(CS) and N-(3-aminopropyl)methacrylamide (APMAm) were reacted in the 
presence of N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) with or 
without N-hydroxysulfosuccinimide (sulfo-NHS) to yield chondroitin sulfate 
methacrylamide (CSMAm). Protons are labeled for 
1
H NMR results in Figure 4.2. 
(b) CS and methacrylic anhydride were reacted in the presence of NaOH to yield 





4.2.2 Characterization of CS Nano- and Microspheres 
4.2.2.1 Proton Nuclear Magnetic Resonance Spectroscopy 
Proton nuclear magnetic resonance (
1
H NMR) was utilized to determine the 
degree of the conjugation of the APMAm groups to the CS chains. The initial 
components (CS and APMAm) and resulting modified CS products (CSMAm and 
CSMA) were solubilized in deuterated water (D2O; Sigma-Aldrich), and 
1
H NMR was 
measured on a Bruker AMX-400 spectrometer (Billerica, MA) at 400 MHz. The resulting 
spectra were analyzed by calibrating the region from 3.61-3.88 ppm according to the 
known number of protons in the chondroitin sulfate backbone. This provided an internal 
standard which allowed monitoring of the amount of modification attached to the 
different modification reactions.  
4.2.2.2 Formation and Characterization of Bulk CS Hydrogels 
Solutions of CSMAm or CSMA at 90% water content in phosphate buffered 
saline (PBS) were crosslinked between 2 glass slides at 1 mm thickness under 15 
mW/cm
2
, 365 nm UV light (UVP, Upland, CA) with 0.2 wt% Irgacure 2959 
photoinitiator (D2959, Ciba, Ludwigshafen, Germany) for 12.5 minutes, and 6 mm 
diameter discs were punched out using a cork borer. After 1 day swelling in PBS, the wet 
weight of crosslinked hydrogels was recorded, and following lyophilization overnight, 
dry weight was recorded. Swelling ratio was calculated as wet weight/dry weight (n=4).  
4.2.2.3 Dynamic Light Scattering and Zeta Potential Measurements of CS Micelles 
Dynamic light scattering (DLS) measurements were taken to determine the 
average diameter of CSMAm micelles in distilled, deionized water (ddH2O), and zeta 
potential measurements were also recorded as a measure of surface charge and colloidal 
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stability in ddH2O. DLS and zeta potential measurements were taken on a NICOMP 
380ZLS (Particle Sizing Systems, Santa Barbara, CA) at 23°C. A helium-neon laser at 
632.8 nm wavelength was used at a detector angle of 90°. Samples of 1.0 mg/mL 
CSMAm were run in ddH2O, while samples of unmodified CS at the same concentration 
served as controls (n=4). Prior to measurement, the solutions were filtered through a 5 
µm pore size cellulose acetate filter (Sartorius, Goettingen, Germany), and the sample 
was briefly centrifuged (14,000 RPM) to remove any dust particles from the solution. 
Hydrodynamic diameter was calculated using the inverse Laplace transform of the 
correlation function [329].  
Zeta potential measures colloid mobility of charged particles in solution under an 
electric field. Zeta potential measurements were taken on 0.1 mg/mL CSMAm solutions 
in an electric field of 4 V/cm (1.6 V, 0.4 cm electrode distance; n=3). Zeta potential was 
calculated according to the Smoluchowski limit [330].  
4.2.2.4 CS Microsphere Fabrication and Characterization 
CS microspheres were fabricated using a water-in-oil, single-emulsion technique 
similar to a previously described protocol [331]. CSMA (55.6 mg) was dissolved in PBS 
(440 µL) and combined with ammonium persulfate (30 µL, 0.3 M) (Sigma-Aldrich) and 
tetramethylethylenediamine (30 µL, 0.3 M) (Sigma-Aldrich) free radical initiators on ice. 
This mixture was added drop-wise into corn oil at 4°C and homogenized at 3,800 RPM 
for 5 minutes. The temperature was then raised to 50°C with stirring for 30 minutes to 
promote crosslinking. The resulting solution was centrifuged at 300 RCF, and the corn oil 
was removed. Microspheres were then washed with dH2O and stored in dH2O at 4°C. 
The diameter of the microsphere population was analyzed using a Z2 Coulter Particle 
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Counter (Beckman Coulter, Fullerton, CA) equipped with a 100 µm aperture. 
Microspheres were suspended in Isoton II diluent (Beckman Coulter) prior to counting. 
For imaging, microspheres were treated with a solution of 1,9-dimethylmethylene 
blue (DMMB; Sigma-Aldrich) for 30 minutes to stain CS purple, washed with ddH2O, 
and imaged using an inverted microscope (Nikon Eclipse TE2000-U, Melville, NY).  
4.2.2.5 Complexation and Release from CS Microspheres 
To examine the ability of negatively charged CS microspheres to electrostatically 
bind positively charged TGF-β1, approximately 2 mg of lyophilized microspheres were 
suspended in 500 µL of 50 ng/mL human recombinant TGF-β1 (Peprotech, Inc., Rocky 
Hill, NJ) and 1% bovine serum albumin (BSA) in PBS. Microspheres were incubated 
with TGF-β1 overnight at 4°C with shaking (n=3).   
To examine the release kinetics of positively charged TGF-β1 and negatively 
charged tumor necrosis factor-α (TNF-α), approximately 2 mg of lyophilized CS 
microspheres were loaded with 5 µL of 5 µg/mL human recombinant TGF-β1 or TNF-α 
(R&D Systems, Minneapolis, MN) per mg of microspheres overnight at 4°C. 
Microspheres were then suspended in 750 µL of solution containing 1% BSA in PBS 
(time 0) and incubated at 37°C with gentle shaking for 5 days.  
At various time points, samples were centrifuged for 90 seconds at 4,000 RPM, 
and the supernatant was sampled and analyzed for factor content using the corresponding 
enzyme-linked immunosorbent assay (ELISA; R&D Systems) kit specific to human 




4.2.3 Cytocompatibility of CS Nano- and Microspheres 
4.2.3.1 In Vitro Cytotoxicity of CS Micelles and Microspheres on 2D BMSC Monolayers 
For CSMAm micelle cytotoxicity studies, bovine bone marrow stromal cells 
(BMSCs) were isolated in a modification of the procedure outlined in [213]. Briefly, 
bone marrow was harvested from the tibia and femur of an immature calf (Research 87, 
Marlborough, MA). Cells were cultured in medium composed of low-glucose DMEM 
(Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (FBS; Thermo 
Scientific Hyclone, Logan, Utah), 1% antibiotic/antimycotic, 0.1% Fungizone 
antimycotic (Invitrogen, Carlsbad, CA), and 1 ng/mL bFGF (Peprotech). The adherent 
BMSCs were expanded until confluence and were then detached with 0.05% 
trypsin/EDTA (Mediatech), frozen in medium containing 20% FBS and 10% dimethyl 
sulfoxide (DMSO; Sigma-Aldrich), and cryopreserved in liquid nitrogen until use (P1).  
Prior to use, BMSCs were thawed and plated for at least 3 days to eliminate 
transitory effects from the thawing process. After this time, cells were trypsinized (P2) 
and plated at 10,000 cells/cm
2
 in a tissue culture-treated 96-well plate. After 24 hours to 
allow cell attachment, culture medium was replaced with 100 µl of medium containing 
CSMAm micelles or CSMA microparticles equivalent to 1, 10, 100, 320 mg per 10
6
 cells 
(0.064, 0.64, 6.4, and 20.5 mg/ml, respectively). After 24 hours of exposure to the 
CSMAm- or CSMA-containing media, cells were stained (30 minutes) with LIVE/DEAD 
stain (Invitrogen). Calcein stains live cells to fluoresce green (excitation/emission: 
494/517 nm), and ethidium homodimer-1 stains dead cells to fluoresce red 
(excitation/emission: 528/617 nm). Dead controls were exposed to 70% methanol prior to 
staining, while live controls were cultured in normal culture medium without CS 
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particles. Fluorescent images were captured using an inverted microscope, and total 
fluorescence of each well was measured in a SpectraMax M2
e
 plate reader (Molecular 
Devices, Toronto, Canada) at the wavelengths specified above (n=3). Relative viability 












where F(517)sample, F(517)LIVE, and F(517)DEAD are the fluorescence at 517 nm of the 
sample, live controls, and dead controls, respectively.  
4.2.3.2 In Vitro Cytotoxicity of CS Microspheres when Incorporated within 3D ESC 
Embryoid Bodies 
Undifferentiated D3 murine embryonic stem cells (ESCs) were maintained on 
gelatin-coated tissue culture dishes in DMEM supplemented with 15% FBS and 10
3
 
U/mL leukemia inhibitory factor (LIF; Millipore, Billerica, MA). Embryoid bodies (EBs) 
were formed using a single-cell suspension by forced aggregation in AggreWell
TM
 400 
inserts (Stem Cell Technologies, Vancouver, CA) [332]. Briefly, 1.2 x 10
6
 cells in 0.5 mL 
of medium were inoculated into AggreWell
TM
 inserts, containing approximately 1,200 
wells per insert, and centrifuged at 200 RCF for 5 minutes to cluster cells in the wells. 
Subsequently, 200 µL of CS microsphere solution was added in a 4:1 microsphere-to-
ESC ratio, and a second centrifugation was performed at 200 RCF for 5 minutes. After 24 
hours of culture, aggregates were removed from the wells using a wide-bore pipette and 
transferred to suspension culture on a rotary orbital shaker (40 RPM) to maintain the 
homogeneity of the population [333].  
CS microsphere incorporation within EBs was examined through histological 
sections of EBs after 3 days of culture. EBs were sampled and fixed in a 10% formalin 
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solution. The EBs were washed in PBS and resuspended in HistoGel (Thermo Richard-
Allan Scientific, Kalamazoo, MI) prior to paraffin processing. Sections of 5 µm were 
stained using Safranin-O (Sigma-Aldrich) for GAG detection, Fast Green (Sigma-
Aldrich) for cytoplasm, and Weigert’s hematoxylin (Sigma-Aldrich) for cell nuclei and 
imaged using a brightfield microscope (Nikon Eclipse 80i). 
EBs with and without CSMA microspheres were also stained with LIVE/DEAD 
stain (30 minutes) and imaged by laser-scanning confocal microscopy (LSM 510; Carl 
Zeiss, Oberkochen, Germany) to examine the cytotoxicity of CSMA microspheres on 
ESCs within 3D EBs.  
4.2.4 Statistical Analysis 
All values were reported as mean ± standard deviation. Statistical significance 
was determined using Minitab Statistical Software (v15, State College, PA) with a one-
way analysis of variance (ANOVA) with Tukey’s multiple comparison test (p≤0.05) for 
swelling ratio and cytotoxicity analysis and with a 2-sample t-test (p≤0.05) for growth 
factor loading efficiency and cumulative release. For swelling ratio analysis, the factor 
was hydrogel formulation. For cytotoxicity analysis, the factor was CS concentration. For 
growth factor loading efficiency and cumulative release, TGF-β1 and TNF-α cumulative 






4.3.1 Characterization of CS nano- and microspheres 
4.3.1.1 Proton nuclear magnetic resonance spectroscopy 
1
H NMR spectra indicate that APMAm was successfully conjugated to CS by the 
EDC reaction. CSMAm product synthesized in the presence of sulfo-NHS clearly showed 
the appearance of vinyl groups, found in the APMAm moiety (Figures 4.2b-d; peaks B1 
and B2, corresponding to the labeled protons in Figure 4.1a). The modified CS product 
also possessed proton peaks C and E, as labeled in Figures 4.2b-c, which were present in 
APMAm. 
1
H NMR spectra also suggested that the degree of modification increased with 
increased ratio of starting reagents per CS disaccharide equivalent. While vinyl groups 
were clearly visible in 4:1, 3:1, and 5:2 molar ratio reactions, vinyl peaks were barely 
distinguishable in the 7:10 reaction product (Figure 4.2c,d). At 1:5 molar ratio and when 
synthesized at 4:1 ratio without sulfo-NHS, vinyl peaks were not visible (Figure 4.2e,f). 
Similarly, peaks C and E did not appear in these reaction products. This indicated that 
despite a modification of the CS from the original reagent (as indicated by the light 
scattering data below), APMAm protons were not visible by 
1
H NMR at 1:5 molar ratio 
and without sulfo-NHS. Successful methacrylation of CS to form CSMA via reaction 
with methacrylic anhydride was also verified by 
1
H NMR. 
4.3.1.2 Hydrogel formation and swelling 
CSMAm crosslinking and swelling results in PBS also indicated that the degree of 
modification increased with increasing ratio of starting reagents per CS disaccharide 
equivalent. While 1:5 and 7:10 ratio reactions and the reaction without sulfo-NHS 
resulted in products that did not form robust hydrogels, at 5:2 molar ratio and above, 
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CSMAm crosslinked to form bulk hydrogels (Table 4.1). As the molar ratio increased 
from 5:2 to 3:1 to 4:1, swelling ratio significantly decreased from 39.8 ± 1.8 to 20.4 ± 1.2 
to 12.8 ± 0.6, respectively. Decreased swelling is indicative of increased crosslinking 
density [123], likely as a result of higher degree of substitution of the methacrylamide in 
the EDC reaction. For comparison, crosslinked CSMA materials used for microsphere 




H NMR spectra of (a) chondroitin sulfate, (b) APMAm, and reaction 
products synthesized at (c) 4:1, (d) 7:10, and (e) 1:5 molar ratios of APMAm, EDC, 
and sulfo-NHS to CS disaccharide, as well as (f) 4:1 ratio without sulfo-NHS. 
Protons are labeled according to corresponding diagrams in Figure 4.1a, and 




Table 4.1. Molar ratios of reactants in EDC modification of CS and resulting 
swelling ratios of crosslinked hydrogels in PBS 
CS 
(by disaccharide MW) 
Molar Ratio to CS 
Swelling Ratio 
APMAm EDC Sulfo-NHS 
2.5 mM 4:1 4:1 None No Gel 
2.5 mM 1:5 1:5 1:5 No Gel 
2.5 mM 7:10 7:10 7:10 No Gel 
2.5 mM 5:2 5:2 5:2 39.8 ± 1.8 * 
2.5 mM 3:1 3:1 3:1 20.4 ± 1.2 * 
2.5 mM 4:1 4:1 4:1 12.8 ± 0.6 * 
* indicates statistically different from all other samples (p≤0.05) 
 
4.3.1.3 Size distribution of CS micelles  
Highly substituted CSMAm synthesized in the presence of sulfo-NHS did not 
appear to form stable micelles in an aqueous environment; therefore, only the 4:1 molar 
ratio without sulfo-NHS was used for micelle characterization. In order to accurately 
characterize the size of the CSMAm micelles, DLS analysis was performed. Micelle 
formation was examined by DLS for independent synthesis batches (n=4) and was 
verified to possess similar diameters. CSMAm micelles formed with an average diameter 
of 324.1 ± 8.5 nm in ddH2O (Figure 4.3). A lower intensity collection of smaller 
CSMAm micelles appeared to form at 73.2 ± 4.4 nm, as well. Unmodified CS at the same 
concentration, did not produce detectable scattering by DLS. Zeta potential 






Figure 4.3. Size characterization of CSMAm micelles. Dynamic light scattering 
measurements of hydrodynamic diameter indicated that a bimodal distribution was 
present with average diameters of 324.1 ± 8.5 nm and 73.2 ± 4.4 nm. Particle sizing 
measurements were consistent for 4 separate samples (shown in red, blue, green, 
and orange). 
 
4.3.1.4 Morphology and size distribution of CS microspheres 
The CS microspheres had a smooth, round morphology, and Coulter Counter 
analysis indicated that the microspheres exhibited a unimodal size distribution with an 
average diameter of 4.3 ± 0.93 µm (Figure 4.4a,b). Additionally, the microparticles 
stained positively by DMMB for sulfated GAG, appearing purple (Figure 4.4a).  
4.3.1.5 Complexation and release from CS microspheres 
To verify that a model positively charged growth factor was able to 
electrostatically complex with CS, the ability of CS microspheres to bind TGF-β1 in 
solution was examined. When the CS microspheres were incubated overnight with 25 ng 
of TGF-β1 (500 µL at 50 ng/mL), 97.4 ± 1.3% of free TGF-β1 in solution became 
incorporated with the CS microspheres. Additionally, in the following release study, 
positively charged TGF-β1 exhibited no appreciable release after loading in CS 
microspheres. Only 1.4 ± 0.3% (0.34 ± 0.08 ng per mg microspheres) of loaded TGF-β1 
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was observed in solution at time 0, representing a low amount of unloaded or loosely 
affiliated growth factor and high loading efficiency, and only 0.2% (0.04 ng) additional 
release was detected over the following 5 days (Figure 4.4c). In contrast, negatively 
charged TNF-α, loaded identically to TGF-β1, demonstrated 17.7 ± 3.5% (4.43 ± 0.87 ng 
per mg microspheres) of loaded TNF-α in solution at time 0, representing a significantly 
lower loading efficiency than TGF-β1, and 43.9 ± 9.1% cumulative release (10.97 ± 2.27 
ng) over the first 15 hours from CS microspheres with no further detectable release after 
15 hours (Figure 4.4c). Cumulative release of TNF-α from 3 hours to 5 days, correcting 
for differences in loading, was significantly greater than TGF-β1 released. Overall, after 
5 days, significantly more release of TNF-α was observed compared to TGF-β1.  
4.3.2 Cytocompatibility of CS nano- and microspheres 
4.3.2.1 In vitro cytotoxicity of CS micelles and microspheres on 2D BMSC monolayers 
LIVE/DEAD staining of bovine BMSCs cultured in monolayer in the presence of 
increasing concentrations of CSMAm micelles and CSMA microspheres revealed that 
cells remained largely viable at the lowest concentrations of 1 and 10 mg/10
6
 cells with 
1.21 ± 0.14 and 0.77 ± 0.05 viability, respectively, for CSMAm micelles and 1.09 ± 0.11 
and 1.12 ± 0.29 viability, respectively, for CSMA microspheres, compared to live 
controls which possessed normalized viabilities of 1.00 ± 0.08 and 1.00 ± 0.13 for 
CSMAm and CSMA experiments, respectively (Figure 4.5a). Viability of all 1 and 10 
mg/10
6
 cells samples was not statistically different from live controls. Cells appeared 
mostly green (live) and possessed a spread morphology, characteristic of BMSCs (Figure 
4.5b,c). At 100 mg/10
6
 cells, a significant decrease in viability was observed in the 
presence of CSMAm with 0.38 ± 0.06 viability, compared to live controls, as BMSCs 
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experienced a large decrease in cell density and spreading (Figure 4.5a,d), while viability 
did not significantly decrease in CSMA-containing medium (0.98 ± 0.16 viability; Figure 
4.5a,d). At the 320 mg/10
6
 cells concentration, very few cells remained adhered to the 
surface (Figure 4.5e) in both CSMAm and CSMA samples, resulting in a significant 
decrease in viability to 0.18 ± 0.07 and -0.05 ± 0.06, respectively.  
 
 
Figure 4.4. Characterization of CSMA microspheres. (a) CS microspheres possessed 
a smooth, rounded morphology and stained positively for sulfated GAG by DMMB 
(purple). Scale bar = 20 µm. (b) CS microspheres exhibited a unimodal distribution 
with an average diameter of 4.3 ± 0.93 µm. (c) Positively charged TGF-β1 (triangles) 
experienced very little release from negatively charged CS microspheres after 5 
days; however, negatively charged TNF-α (squares) experienced large early release 
within 15 hours. * indicates statistically different loading efficiency (0 hours) 
compared to TGF-β1 loaded samples. + indicates statistically different cumulative 




Figure 4.5. LIVE/DEAD cytotoxicity analysis of bovine marrow stromal cells 
cultured in 2D monolayer in the presence of CSMAm micelles and CSMA 
microparticles. (a) Fraction of live cells per well compared to live controls, as 
determined by fluorescence values recorded at 517 nm wavelength. LIVE/DEAD 
fluorescence images in the presence of (b) 1 mg, (c) 10 mg, (d) 100 mg, and (e) 320 
mg CSMAm or CSMA per 10
6
 cells for 24 hours. Live cells appeared green, while 
dead cells appeared red. Scale bar = 200 µm. * indicates statistically different from 
live controls (p≤0.05). 
 
4.3.2.2 In vitro cytotoxicity of CS microspheres when incorporated within 3D ESC 
embryoid bodies 
CS microspheres were successfully incorporated within embryoid bodies using 
the forced aggregation method described. The microspheres stained positively in 
histological sections for sulfated GAG by Safranin-O, appearing red (Figure 4.6b). 
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Surrounding ESCs also appeared to be morphologically normal, compared to control EBs 
(Figure 4.6a), with no signs of cell death or adverse cell response after 3 days, suggesting 
that the incorporation of CS microspheres within 3D stem cell aggregates does not 
negatively impact the extracellular microenvironment. Additionally, LIVE/DEAD 
staining of EBs observed similar degrees of viability with CSMA microspheres 
incorporated (Figure 4.6d), when compared to control EBs (Figure 4.6c), indicating that 
ESCs remained largely viable when CSMA microspheres were incorporated within 3D 
EBs.   
 
Figure 4.6. Cytotoxicity of mouse embryonic stem cells with CS microspheres 
incorporated within 3D embryoid bodies. (a) Cells in embryoid bodies without CS 
microspheres. (b) CS microspheres stained positively for sulfated GAGs by 
Safranin-O (red stain; black arrows). Surrounding cells appeared morphologically 
normal, with no signs of cell death after 3 days. Scale bar = 50 µm. A boxed region 
of cells and microspheres is also shown at higher magnification. Scale bar = 20 µm. 
(c) LIVE/DEAD fluorescence images of embryoid bodies without CS microspheres 
and (d) with incorporated CS microspheres, showed similar degrees of viability. 





In the first part of this study, a model reaction using EDC (and sulfo-NHS) to 
conjugate a methacrylamide moiety to CS was used to determine the effects of degree of 
modification on the properties of the resulting GAG-based material. This approach can be 
applied to any polysaccharide possessing a carboxylic acid moiety, including dermatan 
sulfate, heparin, heparan sulfate, and hyaluronic acid [334]. The resulting CSMAm 
material demonstrated increasing degrees of modification with greater molar ratios of 
starting reagents, resulting in higher degrees of crosslinking, as verified by 
1
H NMR data 
and significantly decreased swelling in bulk hydrogels (Figure 4.2 and Table 4.1).  
Interestingly, at lower degrees of modification, CSMAm self-assembled into 
micelles in aqueous solution. When reacted at 1:5 molar ratio and without sulfo-NHS, 
proton peaks associated with APMAm were not visible by 
1
H NMR (Figure 4.2e,f), 
though a modification of CS was apparent by the formation of nanospheres, as confirmed 
by DLS analysis (Figure 4.3). It is likely that the APMAm groups were not visible by 
1
H 
NMR, because these hydrophobic moieties were internalized within the micelle structure 
that formed in the NMR solvent (water). Similar results were observed in 
1
H NMR 
spectra of CS-PLLA micelles in D2O, where internal protons were not visible due to 
limited mobility within the micelle core [324].  
In this study, EDC chemistry was used to confirm that the degree of conjugation, 
and resulting molecular structure, could be controlled by altering the ratios of the starting 
reactants during synthesis; however, in order to efficiently scale up the size of the 
reaction while maintaining crosslinking capabilities to form microparticles, methacrylate 
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groups were added to CS by reacting the GAG with methacrylic anhydride. Resulting 
CSMA was crosslinked in a water-in-oil, single-emulsion to form CS microspheres. 
While the microspheres described here had an average diameter of 4.3 ± 0.93 µm (Figure 
4.4a,b), the size of the microparticles could be easily modified by altering the emulsion 
conditions, such as speed of mixing and CSMA concentration, prior to crosslinking 
[335]. The results of this work suggested that by altering the degree of conjugation, CS-
based materials can be developed that can be presented to cells on different size scales, 
including nanoscale micelles and larger microspheres, as well as controlled degree of 
crosslinking within particles. Therefore, this set of materials provides a versatile platform 
to explore presentation and release of various growth factors because the basic chemistry 
of the delivery vehicle is not altered, while a wide range of particle sizes is achieved.  
Zeta potential results indicated that CSMAm micelles possessed of zeta potential 
of -38.7 ± 1.1 mV, confirming that the micelles were negatively charged and stable in 
solution and suggesting that these micelles may have application in delivery of various 
cationic factors. Similarly, CSMA microspheres were shown to electrostatically complex 
with TGF-β1 at physiological pH. TGF-β1 was capable of a higher loading efficiency 
than TNF-α1, as indicated by the time 0 data point, despite identical loading conditions, 
likely due to electrostatic interactions. Considerable release of TNF-α was also observed 
from CS microspheres over the first 15 hours; however, minimal TGF-β1 release was 
seen over 5 days, indicating that TGF-β1 remained bound to the CS microspheres during 
this time (Figure 4.4c). TGF-β1 possesses an isoelectric point (pI) of 9.5 and thus was 
selected to represent a positively charged growth factor [276], while TNF-α has a pI of 
5.3, making it negatively charged at physiological pH [336]. Such results are comparable 
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to other CS-based hydrogels and microspheres, which have been reported to retain 
positively charged lysozyme, aprotonin, and vasopressin [325, 337]. TGF-β isoforms are 
important for a number of processes in mammalian development [338-339], and have 
been particularly implicated in chondrogenesis in vivo [340] and in vitro [341-342], 
making this a relevant growth factor to investigate for directing differentiation of stem 
cells. While 100% of loaded TNF-α was not released over the time course of this study, 
as might be expected with little affinity between the cytokine and the CS matrix, this 
could be explained by the potential degradation of the protein over time in solution, 
resulting in artificially low ELISA readings after release [343].  
Cumulative release data from these experiments suggested that significantly more 
TNF-α was liberated than TGF-β1, thus supporting the use of these materials for 
controlled delivery via electrostatic interaction with growth factors. Delivery kinetics can 
be further tailored by customizing the size and crosslinking density of the particles by 
altering the synthesis and fabrication parameters [344-345]. In combination with the 
release of growth factors through dissociation from the CS-based carrier, these 
biomaterial carriers could potentially be enzymatically cleaved by chondroitinase, a 
naturally secreted enzyme that digests chondroitin sulfate [346], thereby providing a 
second method for localized delivery.   
In addition to control over size and the potential for degradation, the CS-based 
particles presented here are particularly advantageous because both types of particles are 
fabricated almost entirely from only CS molecules, for nearly uniform biochemical 
presentation to target cells. In previous work, CS has been combined with synthetic 
polymers like PLLA and PLGA, as well as natural materials including chitosan, alginate, 
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and gelatin [324, 326, 347-349] to produce micron-scale particles.  However, to the best 
of our knowledge, this is the first time that CS microspheres and micelles have been 
synthesized without significant modification with other large polymers, making this 
system beneficial for specifically probing GAG-stem cell interactions.  
While CS plays a role in many developmental processes, CS delivery vehicles 
may be particularly useful to promote chondrogenesis. CS-containing proteoglycans 
versican and perlecan regulate mesenchymal condensation and growth factor signaling 
during cartilage development [14-15], and culture in CS-containing hydrogels 
upregulated expression and production of chondrocytic ECM by encapsulated 
mesenchymal stem cells [8]. Therefore, in the future, the use of CS-based materials for 
controlled growth factor delivery may be advantageous as a means to direct cell 
differentiation to promote regeneration of cartilaginous tissues.  
As a next step in the development of these materials as bioactive factor delivery 
vehicles, the cytotoxicity of CS was investigated in vitro using bovine BMSCs and 
murine ESCs. BMSCs and ESCs were chosen for their multipotent and pluripotent 
potential, respectively [77, 350]. In this study, BMSC monolayers were cultured with the 
presence of CS micelles and microspheres in the media for 24 hours to determine 
cytotoxicity in 2D, and CS microspheres were incorporated into ESC embryoid bodies 
for 3 days to examine cytocompatibility within 3D cell spheroids. ESCs are often 
cultured and differentiated within embryoid bodies; however, these dense, multicellular 
spheroids possess numerous boundaries to diffusion [322]. CS particles could potentially 
be utilized to deliver growth factors throughout the EB to improve homogeneous 
differentiation, compared to diffusion of soluble factors from the medium [322].  
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BMSCs, cultured in 2D with moderate concentrations of CSMAm micelles and 
CSMA microspheres of 1 and 10 mg/10
6
 cells, remained viable with no statistical 
difference from live controls (Figure 4.5a-c), while CSMA microspheres also remained 
cytocompatible up to 100 mg/10
6
 cells. Similarly, ESCs surrounding CS microspheres 
incorporated into EBs appear to be morphologically healthy with no apparent cell death 
(Figure 4.6), suggesting that CS microspheres could potentially be used to deliver growth 
factors within dense cell aggregates. At the highest concentration tested, 320 mg/10
6
 cells 
(as well as 100 mg/10
6
 cells for CSMAm), BMSCs experienced statistically decreased 
viability after 24 hours with the presence of CSMAm micelles and CSMA microspheres 
in the culture media (Figure 4.5a,d-e). Cell death may have resulted at high 
concentrations due to endocytosis of nanoscale CSMAm micelles by cells [323], or the 
high negative surface charge of CS particles may have interacted with receptors on the 
cell membrane [351] or altered the osmotic pressure of the medium, though these 
mechanisms were not further explored in this study. The range of concentrations in these 
studies, equivalent to 0.064, 0.64, 6.4, and 20.5 mg/ml, included and exceeded previously 
reported values used for cytotoxicity testing of CS-based microspheres and were defined 
according to ASTM International Standards F1903 and F813 regarding cytotoxicity 
testing of particles and materials, respectively [324, 326, 352-353]. Only 1 and 10 mg 
CS/10
6
 cells samples (0.064 and 0.64 mg/ml, respectively), which experienced no 
significant difference in cell viability from live controls, fell within previously reported 
ranges for cytotoxicity testing (0-5 mg/mL) of CS-PLLA microspheres [326]. Taken 
together, these results indicated that CS materials did not appear to affect the morphology 
of stem cells when cultured at moderate concentrations.  
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Overall, these studies have demonstrated the formation of novel CS-based 
particles over a range of size scales with significant potential for use as ECM-derived 
carriers for delivery of charged growth factors to promote stem cell differentiation.  
 
4.5 Conclusions 
The results of these studies demonstrated that CS chains were successfully 
modified to form amphiphilic self-assembling CS micelles on a nanoscale (~73 nm and 
~320 nm), as well as microscale fabrication of CS microspheres (~4 µm) for a wide range 
of sizes, and that CS microspheres retained their ability to bind positively charged growth 
factors. This flexibility in particle size can potentially provide a large degree of control 
for release of cationic factors from these CS materials, and the use of naturally-derived 
polysaccharide matrix without modification by other polymers may be especially 
advantageous in better understanding the role of GAGs in cell differentiation. Therefore, 
CS nano- and microspheres with the ability to deliver growth factors via electrostatic 
interaction provides a controlled, yet extremely versatile platform to further explore 
means to direct differentiation of stem cells for a variety of applications in tissue 





CHEMICAL DESULFATION OF CHONDROITIN SULFATE FOR 




The highly sulfated GAGs heparin and heparan sulfate are known to play 
important roles in sequestration of positively charged growth factors in vivo, including 
basic fibroblast growth factor (bFGF), insulin-like growth factor (IGF), vascular 
endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and 
transforming growth factor-β (TGF-β) [263, 272, 319]. Specifically, sulfate groups 
contribute to the highly negative fixed charge density of sulfated GAGs and their 
associated proteoglycans, facilitating electrostatic interactions with basic amino acid 
residues in positively charged growth factors. Due to its high sulfation, heparin possesses 
a stronger affinity than less sulfated GAGs, including chondroitin sulfate and the 
nonsulfated GAG hyaluronan [268, 354-357], and selective desulfation of heparin 
modulates binding in a sulfation-dependent manner and with special importance of 2-O-
sulfation for binding [265-267, 269-271, 358-359].  
While heparin binding has been investigated in detail in vivo and in vitro, growth 
factor interactions with chondroitin sulfate (CS) have not been as well characterized. CS 
is especially prominent in cartilaginous tissues, as part of aggrecan proteoglycan, and 
while CS is known to play an important role in maintaining osmotic pressure within 
cartilaginous tissues, its role in growth factor signaling is currently not well understood. 
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Despite its lower degree of sulfation, compared to heparin, CS has also been shown to 
sequester several “heparin-binding” growth factors in vitro, and these electrostatic 
interactions have been exploited for controlled delivery and sustained release of growth 
factors, including PDGF-BB and IGF-1 [22, 262, 264]. Additionally, oversulfation of CS 
has been shown to enhance binding affinity in a sulfation-dependent manner, including to 
the chondrogenic growth factor TGF-β1, suggesting that sulfation regulates CS 
interactions with growth factors [25, 261]. 
While oversulfation of CS has been investigated to determine the role of sulfates 
in growth factor interactions, the nonsulfated GAG hyaluronan has commonly been used 
as a nonsulfated control. While hyaluronan is structurally similar to CS, hyaluronan plays 
very different roles than CS in vivo, and hyaluronan has activity independent of CS, 
including roles in ECM interactions, growth factor signaling, and known cell surface 
receptors like CD44 and receptor for hyaluronan-mediated motility (RHAMM) [360-
364]. Use of a nonsulfated chondroitin variant would facilitate proper comparison across 
varying degrees of sulfation, while maintaining a consistent polysaccharide backbone and 
structure and only altering the sulfation pattern and resulting charge density of CS-based 
materials. The role of a nonsulfated chondroitin in growth factor binding and signaling 
has yet to be investigated; therefore, to further investigate the role of sulfation in 
interactions with growth factors, CS was chemically desulfated via acid methanol 
treatment to produce chondroitin. Desulfated chondroitin was then characterized for 
sulfation pattern and total charge to ensure that sulfates were removed without significant 
modification of the remaining GAG backbone. 
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As a naturally-derived cartilaginous ECM molecule, CS is a promising material 
for cartilage differentiation and repair. Additionally, the natural ability of CS to sequester 
growth factors may facilitate interaction with chondrogenic growth factors, such as TGF-
β1, IGF-1, and various bone morphogenetic proteins (BMPs), while controlled 
desulfation of CS materials would offer further control over growth factor retention and 
release to promote differentiation of mesenchymal stem cells (MSCs). To examine the 
role of sulfation in growth factor interactions, CS and chondroitin were methacrylated 
and crosslinked in order to form bulk CS and chondroitin-based hydrogels containing 
varying ratios of CS and chondroitin to alter the relative degree of sulfation within the 
constructs. Release of chondrogenic growth factor TGF-β1 from CS and chondroitin 
hydrogels over 7 days and sequestration of soluble TGF-β1 out of solution were 
determined to examine the role of sulfation on interactions with TGF-β1. 
 
5.2 Materials and Methods 
5.2.1 Desulfation of Chondroitin Sulfate 
Chondroitin sulfate was desulfated using an acidic methanol treatment for up to 7 
days per established protocols [365-366]. Chondroitin sulfate A (primarily chondroitin-4-
sulfate, Sigma-Aldrich, St. Louis, MO) or chondroitin sulfate C (primarily chondroitin-6-
sulfate, Wako Chemicals USA, Richmond, VA) was stirred at 5.0 mg/mL in methanol 
(VWR, Radnor, PA) containing 0.5% v/v acetyl chloride (Acros Organics, Geel, 
Belgium). CS was centrifuged and acidic methanol was replaced either on days 1, 2, and 
3 for a 3-day reaction or on days 1, 3, and 7 for a 7-day reaction to produce a methyl ester 
of chondroitin (Figure 5.1). The product was then dissolved in 20 mL distilled, deionized 
 
95 
water (ddH2O) per gram of starting CS before precipitation in an excess of ethanol. The 
methyl ester of chondroitin was washed in ethanol and ethyl ether (Fisher, Waltham, 
MA), vacuum dried at <5 mmHg, and stored at 4 °C. 
Methyl ester of chondroitin was demethylated at 25 mg/mL in 0.1 M potassium 
hydroxide (KOH, Fisher) for 24 hours to produce chondroitin (Figure 5.1). The 
chondroitin product was then neutralized in 4 mL 100 mg/mL potassium acetate (Fisher) 
in 10% v/v acetic acid (VWR) per gram of starting product, and precipitated in an excess 
of ethanol. Chondroitin was washed in ethanol and ethyl ether, vacuum dried, and stored 
at 4°C until use. 
 
 
Figure 5.1. Desulfation reaction of chondroitin sulfate. Chondroitin sulfate was 
desulfated in acidic method for up to 7 days to form a methyl ester of chondroitin. 
The methyl ester was demethylated in potassium hydroxide for 24 hours to yield 
chondroitin. 
 
5.2.2 Characterization of Desulfated Chondroitin 
5.2.2.1 Dimethylmethylene Blue Assay 
Removal of sulfate groups in chondroitin was confirmed by dimethylmethylene 
blue (DMMB) assay for sulfated GAGs [302]. Standard curves from 0 to 50 μg/mL 
chondroitin or chondroitin sulfate were assayed according to established protocols by 
DMMB, and absorbance was measured at 520 nm in a plate reader (SpectraMax M2e; 
Molecular Devices, Sunnyvale, CA) as a measure of sulfation. The slopes of the 
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chondroitin standard curves were compared to the CS standard curve to determine 
percent desulfation of the chondroitin product.  
5.2.2.2 Fourier Transform Infrared Spectroscopy 
Because chondroitin sulfate C after 7 days in acidic methanol showed the greatest 
degree of sulfation, that chondroitin product was used in all future experiments, and 
compared to unmodified CS-C. To further verify the removal of sulfate groups in 
chondroitin, CS and chondroitin materials were analyzed by Fourier transform infrared 
(FTIR) spectroscopy. A 3 mg/mL solution of CS and desulfated chondroitin in deuterated 
water (D2O; Sigma-Aldrich) were spin coated onto a silicon crystal and FTIR was 
measured using a Bruker Vertex 70 ATR-FTIR spectrometer (Billerica, MA) with 
atmospheric compensation.  
5.2.2.3 Strong Anion Exchange High Performance Liquid Chromatography 
Samples were analyzed by strong anion exchange high performance liquid 
chromatography (SAX-HPLC) by the University of Georgia Complex Carbohydrate 
Research Center (CCRC) to determine the disaccharide composition and average charge 
density of the CS and chondroitin materials. A 1 mg/mL GAG solution of either CS or 
chondroitin in 50 mM ammonium acetate (NH4OAc) buffer, pH 8 was digested into 
disaccharides by 0.1 mU/mL of chondroitinase ABC (Sigma-Aldrich) at 37°C for 24 
hours. The chondroitinase enzyme was inactivated by heating to 100°C for 2 minutes, 
and the sample was centrifuged prior to HPLC analysis. 
SAX-HPLC was carried out on an Agilent 1200 system (Santa Clara, CA) using a 
4.6250 mm Waters Spherisorb analytical column (Milford, MA) with 5 m particle size 
at 25°C, using an injection volume of 10 μL and a flow rate of 1.0 mL/min. The 2.5 mM 
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sodium phosphate (Na3PO4) solvent at pH 3.5 was transitioned from a concentration of 
0.036 M NaCl up to 1.2 M NaCl over the course of 55 minutes, gradually increasing the 
ionic strength of the buffer and causing elution of the disaccharides based on electrostatic 
charge, with more negatively charged disaccharides eluting later.  
Disaccharide detection was performed by post-column derivatization. A 1:1 
mixture of 0.25 M NaOH and 1% 2-cyanoacetamide was added to the eluent from the 
column from a binary HPLC pump at 0.5 mL/min. The eluent was then heated to 120°C 
in a 10-m reaction coil, followed by cooling in a 50-cm cooling coil, and directed into a 
Shimadzu fluorescence detector (excitation: 346 nm, emission: 410 nm; Kyoto, Japan). 
Based on these results, a predictive model was used to calculate average charge, based on 
known disaccharide structures containing negatively charged sulfate and carboxylate 
groups. 
5.2.2.4 Size Exclusion High Performance Liquid Chromatography 
 CS and chondroitin samples were also analyzed by size exclusion high 
performance liquid chromatography (SEC-HPLC) by the University of Georgia CCRC to 
determine the average molecular weight of the CS and chondroitin chains. Solutions of 
CS or chondroitin were prepared at 2 mg/mL in 50 mM sodium sulfate (Na2SO4) buffer, 
pH 5.0, and partially depolymerized heparin fractions (4.2, 9.0, 12.0, 15.0, and 20.0 kDa) 
were used as molecular weight standards. Separations were carried out using a TSKGel 
G3000SWXL column (Tosoh Bioscience, Stuggart, Germany, 7.8 mm ID x 30 cm) and a 
TSKGel G2000SWXL column (7.8 mm ID x 30 cm), connected in series, on an Agilent 
1200 LC instrument using refractive index detection with an injection volume of 50 μL 
and a flow rate of 0.5 mL/min.  
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A standard curve was constructed based on the molecular weights and elution 
volumes of the heparin standards. The data were baseline corrected, and the retention 
times were converted to molecular weights using the standard curve. The weight fraction 
wi of each data point was calculated by dividing the detector response by the sum of 
detector responses over the whole peak width. The weight average molecular mass was 
calculated as Mw=∑wiMi, and the number average molecular mass was calculated as 
Mn=1/∑(wi/Mi). Polydispersity index (PI) was calculated as PI=Mw/Mn. 
5.2.3 Synthesis of Crosslinkable Hydrogel Materials 
5.2.3.1 PEG-DA Synthesis 
Poly(ethylene glycol)-diacrylate (PEG-DA) polymers were synthesized according 
to established protocols [191]. 3,400 Da (Mn) PEG (Sigma-Aldrich) was solubilized in 
distilled, anhydrous methylene chloride (MeCl, Fisher) to produce a 60% (m/v) solution. 
Triethylamine (TEA, Sigma-Aldrich) was added to the dissolved PEG, and acryloyl 
chloride (AcCl, Sigma-Aldrich) was slowly added dropwise at 2:1 AcCl:PEG and 1:1 
AcCl:TEA molar ratios to create a 40% w/v solution. The reaction was allowed to 
proceed at room temperature under nitrogen gas, and the reaction was left stirring 
overnight to ensure completion. 2 M potassium carbonate (K2CO3, Fisher) was used at a 
2:1 K2CO3:AcCl molar ratio to extract TEA to the aqueous phase. The organic phase was 
allowed to separate from the aqueous phase, and anhydrous magnesium sulfate (MgSO4, 
Fisher) was used to remove any remaining aqueous phase from the solution. PEG-DA 
was then precipitated in ethyl ether and filtered, followed by vacuum drying at <5 mmHg. 




5.2.3.2 OPF Polymer Synthesis 
Oligo(poly(ethylene glycol) fumarate) 10K polymers were synthesized according 
to established protocols [367]. 10,000 Da (Mn) PEG (Sigma-Aldrich) was azeotropically 
distilled in toluene (Fisher) and then combined with distilled, anhydrous MeCl to produce 
a 40% (v/v) solution. Fumaryl chloride (FuCl, Sigma-Aldrich) and TEA were slowly 
added dropwise over a period of 2 hours at 0.9 FuCl:PEG and 1:2 FuCl:TEA molar 
ratios. During this time, the reaction was allowed to proceed at 0°C under nitrogen gas, 
after which the reaction was left stirring for 72 hours under nitrogen at room temperature 
to ensure reaction completion. After rotovaporing (Buchi, Flawil, Switzerland) to remove 
excess MeCl, the resulting polymer was recrystallized twice with ethyl acetate (Fisher) 
and washed three times in ethyl ether, followed by vacuum drying at <5 mmHg. Dry 
polymers were stored in sealed containers at -20°C before use.  
5.2.3.3 Methacrylation of Chondroitin Sulfate and Chondroitin 
CS and chondroitin were methacrylated with glycidyl methacrylate per 
established protocols [368]. CS or chondroitin was dissolved at 1% w/v in a 50:50 
mixture of acetone (VWR) and ddH2O and allowed to stir at room temperature overnight. 
A 20-fold molar excess of TEA per CS or chondroitin disaccharide was added to the 
solution, and a 20-fold molar excess of glycidyl methacrylate (GMA, Sigma-Aldrich) per 
disaccharide was added dropwise to the solution. The reaction was allowed to stir at room 
temperature for 24 hours to produce CS-methacrylate (CS-MA) (Figure 5.2) and 
chondroitin-methacrylate (Ch-MA). The resulting products were dialyzed first in 50:50 
acetone:water for 24 hours (1,000 Da MWCO), and then in distilled water (dH2O) for 2 
days to remove unreacted reagents. The methacrylated products were lyophilized 
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(Labconco, Kansas City, MO) for 4 days to produce a dry product, and stored at -20°C 
until use.  
 
 
Figure 5.2. Chondroitin sulfate methacrylation reaction. Chondroitin sulfate was 
methacrylated with glycidyl methacrylate in 50:50 acetone:ddH2O for 24 hours in 
the presence of triethylamine to form chondroitin sulfate methacrylate (CS-MA). 
 
5.2.4 Characterization of Crosslinkable Hydrogel Materials 
5.2.4.1 Gel Permeation Chromatography 
PEG-DA (Mn = 3760 ± 50, PI = 1.1 ± 0.02), PEG 3.4K (Mn = 3440 ± 30, PI = 1.1 
± 0.001), OPF 10K (Mn = 28,100 ± 760, PI = 5.2 ± 0.4), and PEG 10K (Mn = 12,900 ± 
210; PI = 1.1 ± 0.002) were characterized via gel permeation chromatography as 
previously reported [174]. The molecular weight distribution of PEG-based polymers was 
characterized by gel permeation chromatography (Prominence; Shimadzu) equipped with 
a refractive index detector (Shimadzu). Polymer samples were dissolved in chloroform, 
filtered (0.45 μm filter, Whatman, Maidstone, UK), and injected into a column (Waters) 
at a flow rate of 1 mL/min (n=3).  
5.2.4.2 Proton Nuclear Magnetic Resonance  
Proton nuclear magnetic resonance (
1
H NMR) was utilized to determine the 
degree of the conjugation of the GMA groups to the CS and chondroitin chains. The 
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initial components (CS, chondroitin, and GMA) and resulting modified products (CS-MA 
and Ch-MA) were solubilized in D2O, and 
1
H NMR was measured on a Bruker AMX-
400 spectrometer at 400 MHz. The resulting spectra were analyzed by calibrating the 
region from 4.18-3.75 ppm according to the known number of protons in the chondroitin 
sulfate backbone, providing an internal standard to determine the degree of modification 
by the methacrylation reaction.  
5.2.4.3 Degradation of Modified Chondroitin Sulfate and Chondroitin Materials 
To determine if the ability of chondroitinase enzyme to degrade CS was affected 
by either desulfation, methacrylation, or crosslinking, the degradation of modified CS-
MA and Ch-MA was determined in solution and in crosslinked hydrogels. Soluble 
chondroitinase activity was assayed per established protocols [369-371]. 2 mg/mL CS-
MA and chondroitin-MA solutions in a buffer of 250 mM 
tris(hydroxymethyl)aminomethane (Tris, Sigma-Aldrich), 300 mM sodium acetate 
(Sigma-Aldrich) with 0.05% bovine serum albumin (BSA, Sigma-Aldrich) at pH 8.0 
were incubated with 0.06 U/mL chondroitinase ABC. Accumulation of the Δ
4,5
-
unsaturated disaccharide degradation product at 37°C was monitored by measuring the 
increase in absorbance at 232 nm UV light in a UV-transparent 96-well assay plate 
(Corning Incorporated, Corning, NY) by a plate reader (SpectraMax M2e; Molecular 
Devices) every minute for 1 hour, compared to CS-MA and Ch-MA blanks without 
enzyme (n=3).  
To determine the ability of crosslinked CS-MA and Ch-MA hydrogels to degrade 
in the presence of chondroitinase enzyme, 100% CS-MA or 100% Ch-MA hydrogels at 
90 wt% H2O were crosslinked in 6 mm diameter, 1 mm deep cylindrical molds with 
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0.018 M ammonium persulfate (APS, Sigma-Aldrich) and tetramethylethylenediamine 
(TEMED, Sigma-Aldrich) for 10 minutes at 37 °C, and swelled overnight in phosphate-
buffered saline (PBS). CS-MA and Ch-MA hydrogels were then transferred into 0.125 
U/mL chondroitinase ABC in 250 mM Tris, 300mM sodium acetate buffer with 0.05% 
BSA at pH 8.0 and incubated at 37°C. Complete degradation was determined when the 
bulk hydrogel was no longer visible in solution (n=3).  
5.2.4.4 Swelling of GAG/PEG Hydrogels 
Polymer solutions containing a 1:1 ratio of OPF 10K:PEG-DA and either 10% or 
50% CS-MA or Ch-MA at 90% water content in PBS were crosslinked in 6 mm 
diameter, 1 mm deep cylindrical molds with 0.018 M APS/TEMED thermal initiator 
system for 10 minutes at 37°C, and swelled overnight in PBS. A 60% PEG-DA:40% OPF 
mixture that possessed similar swelling properties to 50% Ch-MA formulations was used 
as a PEG-only swelling control for 50% Ch-MA. After 1 day swelling in PBS, the wet 
weight of crosslinked hydrogels was recorded, and following lyophilization overnight, 
dry weight was recorded. Swelling ratio was calculated as wet weight/dry weight (n=5).  
As an estimate of osmotic pressure based on fixed negative charge in GAG 
hydrogels, Donnan swelling pressure was estimated in a 0.15 M NaCl solution at 37°C. 
According to Donnan equilibrium, electroneutrality, and osmotic pressure laws, Donnan 
osmotic pressure is calculated by the equation: 
                        





), T is the absolute temperature (310 K), c
F
 is the fixed charge density in mol of 
charge per L of interstitial fluid, and c
*
 is the salt concentration of the external electrolyte 
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solution (0.15 M NaCl) [372-374]. Fixed charge density was calculated based on the 
GAG disaccharide concentration in the hydrogels, as well as the average charge per 
disaccharide, determined by SAX-HPLC, as described in Section 5.2.2.3. 
5.2.5 Interaction of CS and Chondroitin Hydrogels with TGF-β1 
5.2.5.1 Release of TGF-β1 from CS and Chondroitin Hydrogels 
To investigate the role of sulfate moieties in the electrostatic complexation and 
release of positively charged TGF-β1, 1:1 OPF:PEG-DA hydrogels containing 10% CS-
MA, 50% CS-MA, or 50% Ch-MA (90 wt% H2O) were sterilely crosslinked in 6 mm 
diameter, 1 mm deep cylindrical molds with 0.018 M APS/TEMED for 10 minutes at 
37°C, and swelled overnight in PBS. Hydrogels were then lyophilized for 24 hours, and 
loaded by reswelling with 15 µL of 12.5 µg/mL TGF-β1 solution (Peprotech, Rocky Hill, 
NJ) for 16 hours at 4°C. Loading correlated to a ~1:500,000 TGF-β:disaccharide molar 
ratio in 50% GAG hydrogels and to a ~1:100,000 TGF-β:disaccharide molar ratio in 10% 
CS. Hydrogels were then incubated at 37°C in 500 μL 1% BSA in PBS for 7 days. At 0, 
5, 12, and 24 hours, and after 2, 3, 5, and 7 days, the supernatant was sampled and 
analyzed for TGF-β1 content by enzyme-linked immunosorbent assay (ELISA, R&D 
Systems, Minneapolis, MN). Cumulative release was calculated for each hydrogel over 7 
days (n=4).  
5.2.5.2 Formation of 50% Total GAG Hydrogels with Varying Sulfation 
To demonstrate that hydrogels can be fabricated with a constant GAG content and 
varying degrees of sulfation, CS-MA and Ch-MA were incorporated into 1:1 OPF:PEG-
DA hydrogels at varying mass ratios while maintaining total GAG content constant at 50 
wt%, according to Table 5.1. A 60% PEG-DA:40% OPF mixture that possessed similar 
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swelling properties to 50% Ch-MA formulations was used as a PEG-only swelling 
control for 50% Ch-MA. Polymer was dissolved in PBS for an initial water content of 
90% w/w, and all macromer solutions were filter sterilized through a 0.2 μm pore filter 
(Nalgene, Rochester, NY). 30 μL of macromer solution was crosslinked with 0.018 M 
APS/TEMED for 10 minutes at 37°C in cylindrical molds, resulting in hydrogel disks 
that were 6 mm diameter and 1 mm thick. All hydrogels were swelled in PBS. After 7 
days in PBS to demonstrate the retention of GAG, hydrogels were stained overnight in 
DMMB solution (n=2).  
 
Table 5.1. Hydrogel formulations with 50 wt% total GAG 
 
Mass Ratios of Total Dry Polymer 
CS-MA Ch-MA PEG-DA OPF 10K 
50% CS-MA 50% 0% 25% 25% 
10% CS-MA/ 
40% Ch-MA 
10% 40% 25% 25% 
1% CS-MA/ 
49% Ch-MA 
1% 49% 25% 25% 
50% Ch-MA 0% 50% 25% 25% 
PEG Control 0% 0% 60% 40% 
 
5.2.5.3 Pull-Down (Depletion) of TGF-β1 from Solution by CS-MA and Ch-MA 
Hydrogels 
To investigate the role of sulfation in TGF-β1 sequestration by 3D hydrogels, 
TGF-β1 pull-down (or depletion) from solution by PEG-based hydrogels containing 
varying amounts of CS-MA or desulfated Ch-MA was investigated. CS-MA and Ch-MA 
hydrogels were fabricated as described in Section 5.2.5.2, according to the 50% CS-MA, 
10% CS-MA/40% Ch-MA, and 50% Ch-MA formulations in Table 5.1. A 60% PEG-
DA:40% OPF mixture that possessed a similar swelling properties to 50% Ch-MA 
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formulations was used as a PEG-only swelling control. All hydrogels were swelled 
overnight in PBS.  
After unconstrained swelling in PBS overnight, hydrogels were incubated in 1.0 
mL solution of 2.0 ng/mL TGF-β1 in 1% BSA in PBS for 24 hours at 37°C with gentle 
shaking. To inhibit electrostatic binding with hydrogels, pull-down was also measured 
with an additional 0.5 M NaCl or 10 mg/mL soluble CS in the TGF-β1 solution. The 
TGF-β:disaccharide molar ratio in the solutions correlated to a ~1:50,000,000 molar ratio 
in 50% GAG hydrogels and to a ~1:10,000,000 molar ratio in 10% CS. After 24 hours, 
the supernatant was collected and frozen at -20°C until analysis. TGF-β1 pull-down by 
the hydrogels was determined by assaying the remaining TGF-β1 in solution by ELISA 
(n=5). 
5.2.6 Statistical Analysis 
All values were reported as mean ± standard deviation. A one- or two-factor 
analysis of variance (ANOVA) was used to determine statistical significance of groups, 
and Tukey's post hoc multiple comparison test with significance set at p≤0.05 indicated 
significance between individual samples. For all one-factor ANOVAs (swelling and 
TGF-β1 release), the factor was hydrogel type. For pull-down experiments, the two 
factors were hydrogel type and buffer composition. Statistical analysis was carried out 





5.3.1 CS-C was desulfated after 7-day acidic methanol treatment 
DMMB assay was used to measure sulfation level of the chondroitin products 
after acidic methanol treatment. While CS-A only experienced 54% desulfation after 3 
days, CS-C experienced removal of 80% of the sulfates after the same time (Figure 5.3a). 
Extension of the acidic methanol treatment time from 3 to 7 days resulted in nearly 
complete desulfation of CS-C, as indicated by zero slope in the desulfated chondroitin 
standard curve by DMMB assay. As further confirmation of desulfation, FTIR 
spectroscopy was used to examine the bonds present in CS and chondroitin. FTIR 
spectroscopy verified the disappearance of sulfate peaks at 1100-1250 cm
-1
 (Figure 5.3b, 
black box), while the remaining bonds in CS appeared to remain unchanged.  
 
 
Figure 5.3. CS-C was desulfated by acidic methanol treatment for 7 days. (a) 
Dimethylmethylene blue (DMMB) assay standards for CS showed a linear trend 
with positive slope, indicating the presence of sulfates; however, the standard for the 
chondroitin product from CS-C desulfated for 7 days showed zero slope indicating 
the absence of sulfate groups in chondroitin. CS-A and CS-C experienced 
incomplete desulfation after 3 days, but CS-C showed greater susceptibility to 
desulfation in the same time than CS-A. (b) Fourier transform infrared (FTIR) 
spectroscopy showed the absence of sulfate peaks from 1100-1250 cm
-1
 (in black 




5.3.2 Disaccharide composition of chondroitin indicated a reduction of negative 
charge density 
SAX-HPLC analysis was performed to determine the disaccharide composition of 
CS-C and desulfated chondroitin. It was determined that CS-C disaccharides were 
approximately 57.8% 6-sulfated and 26.8% 4-sulfated, as well as 1.3% nonsulfated 
(Table 5.2). The desulfated chondroitin product, however, was 98.5% nonsulfated and 
only 1.5% 6-sulfated. From the elution profiles, nonsulfated disaccharides, which are the 
least charged, eluted earliest (9-11 min), followed by the monosulfated disaccharides (18-
23 min), and the most negatively charged disulfated disaccharides eluting latest (41-47 
min) (Figure 5.4a-b). The observed shift in desulfated chondroitin to a primarily 
nonsulfated form also indicates a reduction in negative charge density in chondroitin, 
compared to CS. Based on these results, a predictive model calculated CS to have an 
average charge of -2.3 per disaccharide, while chondroitin had an average charge of -
1.02, indicating that desulfation resulted in a decrease in negative charge density of CS 
by over two-fold.  
 














CS 1.3% 57.8% 26.8% 12.7% 0.7% 0.7% 
Chondroitin 98.5% 1.5% nd Nd nd nd 
ΔUA = Δ
4,5
-unsaturated uronic acid, GalNAc = N-acetylgalactosamine, nd = not detected  
 
SEC-HPLC analysis was also performed to determine the average molecular 
weight of the full CS and chondroitin chains. It was determined that CS had a weight 
averaged molecular mass (Mw) of 17,880 Da and a number averaged molecular mass 
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(Mn) of 16,300 Da (PI=1.1) (Figure 5.4c). Chondroitin, however, was notably smaller 
with an Mw of 6,310 Da and an Mn of 5,230 Da (PI=1.2), resulting in a later elution time 
than CS (Figure 5.4d). This represented a 67.9% decrease in molecular weight (Mn) from 
CS, while sulfates only accounted for 17.1% of mass based on disaccharide composition. 
 
 
Figure 5.4. SAX-HPLC and SEC-HPLC analysis of CS and chondroitin. (a-b) SAX-
HPLC analysis of (a) CS and (b) chondroitin disaccharide composition showed a 
shift in negative charge density in CS and chondroitin materials. Nonsulfated 
disaccharides (charge: -1) eluted from 9-11 min, monosulfated disaccharides 
(charge: -2) eluted from 18-23 min, and disulfated disaccharides (charge: -3) eluted 
from 41-47 min. Based on disaccharide composition, CS possessed an average 
charge of -2.3 per disaccharide, while chondroitin was 98.5% nonsulfated and 
possessed an average charge of -1.02 per disaccharide. (c-d) SEC-HPLC analysis of 
(c) CS and (d) chondroitin molecular weight suggested that while CS had a Mn of 
16.3 kDa (PI=1.1), and chondroitin was smaller with an Mn of 5.23 kDa (PI=1.2), 









 NMR spectra indicated that GMA was successfully conjugated to CS. Vinyl 
peaks were visible at 5.6 and 6.0 ppm, confirming the methacrylation of CS and 
chondroitin by GMA to form CS-MA and Ch-MA, respectively (Figure 5.5, in black 
boxes). Peak integration also indicated that on average one GMA molecule was 





H NMR analysis of methacrylated CS and chondroitin. 
1
H NMR 
confirmed methacrylation of CS and chondroitin with glycidyl methacrylate. 
Compared to (a) CS and (b) chondroitin, 
1
H NMR spectra verified the presence of 
vinyl groups (in black boxes) in (c) CS-MA and (d) Ch-MA at 5.6 and 6.0 ppm, 




5.3.4 Chondroitinase ABC maintains enzymatic activity to degrade CS-MA and Ch-
MA 
Soluble methacrylated CS and chondroitin degraded in chondroitinase ABC with 
an increase in absorbance of 232 nm UV light over time, indicating an increase of Δ
4,5
-
unsaturated disaccharide degradation products (Figure 5.6). Complete degradation of CS-
MA and Ch-MA occurred within ~30 minutes in solution. Additionally, crosslinked CS-
MA and Ch-MA hydrogels completely degraded overnight in chondroitinase enzyme.  
 
 
Figure 5.6. Degradation of CS-MA and Ch-MA by chondroitinase ABC. 2 mg/mL 
soluble CS-MA and chondroitin-MA materials were degradable in the presence of 
0.06 U/mL chondroitinase ABC, as detected by absorbance of 232 nm light. 
 
5.3.5 Swelling of PEG hydrogels containing CS-MA and Ch-MA  
50% CS-MA hydrogels possessed a fold swelling ratio of 25.2 ± 1.4, and 50% 
CS-MA swelled signficantly more than 50% Ch-MA hydrogels which swelled 16.9 ± 2.1 
fold. 10% CS-MA with a 22.7 ± 2.4 fold swelling ratio, however, did not swell 
significantly differently from 50% CS-MA (Figure 5.7a). 60% PEG-DA/40% OPF 10K 
hydrogels (17.1 ± 0.5 fold) that swell similarly to 50% Ch-MA hydrogels were fabricated 
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as a PEG-based swelling control. Based on estimatations of Donnan osmotic pressure in a 
0.15 M NaCl electrolyte solution, 50% CS-MA hydrogels possessed an osmotic pressure 
of 280 kPa while 50% Ch-MA hydrogels had lower osmotic pressure of 93 kPa, 
representing a 3.0-fold difference in osmotic swelling pressure based on charge alone.  
5.3.6 TGF-β1 retention and release by CS and chondrotin 
TGF-β1 release studies from CS-MA and Ch-MA hydrogels observed increased 
release of TGF-β1 correlating with decreased sulfation. Hydrogels containing 50% CS 
displayed the greatest retention of TGF-β1 over 7 days, with only 3.6 ± 1.0 ng TGF-β1 
released after 7 days (Figure 5.7b). 10% CS hydrogels demonstrated significantly greater 
TGF-β1 release than 50% CS-MA with 5.6 ± 0.5 ng TGF-β1 released. Additionally, 50% 
chondroitin hydrogels exhibited the greatest release of 6.8 ± 0.2 ng TGF-β1.  
 
 
Figure 5.7. Swelling and TGF-β1 release from CS-MA and Ch-MA hydrogels. (a) 
Crosslinked 50% Ch-MA hydrogels swelled significantly less than 50% CS-MA and 
10% CS-MA hydrogels. 40% OPF/60% PEG-DA hydrogels were formed as PEG-
based swelling controls for 50% Ch-MA. (b) 50% CS-MA hydrogels demonstrated 
greatest retention of TGF-β1 over 7 days, while 10% CS-MA gels exhibited greater 
release, and 50% chondroitin-MA gels displayed the greatest release, indicating that 
TGF-β1 release decreased with increasing degrees of sulfation. * indicates 
significantly lower fold swelling that 50% CS-MA (p≤0.05). # indicates significantly 
lower fold swelling that 10% CS-MA (p≤0.05). + indicates significantly greater 




5.3.7 TGF-β1 pull-down by hydrogels with varying CS content 
GAG-containing hydrogels were fabricated containing varying amounts of CS-
MA. While total GAG was maintained at 50 wt%, the fraction of CS-MA was varied with 
the remainder balanced with nonsulfated Ch-MA. A pink/purple color indicated the 
present of sulfated GAG in a concentration-dependent manner, while a blue color 
indicated the absence of sulfates. Staining with DMMB indicated that CS-containing 
hydrogels stained positively for sulfation after 7 days, and increasing degrees of staining 
were apparent in hydrogels as sulfation increased up to 50% CS, while PEG only 
hydrogels remained blue (Figure 5.8a).  
In pull-down (depletion) studies from solution, all hydrogels exhibited significant 
pull-down of TGF-β1, compared to blank wells without gels, where less TGF-β1 
remaining in solution indicated greater pull-down; however, pull-down in 50% CS-MA 
hydrogels was significantly greater than less sulfated hydrogel formulations (Figure 
5.8b). 50% CS-MA depleted 55.9 ± 1.5% of available TGF-β1 out of solution, compared 
to blanks. Ch-MA and PEG control hydrogels, on the other hand, experienced the least 
pull-down of TGF-β1 with 29.4 ± 2.7% and 33.8 ± 3.0% depletion, respectively. 
Hydrogels containing 10% CS-MA/40% Ch-MA responded in a concentration-dependent 
manner with 36.4 ± 3.3% depletion, which was significantly greater pull-down than 50% 
Ch-MA and less than 50% CS-MA, indicating that greater depletion of TGF-β1 was 




Figure 5.8. TGF-β1 pull-down by CS-MA and Ch-MA hydrogels with varying 
degrees of sulfation. (a) DMMB staining indicated increasing degrees of sulfation in 
hydrogels from 0% to 50% CS-MA content after 7 days. Sulfated GAGs stained 
purple/pink, while nonsulfated materials remained blue. All hydrogels contained 
50% total GAG (with CS balanced with chondroitin). Scale bars = 1.0 mm. (b) All 
hydrogels demonstrated significant pull-down compared to blanks (p≤0.05), where 
less TGF-β1 remaining in solution indicated greater pull-down. 50% CS-MA 
hydrogel exhibited the greatest pull-down of soluble TGF-β1 out of solution, while 
nonsulfated 50% Ch-MA and PEG control hydrogels exhibited the least depletion in 
1% BSA. 10% CS-MA/40% Ch-MA hydrogels corresponded in a sulfation-
dependent manner with an intermediate level of depletion. Incubation in 0.5 M 
NaCl and 10 mg/ml soluble CS significantly decreased depletion by 50% Ch-MA, 
but not 50% CS-MA hydrogels. § indicates significantly greater pull-down than 
PEG controls (p≤0.05). * indicates significantly greater pull-down than 50% Ch-MA 
(p≤0.05). # indicates significantly greater pull-down than 10% CS-MA/40% Ch-MA 
(p≤0.05). + indicates significantly less pull-down than the same hydrogel type in 1% 
BSA (p≤0.05). 
 
In the presence of 0.5 M NaCl, pull-down of TGF-β1 by 50% Ch-MA and 10% 
CS-MA/40% Ch-MA hydrogels significantly decreased, while pull-down by 50% CS-
MA did not decrease. Depletion by 50% Ch-MA hydrogels decreased to 14.8 ± 2.0%, and 
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depletion by 10% CS-MA/40% Ch-MA decreased to 23.0 ± 2.7% in 0.5 M NaCl. 
Additionally, in 10 mg/mL soluble CS, a similar response was observed. In the presence 
of 10 mg/mL soluble CS, pull-down by 50% Ch-MA hydrogel was significantly 
decreased to 16.4 ± 1.8% depletion; however, pull-down by crosslinked 50% CS-MA 
hydrogels did not decrease. TGF-β1 pull-down by PEG control hydrogels, on the other 
hand, remained unchanged in 0.5 M NaCl, compared to in 1% BSA, with 33.1 ± 3.5% 
depletion, while soluble CS resulted in a slight decrease in depletion by PEG controls to 
26.7 ± 5.5%. 
 
5.4 Discussion 
Together these studies demonstrated that CS could be desulfated without 
modification of the original CS chemical structure, CS and chondroitin materials could be 
crosslinked to form hydrogels, and CS-based hydrogels sequestered TGF-β1 in a 
sulfation-dependent manner. Chondroitin sulfate C was successfully desulfated by acidic 
methanol treatment after 7 days to yield chondroitin. DMMB assay, FTIR spectroscopy, 
and SAX-HPLC collectively indicated that chondroitin was ~98.5% nonsulfated after 7 
days of chemical desulfation (Figures 5.3, 5.4a-b). FTIR and SAX-HPLC analysis also 
suggested that the remaining bonds and chemical structure of the CS disaccharides 
appeared to remain unmodified, and that desulfation was specific to removal of the 
sulfate groups. SAX-HPLC estimated that desulfation of CS resulted in a 2.3-fold 
reduction in negative charge density, due to removal of negatively charged sulfates 
(Figure 5.4a-b); however, due to the presence of carboxylates in the GAG backbone, 
chondroitin chains remained moderately negatively charged with approximately one 
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negatively charged group per disaccharide unit. These results present desulfated 
chondroitin materials as a highly controlled system to investigate of the role of sulfation 
and resulting negative charge density, without altering the chemical composition of the 
remaining polysaccharide GAG backbone.  
Additionally, results from the DMMB assay suggested that CS-C, which is 
primarily sulfated at the 6-carbon, may be more susceptible to desulfation by acidic 
methanol treatment than CS-A, which is sulfated at the 4-carbon. After 3 days, CS-C 
underwent 80% desulfation, while CS-A only exhibited 54% desulfation, as measured by 
DMMB assay, suggesting that sulfation of the 6-carbon was more susceptible to cleavage 
by acidic methanol treatment. The 6-carbon of the N-acetylgalactosamine sugar of CS 
hangs away from the ring structure (Figure 5.1), while the 4-carbon is one of the 
members of the ring. This suggests that the ring structure may either limit accessibility to 
4-O-sulfates for cleavage or may decrease the susceptibility of the 4-carbon to 
modification, slowing the rate of desulfation. Extended treatment with acid methanol 
after 7 days resulted in nearly complete desulfation of CS-C, suggesting that desulfation 
of CS was time-dependent with increasing desulfation over time (Figure 5.3a). These 
results suggested that a wide range of degrees of sulfation could be produced by 
increasing or decreasing the treatment time up to 7 days. In conjugation with various 
chemical methods of oversulfation [25-26], a diverse assortment of sulfated materials, 
with varying degrees of charge, could be developed from a single GAG structure. While 
desulfated chondroitin remains moderately negatively charged due to the presence of 
carboxylates, desulfation by acid methanol treatment methylated these carboxylate 
groups, producing a neutrally charged methyl ester intermediate. While this intermediate 
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was subsequently demethylated in KOH to form chondroitin for the purposes of these 
studies in which only sulfation was altered, the methyl ester of chondroitin could 
potentially be used as a neutrally charged alternative for further control of charge to study 
electrostatic interactions with GAGs.  
SEC-HPLC analysis, however, suggested that desulfated chondroitin chains may 
be of shorter average length than the starting CS chains (Figure 5.4c-d). Acidic methanol 
treatment for 7 days may result in some degradation or chain shortening in chondroitin 
materials, possibly due to hydrolysis at low pH. To accurately characterize the true 
molecular weight of these materials, however, HPLC analysis would require further 
investigation to examine the interaction of charged GAG chains with the chromatography 
columns. In these experiments, the molecular weights of CS and chondroitin, which 
possess varying degrees of charge, were quantified relative to standards of partially 
depolymerized heparin, which is even more negatively charged than CS; therefore, a 
more thorough investigation would be required in differing buffer compositions to 
minimize the differential interactions of negatively charged GAG chains with the 
columns and to accurately quantify the molecular masses of CS and chondroitin. If 
further analysis determines that the average chain length of chondroitin is, in fact, 
substantially shorter than CS, the reaction parameters of the acid methanol treatment may 
be altered to minimize degradation. While shorter reaction time in 0.5% v/v acetyl 
chloride resulted in incomplete desulfation after 3 days, altering the concentration of 
reagents along with reaction time may be able to limit potential degradation of 
chondroitin. Reaction in either lower concentrations of acetyl chloride for a longer time 
or higher concentrations for a shorter time may be able to minimize potential chain 
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shortening in chondroitin materials. Additionally, other chemical and enzymatic 
procedures have been developed to desulfate CS, and these techniques could be explored 
as alternative chemistries to prevent degradation of chondroitin chains [375-378].  
Nevertheless, while molecular weight is important in material properties and 
growth factor interactions, methacrylation and crosslinking of CS-MA and Ch-MA 
materials, as performed in these studies, were expected to mitigate potential differences 
in molecular mass, as GAG chains were crosslinked together and became immobilized 
with a highly crosslinked polymer network. Methacrylation of CS and chondroitin with 
GMA permitted crosslinking of GAG materials by free radical initiation, and 
1
H NMR 
analysis suggested that CS-MA and Ch-MA were similarly methacrylated, approximately 
once every ~4 disaccharides on average (Figure 5.5), indicating that similar crosslinking 
density of the two GAGs may result in comparable materials. Crosslinked CS-MA and 
Ch-MA hydrogels, however, did demonstrate significant differences in swelling 
properties, as 50% CS-MA hydrogels swelled significantly more than 50% Ch-MA gels 
in PBS (Figure 5.7a). These differences in swelling may be attributed in part to 
differences in osmotic pressure within the hydrogel networks, resulting from the disparity 
in negative charge density. The high negative charge density in CS-MA hydrogels is 
expected to attract high concentrations of positively charged molecules, while repelling 
negatively charged molecules, thus increasing the osmolarity of the interstitial fluid and 
creating a Donnan effect [379]. Donnan osmotic pressure in these materials was 
estimated to be approximately 3.0-fold higher in 50% CS-MA hydrogels in a 0.15 M 
NaCl solution than in 50% Ch-MA, based the higher negative charge of CS GAGs [45, 
380]. Therefore, for use as a swelling control for release studies and future cellular 
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experiments, PEG-based controls composed of 60% PEG-DA/40% OPF were designed to 
possess similar swelling properties to 50% Ch-MA hydrogels, but in the absence of 
charged GAGs.  
Chemical modification though desulfation of CS and subsequent methacrylation 
of CS and chondroitin did not appear to inhibit the ability of chondroitinase enzyme to 
degrade these products in solution (Figure 5.6). Additionally, crosslinked CS and Ch 
hydrogels completely degraded in chondroitinase enzyme, indicating that crosslinking of 
CS-MA and Ch-MA also did not prevent degradation of the hydrogel networks by 
chondroitinase. Enzymatic degradation of these biomaterials is especially important to 
permit interaction of the naturally-derived GAG matrix with surrounding cells. Cell-
secreted chondroitinase enzyme could facilitate cell-mediated degradation of CS-MA and 
Ch-MA materials, and enzymatic degradation may permit localized remodeling of GAG 
matrix.  
Desulfation of CS was found to alter the ability of CS to both retain and release 
the chondrogenic growth factor TGF-β1 in vitro. CS-MA and Ch-MA hydrogels were 
loaded with TGF-β1 and release was monitored over 7 days. In these studies, 50% CS-
MA materials were found to largely retain TGF-β1, while decreasing the CS content to 
10% CS-MA resulted in significantly greater release (Figure 5.7b). Additionally 50% Ch-
MA, which maintained a constant GAG content compared to 50% CS-MA but with a 
reduction in sulfation and negative charge, showed significantly more release than 50% 
CS-MA, suggesting that sulfation of CS plays a fundamental role in the retention of 
growth factors. These differences in growth factor retention were observed in spite of 
differences in swelling between CS-MA and Ch-MA hydrogels. CS-MA hydrogels 
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swelled significantly more than Ch-MA gels (Figure 5.7a); therefore, the estimated mesh 
size of CS-MA materials would be expected to be higher than Ch-MA [380]. While one 
would expect an increase in mesh size to facilitate greater growth factor release from CS-
MA hydrogels, Ch-MA materials with a smaller mesh size experienced significantly 
greater release of TGF-β1 than CS-MA. These results suggested that TGF-β1 was 
retained via electrostatic interactions with negatively charged sulfates in CS, rather than 
simply physical entrapment within the hydrogel network, and that sulfation can be 
carefully controlled within this system to alter the release kinetics of TGF-β1 from CS-
based materials.  
In particular, sulfated and desulfated CS-based materials may be promising tools 
to deliver TGF-β1 for cartilage regeneration. CS proteoglycans are expressed during early 
cartilage development [14-15], and sulfated GAGs have been shown to potentiate TGF-
β1 signaling [274, 278]. TGF-β1 plays a critical role in promoting chondrogenesis and is 
positively charged at physiological pH, facilitating electrostatic interaction with sulfated 
GAGs [6, 24]. In response to TGF-β1 signaling, cartilage may also regulate subsequent 
CS production and sulfation patterning, suggesting that a potential feedback loop may 
exist in which sulfated GAGs regulate growth factor signaling [230, 279].  
In addition to examining release from CS-MA and Ch-MA materials, the ability 
of CS-MA and Ch-MA hydrogel to “pull-down” soluble TGF-β1 out of solution was 
explored in CS-MA and Ch-MA hydrogels. Sequestration and retention appear to be 
more analogous to in vivo environments, in which proteoglycans are believed to sequester 
growth factors and possibly direct these signals for tissue patterning and differentiation 
[220, 230]. This system is also comparable to culture of GAG-based constructs in 
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chondrogenic media, in which hydrogels may be able to sequester TGF-β1 to promote 
signaling and differentiation. Pull-down was examined using hydrogels in which the total 
GAG content was maintained at 50% while the balance of CS-MA and Ch-MA was 
varied proportionally to alter the degree of sulfation (Figure 5.8a). Staining with DMMB 
demonstrated CS was retained within the hydrogel scaffolds after 1 week and increasing 
CS content was visible from 0% CS-MA (with 50% Ch-MA) up to 50% CS-MA (with 
0% Ch-MA) by increased intensity of DMMB staining. Pull-down experiments in these 
gels demonstrated that 50% CS-MA hydrogels sequestered soluble TGF-β1, “pulling” it 
out of solution and sequestering TGF-β1 within the hydrogel network in 1% BSA (Figure 
5.8). Decreasing the sulfation of the GAG matrix reduced the observed interaction with 
TGF-β1 in a concentration-dependent manner in 10% CS-MA/40% Ch-MA hydrogels 
and in 50% Ch-MA hydrogels, indicating that sulfation and charge play important roles 
in facilitating depletion of TGF-β1. Interestingly, increasing the ionic strength of the 
buffer with an additional 0.5 M NaCl significantly inhibited pull-down of TGF-β1 by 
50% Ch-MA, while pull-down by 50% CS-MA did not appear to decrease. The moderate 
negative charge of chondroitin may retain a weaker electrostatic interaction with TGF-β1 
that was inhibited in 0.5 M NaCl; however, 0.5 M NaCl was not sufficient ionic strength 
to shield TGF-β1 interactions with 50% CS-MA hydrogels, suggesting that CS-MA may 
possess a stronger ability to bind TGF-β1. Similarly, 10 mg/mL soluble CS decreased 
depletion in 50% Ch-MA, but was unable to competitively inhibit sequestration in 50% 
CS-MA gels. This suggested that TGF-β1 may preferentially bind crosslinked CS-MA 
hydrogels over soluble CS chains in solution.  
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 In related studies, Hintze et al. demonstrated that chemically oversulfated CS and 
hyaluronan were able to sequester TGF-β1 in a sulfation-dependent manner when 
covalently conjugated onto 2D surfaces, as determined by ELISA and surface plasmon 
resonance (SPR), and incubation with 0.3 M NaCl inhibited electrostatic interactions with 
TGF-β1[25]. Similarly, Lyon et al. found that TGF-β1 bound heparin by affinity 
chromatography, and 0.5 M NaCl was sufficient to elute TGF-β1 from the heparin-
agarose columns [274]. This was consistent with a number of studies that have reported 
shielding of a variety of electrostatic protein interactions with sulfated GAGs in 0.5 M 
NaCl [381-383]; however, binding of a number of stronger protein-GAG interactions 
have required concentrations up to 1.5 M NaCl [384-388], suggesting that 50% CS-MA 
hydrogels may possess a relatively strong electrostatic interaction with TGF-β1 in this 
system and that greater ionic strength may be required to shield these interactions. An 
additional study by Hintze el al. showed that 10 mg/mL of soluble GAGs, including CS, 
was able to competitively inhibit binding of BMP-4 to surfaces conjugated with 
oversulfated hyaluronan by ELISA [273]. It is important to note that these other studies 
tested binding to GAG-conjugated 2D surfaces or affinity columns, while the work in this 
dissertation represents the first time that TGF-β1 sequestration has been examined in 
crosslinked GAG hydrogels. Crosslinked hydrogels may immobilize GAG chains in close 
proximity to alter their ability to sequesterTGF-β1.  
TGF-β1 is a growth factor that plays a critical role in promoting chondrogenesis 
and is positively charged at physiological pH, facilitating electrostatic interaction with 
sulfated GAGs. Heparin has been found to electrostatically interact with TGF-β1 and 
TGF-β2, but not the TGF-β3 isoform [274]. TGF-β1 and TGF-β2 are reported to have 
 
122 
isoelectric points (pI) of approximately 9.5 and 8.5, respectively [275-276], while TGF-
β3 has a lower pI of 6.8, suggesting that it is actually negatively charged at physiological 
pH and unable to electrostatically complex with sulfated GAGs [275]. Highly sulfated 
GAGs were also capable of potentiating TGF-β1 activity in mink lung epithelial cells, 
suggesting that GAGs may also have a synergistic effect in TGF-β1 signaling. It was 
hypothesized that TGF-β1 interacts with sulfated GAGs via basic arginine and lysine 
residues at positions 25, 26, 31, and 37 and a histidine at 34 in TGF-β1, along with 
Arg/Lys at position 94 [272, 274]. In the TGF-β1 dimer, these two sites could be 
potentially be engaged by a single GAG chain approximately 60 Å apart or by two 
separate GAG chains. The proposed binding site was also in a similar location, at the tips 
of the β-strand loops, to where TGF-β binds its receptors; however, little competition has 
been reported and in many cases sulfate GAGs appeared to potentiate the signaling 
effects [272]. These studies suggested that GAG-based materials may have significant 
application in controlling interactions with TGF-β1 to promote chondrogenic 
differentiation of MSCs.  
Overall, desulfated chondroitin hydrogels provide a highly controlled system to 
examine the interactions between charged GAGs and growth factors, and these materials 
may have tremendous potential to promote chondrogenic differentiation through 
sequestration of growth factors. 
 
5.5 Conclusions 
These studies present desulfated chondroitin as a potential tool to further 
investigate the role of sulfation in GAG interactions with growth factors. Chondroitin 
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sulfate was chemically desulfated by acidic methanol treatment, and characterization 
supported significant desulfation with little modification of the remaining CS chemical 
structure. Desulfation also resulted in a 2.3-fold decrease in negative charge density in 
chondroitin materials. Methacrylation of CS and chondroitin allowed the formation of 
CS-MA and Ch-MA hydrogels, which remained degradable by chondroitinase enzyme 
for potential cell-mediated degradation. 50% CS-MA hydrogels were able to sequester 
greater amounts of TGF-β1 than desulfated 50% Ch-MA hydrogels, as shown by 
retaining TGF-β1 from release and through TGF-β1 pull-down from solution, suggesting 
that sulfates play an important role in facilitating the electrostatic interactions between 
growth factors and CS. These results present desulfated chondroitin materials as a 
valuable tool to alter GAG sulfation in a highly controlled manner as a promising strategy 
to control binding and interaction with positively charged growth factors, particularly the 
chondrogenic growth factor TGF-β1. Sulfated and desulfated CS-based materials may 
present a promising platform to modulate growth factor interactions to control release or 
sequestration for chondrogenic differentiation of MSCs and development of novel tissue 





DESULFATED CHONDROITIN HYDROGELS UPREGULATED 
GENE EXPRESSION OF CARTILAGINOUS MARKERS BY 
ENCAPSULATED HUMAN MESENCHYMAL STEM CELLS IN 
THE PRESENCE OF TGF-β1 
 
6.1 Introduction 
As a load bearing tissue, damage to articular cartilage can be both debilitating and 
extremely painful. Nearly 466,000 arthroscopic procedures performed on the knee in an 
ambulatory (outpatient) setting were diagnosed with a tear of the medial or lateral 
cartilage or menisci in the United States in 2006 [2]. If severe cartilage damage is 
allowed to persist without appropriate repair, the tissue may degenerate further and 
progress into development of osteoarthritis. In 2005, an estimated 27 million adults in the 
US had clinical osteoarthritis with indirect costs totaling approximately $89 billion per 
year [3-4]. Due to cartilage’s low capacity for healing, novel tissue engineering therapies 
seek to promote repair and regeneration of cartilaginous tissues. Mesenchymal stem cells 
(MSCs) are multipotent progenitor cells that are capable of differentiating into 
cartilaginous tissues, making them a promising cell source for tissue repair [6]; however, 
difficulty recapitulating the complex extracellular matrix (ECM) composition and 
organization of native cartilage remains a significant challenge. Recent research has 
suggested that cartilaginous ECM molecules may play a central role in directing 
differentiation of MSCs down a chondrogenic lineage.  
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Chondroitin sulfate (CS) is a cartilaginous glycosaminoglycan (GAG) that 
appears to play an important role in chondrogenesis in vivo. CS-containing proteoglycans 
versican and perlecan regulate mesenchymal condensation during cartilage development 
[14, 218-219, 223-224], and several enzymes involved in CS initiation, elongation, and 
sulfation are required for proper skeletal development and patterning [16-18]. Recent 
studies have investigated the ability of CS-modified biomaterials to promote 
chondrogenic differentiation in vitro as well. Culture in CS-containing hydrogels 
upregulated expression and production of cartilaginous ECM by encapsulated goat and 
mouse MSCs [8-9], suggesting that CS may play a particularly important role in directing 
stem cell differentiation down a chondrogenic lineage; however, relatively few studies 
have specifically investigated the effect of CS on chondrogenic differentiation of human 
MSCs (as opposed to other mammalian species) [251-252]. 
In cartilaginous tissues, sulfated GAGs play essential roles in maintaining 
cartilage function. Specifically, the high degree of sulfation of CS carries a highly 
negative fixed charge density that facilitates a variety of interactions with cartilaginous 
ECM, signaling molecules, and interstitial fluid. In Chapter 5 of this dissertation, 
nonsulfated chondroitin materials were characterized as a potential system to control 
material interactions with growth factors, including the chondrogenic growth factor TGF-
β1; however, the effects of sulfation of CS in chondrogenic differentiation of MSCs have 
not been investigated. To examine the chondrogenic response to sulfated and nonsulfated 
GAG materials, human MSCs were encapsulated in CS- and chondroitin-containing 
hydrogels and cultured in the presence of chondrogenic medium containing TGF-β1 over 
the course of 6 weeks in vitro. Cell viability and total DNA content were monitored over 
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time, and gene expression and ECM production of encapsulated MSCs were determined 
as measures of chondrogenic differentiation. 
 
6.2 Materials and Methods 
6.2.1 Synthesis of Materials 
6.2.1.1 Desulfation of Chondroitin Sulfate 
Chondroitin sulfate was desulfated using an acidic methanol treatment for up to 7 
days per established protocols [365-366]. Chondroitin sulfate C (primarily chondroitin-6-
sulfate, Wako Chemicals USA, Richmond, VA) was stirred at 5.0 mg/mL in methanol 
(VWR, Radnor, PA) containing 0.5% v/v acetyl chloride (Acros Organics, Geel, 
Belgium). CS was centrifuged and acidic methanol was replaced on days 1, 3, and 7 to 
produce a methyl ester of chondroitin. The product was then dissolved in 20 mL distilled, 
deionized water (ddH2O) per gram of starting CS before precipitation in an excess of 
ethanol. The methyl ester of chondroitin was washed in ethanol and ethyl ether (Fisher, 
Waltham, MA), vacuum dried at <5 mmHg, and stored at 4°C.  
Methyl ester of chondroitin was demethylated at 25 mg/mL in 0.1 M potassium 
hydroxide (KOH, Fisher) for 24 hours to produce chondroitin. The chondroitin product 
was then neutralized in 4 mL of 100 mg/mL potassium acetate (Fisher) in 10% v/v acetic 
acid (VWR) per gram of starting product, and precipitated in an excess of ethanol. 
Chondroitin was washed in ethanol and ethyl ether, vacuum dried, and stored at 4°C until 
use. Removal of sulfate groups in chondroitin was confirmed by dimethylmethylene blue 




6.2.1.2 Methacrylation of Chondroitin Sulfate and Chondroitin 
CS and chondroitin were methacrylated with glycidyl methacrylate per 
established protocols [368]. CS or chondroitin was dissolved at 1% w/v in a 50:50 
mixture of acetone (VWR) and ddH2O and allowed to stir at room temperature overnight. 
A 20-fold molar excess of triethylamine (TEA, Sigma-Aldrich, St. Louis, MO) per CS or 
chondroitin disaccharide was added to the solution, and a 20-fold molar excess of 
glycidyl methacrylate (GMA, Sigma-Aldrich) per disaccharide was added dropwise to 
the solution. The reaction was allowed to stir at room temperature for 24 hours to produce 
CS-methacrylate (CS-MA) and chondroitin-methacrylate (Ch-MA). The resulting 
products were dialyzed first in 50:50 acetone:water for 24 hours (1,000 Da MWCO), and 
then in distilled water (dH2O) for 2 days to remove unreacted reagents. The 
methacrylated products were lyophilized (Labconco, Kansas City, MO) for 4 days to 
produce a dry product, and stored at -20°C until use. Proton nuclear magnetic resonance 
(
1
H NMR) was utilized to determine the degree of the conjugation of the GMA groups to 
the CS and chondroitin chains. 
6.2.1.3 PEG-DA Synthesis 
Poly(ethylene glycol)-diacrylate (PEG-DA) polymers were synthesized according 
to established protocols [191]. 3,400 Da (Mn) PEG (Sigma-Aldrich) was solubilized in 
distilled, anhydrous methylene chloride (MeCl, Fisher) to produce a 60% (m/v) solution. 
TEA was added to the dissolved PEG, and acryloyl chloride (AcCl, Sigma-Aldrich) was 
slowly added dropwise at 2:1 AcCl:PEG and 1:1 AcCl:TEA molar ratios to create a 40% 
w/v solution. The reaction was allowed to proceed at room temperature under nitrogen 
gas, and the reaction was left stirring overnight to ensure completion. 2 M potassium 
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carbonate (K2CO3, Fisher) was used at a 2:1 K2CO3:AcCl molar ratio to extract TEA to 
the aqueous phase. The organic phase was allowed to separate from the aqueous phase, 
and anhydrous magnesium sulfate (MgSO4, Fisher) was used to remove any remaining 
aqueous phase from the solution. PEG-DA was then precipitated in ethyl ether and 
filtered, followed by vacuum drying at <5 mmHg. Dry polymers were stored in sealed 
containers at -20°C until use. PEG-DA (Mn = 3760 ± 50, PI = 1.1 ± 0.02) and PEG 3.4K 
(Mn = 3440 ± 30, PI = 1.1 ± 0.001) were characterized via gel permeation 
chromatography as previously reported [174]. 
6.2.1.4 OPF Polymer Synthesis 
Oligo(poly(ethylene glycol) fumarate) (OPF) 10K polymers were synthesized 
according to established protocols [367]. 10,000 Da (Mn) PEG (Sigma-Aldrich) was 
azeotropically distilled in toluene (Fisher) and then combined with distilled, anhydrous 
MeCl to produce a 40% (v/v) solution. Fumaryl chloride (FuCl, Sigma-Aldrich) and TEA 
(Sigma-Aldrich) were slowly added dropwise over a period of 2 hours at 0.9 FuCl:PEG 
and 1:2 FuCl:TEA molar ratios. During this time the reaction was allowed to proceed at 
0°C under nitrogen gas, after which the reaction was left stirring for 72 hours under 
nitrogen at room temperature to ensure reaction completion. After rotovaporing (Buchi, 
Flawil, Switzerland) to remove excess MeCl, the resulting polymer was recrystallized 
twice with ethyl acetate (Fisher) and washed three times in ethyl ether (Fisher), followed 
by vacuum drying at <5 mmHg. Dry polymers were stored in sealed containers at -20°C 
before use. OPF 10K (Mn = 28,100 ± 760, PI = 5.2 ± 0.4) and PEG 10K (Mn = 12,900 ± 
210; PI = 1.1 ± 0.002) were characterized via gel permeation chromatography as 
previously reported [174]. 
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6.2.2 Encapsulation of Human MSC 
Human MSCs were obtained from the Texas A&M Health Science Center 
College of Medicine Institute for Regenerative Medicine at Scott & White (Temple, TX) 
at passage 1. Cells were seeded at 50 cells/cm
2
 following recommended protocols, in 
growth medium containing α-MEM (Mediatech, Manassas, VA) with 16.3% fetal bovine 
serum (FBS, Atlanta Biologicals, Lawrenceville, GA), 1% antibiotic/antimycotic 
(Mediatech), and 2 mM L-glutamine (Mediatech). Following expansion, cells were 
frozen at passage 2 in liquid nitrogen until further use. For these studies, cells from three 
separate donors were thawed, expanded separately, and combined prior to encapsulation 
at passage 3.  
For cell encapsulation, human MSCs were incorporated at a final cell 
concentration of 20x10
6
 cells/mL into macromer solutions containing a 1:1 ratio of OPF 
10K:PEG-DA and 50% CS-MA or 50% Ch-MA by dry mass. PEG controls containing 
60% PEG-DA:40% OPF, which were designed to swell similarly to 50% Ch-MA as 
described in Chapter 5, were used as swelling controls. Dispersed MSCs were crosslinked 
in hydrogels using 6 mm diameter, 1 mm deep cylindrical molds with 0.018 M 
ammonium persulfate (APS, Sigma-Aldrich) and tetramethylethylenediamine (TEMED, 
Sigma-Aldrich) for 10 minutes at 37 °C. Hydrogels were cultured for 6 weeks at 37°C 
and 5% CO2 in chondrogenic medium composed of high glucose DMEM (Mediatech) 
containing 1% ITS+ culture supplement (Becton, Dickenson, Franklin Lakes, NJ), 1% 
nonessential amino acids (NEAA, Mediatech), 50 μg/mL ascorbate-2-phosphate (Sigma-
Aldrich), and 1% antibiotic/antimycotic (Mediatech). Chondrogenic medium was also 
supplemented with 10 ng/mL TGF-β1 (Peprotech, Rocky Hill, NJ) and 100 nM 
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dexamethasone (Sigma-Aldrich), and culture medium was replaced every 2 days 
throughout the course of the study.  
6.2.3 Analysis of MSC Response in CS-MA and Ch-MA Hydrogels 
6.2.3.1 LIVE/DEAD Staining for Viability 
Viability of human MSCs encapsulated in 50% CS-MA and 50% Ch-MA 
hydrogels was observed by LIVE/DEAD staining over 6 weeks. In this stain, calcein is 
cleaved within the cytosol of viable cells, fluorescing green (ex/em: 494/517 nm), while 
ethidium homodimer-1 is able to enter the ruptured cell membranes of nonviable cells, 
binding nuclear DNA and fluorescing red (ex/em: 528/617 nm). On days 1, 21, and 42, 
after rinsing samples of excess media in PBS with 100 μg/mL CaCl2 and 47 μg/mL 
MgCl2 (Invitrogen, Carlsbad, CA), hydrogels were stained for 60 minutes in 
LIVE/DEAD stain containing 1 µM calcein and ethidium homodimer-1 (Invitrogen). 
Viability within all hydrogel formulations was imaged in PBS via confocal microscopy 
(Carl Zeiss LSM 510, Oberkochen, Germany). Images were captured every 10 μm 
through the entire depth of the hydrogel from three separate regions in each sample 
(n=4).  
6.2.3.2 PicoGreen DNA assay 
Hydrogels were analyzed by PicoGreen assay for DNA content on days 1, 21, and 
42. The PicoGreen assay uses a fluorescent dye that binds to double stranded DNA to 
quantify DNA content. After rinsing in PBS, samples were massed and wet mass was 
recorded. Hydrogels were then homogenized with pestle grinders and mixed with 500 μL 
of distilled water before being frozen at -80°C until analysis. Cells were lysed through a 
series of freeze/thaw cycles and sonication. PicoGreen assay (Invitrogen) was used to 
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evaluate the total DNA content in each sample, according to established protocols [303]. 
Fluorescence was read at excitation 485 nm, emission 525 nm (Molecular Devices 
SpectraMax M2e, Sunnyvale, CA), and DNA content was determined using a standard 
curve of DNA. Within each hydrogel formulation, DNA content of each gel was 
normalized to wet mass to correct for small differences in gel size (n=4). 
6.2.3.3 Reverse transcription polymerase chain reaction 
Gene expression of encapsulated MSCs was analyzed after 1, 21, and 42 days by 
reverse transcription polymerase chain reaction (RT-PCR). After rinsing in PBS, RNA 
was extracted from samples using a QIAshredder tissue homogenizer and RNeasy kit 
with DNase I digestion (Qiagen, Hilden, Germany). Reverse transcription was performed 
using SuperScript III Reverse Transcriptase (Invitrogen) with Oligo(dT)15 primers 
(Promega, Madison, WI) and nucleotides (Promega). Custom designed primers 
(Invitrogen) specific to human mRNA for collagen II, aggrecan, and SOX9 (chondrocytic 
markers), collagen X (hypertrophic chondrocyte marker), collagen I (fibroblastic marker), 
osteocalcin (osteoblastic marker), myoD (myofibroblastic marker), and peroxisome 
proliferator-activated receptor γ2 (PPAR-γ2; adipocytic marker) are shown in Table 5.2. 
Quantitative PCR amplification for each gene target was performed on a StepOnePlus 
System (Applied Biosystems, Carlsbad, CA) with SYBR Green master mix (Applied 
Biosystems). To determine fold regulation over PEG control hydrogels on day 1, the raw 
fluorescence data was processed using LinRegPCR (v12.11; 
http://www.hartfaalcentrum.nl) [389] with glyceraldehyde-3-phosphate dehydrogenase 





Table 6.1. Human primer sequences for quantitative polymerase chain reaction 










































6.2.3.4 Histological staining 
ECM production by encapsulated MSCs was determined by immunostaining on 
days 1, 21, and 42. After rinsing in PBS, samples were placed into a solution of 5% w/v 
sucrose (EMD, Darmstadt, Germany) in PBS under vacuum (-25 inHg). The sucrose 
concentration was gradually increased over the course of 2 hours to 15% sucrose. Next, 
gels were subjected to increasing concentrations of 20% sucrose:OCT (VWR) over the 
course of 4 hours until samples were infiltrated with a 1:2 volume ratio of 20% 
sucrose:OCT. After vacuum infiltration overnight, samples were embedded in 1:2 20% 
sucrose:OCT solution by gentle freezing in liquid nitrogen and stored at -80ºC. Infiltrated 
hydrogels were cryosectioned at 20 μm thickness (Thermo Scientific, Cryostar NX70). 
Sections were fixed in acetone, and OCT was rinsed in PBS. For aggrecan and 
collagen X staining, samples were deglycosylated with 30 µl of 0.75 U/ml chondroitinase 
ABC (Sigma-Aldrich) for 1.5 hours. Samples were blocked with Image-iT FX signal 
enhancer (Invitrogen). For primary antibody binding, sections were incubated overnight 
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at 4°C in monoclonal mouse anti-human collagen I, collagen II, aggrecan (Abcam), or 
collagen X (Sigma). Sections were then incubated for 30 minutes with highly cross-
adsorbed Alexa Fluor 488-conjugated goat polyclonal anti-mouse immunoglobulin G 
(IgG, Molecular Probes, Carlsbad, CA) or IgM (Molecular Probes) for collagen X, and 
counterstained with 0.1 μg/mL 4',6-diamidino-2-phenylindole (DAPI, Anaspec, Fremont, 
CA). Negative controls were stained as described, but using a monoclonal mouse IgG1 
isotype control (Abcam) with no known reactivity with human antigens as the primary 
antibody at 10 μg/mL. Histological sections were imaged using an epifluorescence 
microscope with a 20X magnification objective (Nikon Eclipse 80i, Tokyo, Japan) (n=2). 
6.2.4 Statistical Analysis 
All values were reported as mean ± standard deviation. For statistical analysis, 
PCR amplification data for each gene were first transformed using a Box-Cox 
transformation to obtain a normal distribution for analysis [390]. A two-factor analysis of 
variance (ANOVA) was used to determine statistical significance of groups, and 
Tukey's post hoc multiple comparison test with significance set at p≤0.05 indicated 
significance between individual samples. For DNA and gene expression analysis, the 
factors were hydrogel type and time. Statistical analysis was carried out using Minitab 
(v15.1, State College, PA). 
 
6.3 Results 
6.3.1 Viability in CS-MA and Ch-MA hydrogels during 6 weeks of culture 
LIVE/DEAD staining of human MSCs in 50% CS-MA and 50% Ch-MA 
hydrogels indicated that visible MSCs appeared mostly viable over 6 weeks of culture 
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(Figure 6.1a). Cells remained dispersed evenly throughout the hydrogel scaffolds with a 
spherical shape, and no cell aggregation or spreading was observed. Total DNA content, 
as a measure of cell number, suggested that cellularity decreased over time in all 
hydrogel formulations (Figure 6.1b). DNA content significantly decreased by 
approximately half from day 1 to day 21 in all hydrogels; however, no significant 
differences were observed in DNA content between day 21 and day 42. Additionally, 
DNA content was significantly greater in 50% Ch-MA hydrogels than 50% CS-MA or 
PEG control hydrogels on days 1 and 21, suggesting that 50% Ch-MA hydrogels 
contained a higher cellularity.  
6.3.2 Upregulation of gene expression for chondrocytic markers by MSCs 
encapsulated in 50% Ch-MA hydrogels  
Human MSCs encapsulated in nonsulfated 50% Ch-MA hydrogels significantly 
upregulated gene expression of the cartilaginous ECM molecules collagen II and 
aggrecan on days 21 and 42, over 50% CS-MA hydrogels (Figure 6.2). MSCs in 50% Ch-
MA expressed 83,100 ± 38,800 fold upregulation of collagen II expression, compared to 
only 28 ± 174 in 50% CS-MA and 2,650 ± 6,410 fold in PEG controls (Figure 6.2a). 
Similarly, aggrecan expression in Ch-MA gels was upregulated 76.0 ± 37.3 fold on day 
42, compared to 4.9 ± 11.5 in CS-MA and 59.6 ± 25.5 in PEG (Figure 6.2c). 
Cartilaginous transcription factor SOX9 experienced slight upregulation on day 42 in 
50% Ch-MA with 2.0 ± 1.5 fold regulation, while CS-MA only expressed 0.19 ± 0.11 
fold regulation (Figure 6.2d). Collagen X, an ECM marker of hypertrophic chondrocytes, 
was also significantly upregulated in Ch-MA hydrogels over CS-MA and PEG controls 
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on days 21 and 42 (Figure 6.2e). MSCs in 50% Ch-MA upregulated collagen X by 202 ± 
93 fold on day 42, compared to 11.0 ± 11.0 in CS-MA and 31.8 ± 14.1 in PEG controls.  
 
 
Figure 6.1. Viability and cellularity of human MSCs encapsulated in 50% CS-MA 
and 50% Ch-MA hydrogels. (a) Human MSCs appeared largely viable in all 
hydrogel formulations over 42 days of culture. Cells remained dispersed with a 
rounded morphology. Scale bars = 100 μm. (b) DNA content, as a measure of 
cellularity, decreased over time with a significant decrease observed between day 1 
and day 21 in all hydrogel formulations. Additionally, greater DNA content was 
measured in 50% Ch-MA hydrogels on days 1 and 21, compared to 50% CS-MA 
and PEG controls. * indicates significantly less DNA than day 1 (p≤0.05). # indicates 
significantly less DNA than 50% Ch-MA hydrogels at the same time point (p≤0.05). 
 
Markers for other tissues including fibroblastic marker collagen I, osteoblastic 
marker osteocalcin, myofibroblastic marker MyoD, and adipocytic marker PPAR-γ2 
were also examined. Collagen I did not exhibit downregulation over the course of this 
study (Figure 6.3a). MSCs in PEG hydrogels actually exhibited 23.3 ± 15.2 fold 
upregulation of collagen I by day 42, and Ch-MA gels expressed 6.2 ± 4.2 fold 
regulation. The ratio of collagen II:collagen I relative expression suggested that MSCs in 
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50% Ch-MA hydrogels exhibited nearly equal expression of collagen II and collagen I 





 on day 1 (Figure 6.2b). Osteocalcin displayed slight upregulation in 
encapsulated MSCs over time, but did not exhibit significant differences across hydrogel 
types (Figure 6.3b). MyoD expression demonstrated high variability and no significant 
trends (Figure 6.3c), while PPAR-γ2 did not amplify within 40 PCR cycles, indicating 
low PPAR-γ2 expression at all time points. 
 
 
Figure 6.2. Gene expression of chondrocytic markers by MSCs in 50% CS-MA and 
50% Ch-MA hydrogels. MSCs in 50% Ch-MA hydrogels significantly upregulated 
gene expression of (a) collagen II, (b) ratio of collagen II:collagen I relative 
expression, (c) aggrecan, and (d) SOX9 after 42 days, compared to 50% CS-MA. (e) 
Hypertrophic chondrocyte marker collagen X was also significantly upregulated in 
50% Ch-MA gels on day 21 and 42 over 50% CS-MA and PEG controls. * indicates 
significantly greater than 50% CS-MA at same time point (p≤0.05). # indicates 






Figure 6.3. Gene expression of negative tissue markers by MSCs in 50% CS-MA 
and 50% Ch-MA hydrogels. While (a) collagen I, (b) osteocalcin, and (c) MyoD 
displayed some gene regulation in encapsulated MSCs over time, few differences 
were observed across hydrogel types. * indicates significantly greater than 50% CS-
MA at same time point (p≤0.05). + indicates significantly greater than 50% Ch-MA 
at same time point (p≤0.05). 
 
6.3.3 ECM deposition in GAG-containing hydrogels 
Immunostaining for ECM production demonstrated that greater ECM production 
overall was observed in GAG-containing hydrogels over PEG control hydrogels, which 
showed relatively little staining for ECM (Figure 6.4). While some accumulation of 
cartilaginous ECM collagen II and aggrecan was observed pericellularly over 42 days, 
clear differences were not apparent between Ch-MA and CS-MA formulations (Figure 
6.4a-b). Staining for collagen X, however, exhibited noticeably greater staining in 50% 
CS-MA hydrogels than Ch-MA gels (Figure 6.4c). Deposition of collagen I appeared to 
persist over time but few differences were observed between CS-MA and Ch-MA 





Figure 6.4. Immunostaining for ECM deposition by MSCs in 50% CS-MA and 50% 
Ch-MA hydrogels. (a) Collagen II and (b) aggrecan were produced in small 
quantities by MSCs in CS-MA and Ch-MA hydrogels, compared to relatively little 
deposition in PEG gels. Little difference was observed between 50% CS-MA and 
50% Ch-MA. (c) Greater staining for collagen X was observed in 50% CS-MA gels. 
(d) Collagen I was produced by MSCs, but few differences were observed across gel 





These studies demonstrated that viable MSCs remained dispersed throughout 
GAG-based hydrogels after 6 weeks of culture in vitro, despite significant decreases in 
DNA content over time (Figure 6.1), and that nonsulfated chondroitin materials 
upregulated gene expression of chondrogenic markers in human MSCs, compared to CS 
materials, when cultured in chondrogenic medium (Figure 6.2). MSCs encapsulated in 
50% Ch-MA hydrogels exhibited significantly greater gene expression of collagen II, 
aggrecan, and SOX9 than MSCs in 50% CS-MA gels after 42 days of culture in 
chondrogenic medium containing TGF-β1, suggesting that nonsulfated chondroitin 
materials may promote greater chondrogenic differentiation over CS. As described in 
Chapter 5, 50% Ch-MA hydrogels swelled significantly less than 50% CS-MA; therefore, 
in these experiments, PEG hydrogels that swelled similarly to 50% Ch-MA hydrogels 
were used as swelling controls. MSCs have been shown to regulate differentiation in 
response to both substrate stiffness and pore size in vitro [160, 162, 391-392]; therefore, 
PEG swelling controls were used as approximate controls for material stiffness and 
porosity/mesh size in the absence of charged polysaccharides [45, 380]. In this 
experiment, MSCs in uncharged PEG control hydrogels expressed significant 
upregulation of collagen II, aggrecan, and SOX9 gene expression over 50% CS-MA 
hydrogels after 6 weeks; however, gene expression of chondrogenic markers remained 
less than that observed in MSCs in Ch-MA materials, suggesting that upregulation in 
50% Ch-MA hydrogels was not solely due to differences in swelling properties. 
An investigation of CS-MA and Ch-MA hydrogels, compared to PEG-based 





cells/mL) demonstrated similar trends of upregulation of gene expression by MSCs in 
Ch-MA hydrogels in the presence of chondrogenic medium; however, in the absence of 
TGF-β1 and dexamethasone, chondroitin materials did not exhibit significant 
upregulation of gene expression for cartilaginous markers (Figure A.2). These results 
indicated that nonsulfated chondroitin materials alone were not sufficient to upregulate 
gene expression of cartilaginous markers by MSCs, and that upregulation of 
chondrogenic markers may be dependent on interactions between the chondroitin 
material and chondrogenic cues from exogenously supplemented TGF-β1. Interestingly, 
CS materials did significantly upregulate collagen II gene expression, in the absence of 
TGF-β1 and dexamethasone on day 21, while chondroitin materials did not (Figure A.2), 
suggesting that CS materials may possess the unique ability to promote chondrogenic 
differentiation in the absence of exogenous soluble cues. While this presents an 
interesting potential utility of CS-based materials, due to inconsistency within these CS 
samples and the greater overall response observed in chondroitin materials in the 
presence of chondrogenic medium, these trends have not been examined in further detail. 
Together, these contrasting responses in the presence and absence of chondrogenic media 
suggested that MSCs encapsulated in CS and chondroitin materials differentially regulate 
their response to soluble chondrogenic cues.  
The ability of CS and chondroitin materials to differentially “pull-down” soluble 
TGF-β1 out of solution, as discussed in Chapter 5, is analogous to culture in 
chondrogenic medium, as GAG scaffolds may electrostatically bind and retain TGF-β1 
within their networks. The pull-down experiments presented in Chapter 5 demonstrated 
that 50% CS-MA depleted greater amounts of TGF-β1 from solution than 50% Ch-MA in 
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a sulfation-dependent manner, suggesting that CS-based materials may sequester TGF-β1 
from chondrogenic medium, thus increasing the local concentration of growth factor in 
close proximity to cells or modulating signaling efficiency within GAG-based scaffolds. 
Although enhanced upregulation of chondrogenic markers in Ch-MA materials over CS-
MA hydrogels may appear to contradict this hypothesis, the high negative charge density 
of CS in these materials could potentially decrease TGF-β1 activity or inhibit transport 
within the hydrogel network; therefore, removal of sulfate groups may promote MSC 
differentiation via enhanced growth factor signaling. In studies by Seto et al., similar 
PEG hydrogels containing 10% heparin, a highly sulfated GAG, exhibited restricted 
diffusion of a positively charged model protein into the hydrogel network, and 
encapsulated MSCs co-cultured with osteoblasts demonstrated preferential mineralization 
at the surface of these hydrogels, potentially suggesting sequestration and limited 
transport of osteoblast-secreted soluble factors into the hydrogel scaffolds [393]. 
Noticeable spatial differences in ECM production, as observed by immunostaining, were 
not apparent in the experiments presented here; however, overall ECM deposition 
appeared to remain relatively low throughout all hydrogel types. The highly charged CS 
matrix may also prevent transport of other cell-secreted signals within the hydrogel, 
effectively inhibiting intercellular communication, which plays important roles in 
supporting chondrogenic differentiation and maintaining a chondrocytic phenotype [24, 
38, 394-395]. Nevertheless, it is important to note that chondroitin remains moderately 
negatively charged at physiological pH despite the absence of sulfates, due to the 
presence of carboxylates in the GAG structure, and may retain electrostatic interactions 
with TGF-β1, albeit to a lesser degree than CS. These results suggest that decreasing the 
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degree of sulfation in GAG-based hydrogels may be better suited for promoting 
chondrogenic differentiation of MSCs than highly sulfated CS, and that differential 
sequestration or altered presentation of TGF-β1 to encapsulated MSCs may contribute to 
the observed differences in the gene expression between CS-MA and Ch-MA materials.  
TGF-β1 pull-down experiments, as presented in Chapter 5, also found that PEG 
control hydrogels demonstrated similar degrees of TGF-β1 depletion to 50% Ch-MA gels 
in 1% BSA solutions, even though retention was not influenced by increased ionic 
strength in the presence of 0.5 M NaCl. These results suggested that PEG materials may 
be trapping similar amounts of TGF-β1 from solution as 50% Ch-MA, although the 
observed interaction with neutrally charged PEG-based materials is likely by non-
electrostatic means. Nevertheless, 50% Ch-MA hydrogels enhanced gene expression of 
chondrogenic markers over PEG control hydrogels, despite similarities in TGF-β1 
adsorption and swelling properties (Figure 6.2). These results suggested that the GAG-
based matrix in Ch-MA hydrogels may play a unique role in supporting chondrogenic 
differentiation over PEG-based materials, independent of electrostatic growth factor 
sequestration and swelling, and the polysaccharide network or intermediate degree of 
negative charge in Ch-MA materials may have other undetermined influences on 
chondrogenic differentiation that warrant further investigation. As opposed to TGF-β1 
sequestration by the material scaffolds to enhance MSC response, the materials 
themselves may alter the chondrogenic response by MSCs in the presence of soluble 
chondrogenic cues. As a moderately negatively charged component of cartilaginous 
matrix, chondroitin may alter the stem cell microenvironment through various 
interactions with ECM, cell surface receptors, and signaling molecules (besides TGF-β1) 
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to promote chondrogenic gene expression in encapsulated MSCs, in ways where 
synthetically-derived, neutrally charged PEG materials likely would not.  
Despite significant differences in gene expression between MSCs encapsulated in 
Ch-MA and CS-MA hydrogels, these material effects were not as apparent in 
immunostaining for chondrogenic ECM markers. In general, greater ECM deposition was 
observed pericellularly in GAG-based CS-MA and Ch-MA materials than PEG control 
gels, which exhibited limited staining for ECM overall (Figure 6.4); however, notable 
differences in collagen II and aggrecan deposition were not evident between Ch-MA and 
CS-MA hydrogels, despite significant differences in gene expression. It appears that 
MSCs may have lacked sufficient extracellular space for significant matrix production in 
these tightly crosslinked hydrogel scaffolds, suggesting that degradation of the hydrogel 
network may play a key role in facilitating ECM deposition by encapsulated MSCs. 
While PEG-DA and OPF materials contain hydrolytically degradable ester moieties, PEG 
control hydrogels were not expected to experience significant degradation over the course 
of the 6-week study presented here. CS-MA and Ch-MA are degradable by 
chondroitinase enzyme, as described in Chapter 5; however, chondrogenic human MSCs 
may not produce sufficient amounts of chondroitinase enzyme to effectively degrade the 
GAG network, thus inhibiting the deposition of cartilaginous ECM by encapsulated 
MSCs. A previously study by Varghese et al. reported significant cellular aggregation of 
goat MSCs encapsulated in CS/PEG hydrogels, suggesting that cells of other mammalian 
species may possess greater ability to degrade and remodel the dense CS matrix [8]. Both 
hydrolytic and cell-mediated enzymatic degradation have been functionally incorporated 
into PEG-based hydrogels in order to support scaffold degradation in a controlled manner 
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[169, 185-187, 396], suggesting that similar techniques to enhance material degradation 
may support greater ECM deposition in Ch-MA and CS-MA materials.  
While MSCs significantly upregulated expression of chondrogenic markers in 
50% Ch-MA hydrogels, gene expression of collagen I did not decrease and actually 
appeared to increase over the time course of these experiments (Figure 6.3a). Collagen 
type I is normally produced in high amounts by undifferentiated MSCs, but is not 
normally present in hyaline cartilage [105]. While expression of collagen type II was very 




 ratio of 
collagen II:collagen I relative expression, by day 42 MSCs exhibited a significantly 
greater collagen II:collagen I ratio of 1.03 ± 1.20, despite some large variability, 
suggesting that collagen II and collagen I may have been expressed in comparable 
amounts at the mRNA level after 6 weeks (Figure 6.2b). As key differentiation markers 
of osteogenic, myofibroblastic, and adipocytic phenotypes were not significantly 
regulated in these studies, these gene expression results are representative of a more 
fibrochondrocytic phenotype. Fibrocartilaginous tissues appear in the menisci, annulus 
fibrosis of intervertebral discs, temporomandibular joint, as well as the insertions of 
tendon/ligament into bone, and contain a fibrous collagen I matrix along with 
cartilaginous ECM, including collagen II and aggrecan [27-29].  
Hypertrophy of chondrogenic MSCs remains a key challenge to in vitro 
chondrogenic differentiation [97, 103-104], and gene expression of collagen X, an ECM 
marker of hypertrophic chondrocytes, was significantly upregulated in 50% Ch-MA 
hydrogels, compared to CS-MA and PEG control gels. In contrast, immunostaining 
results suggested that CS-MA materials may actually facilitate greater production or 
 
145 
retention of collagen X matrix than Ch-MA hydrogels, even though relatively little ECM 
production by encapsulated cells was observed overall. Because sulfated GAGs are 
known to interact with a variety of ECM molecules [334, 397], it is important to consider 
that CS hydrogels may also differentially retain ECM within the scaffolds, compared to 
chondroitin. While some collagens can electrostatically interact with GAGs [398] and 
collagen X is highly glycosylated in vivo [399], the differential effects of sulfation on 
ECM retention require further investigation in greater depth, specifically in degradable or 
larger mesh size materials that may support greater degrees of ECM production.  
DNA content within hydrogel constructs appeared decrease over time with a 
significant decrease between days 1 and 21 in all hydrogel types. This result is consistent 
with long-term culture in other PEG-based hydrogels in which the small mesh size and 
low overall degradability of the scaffold prevent cell division, due to limited space within 
the dense polymer matrix. A fraction of encapsulated cells likely undergo cell death over 
time, resulting in a decrease in total DNA [197, 207, 393]. Additionally, undifferentiated 
MSCs require the presence of adhesive cues that promote integrin binding to maintain 
cell viability in hydrogel materials [400]; however, persistence of these adhesive cues 
over time may inhibit the long-term chondrogenic response of MSCs [213]. MSCs 
express fibronectin during pre-cartilaginous condensation in the developing mesenchyme, 
then downregulate expression during differentiation into chondrocytes [24, 401], 
suggesting that early presentation of adhesive proteins or peptides may promote MSC 
viability following encapsulation and that removal of these adhesive signals over time 
may be necessary to support chondrogenic differentiation of MSCs [137].  
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It is also important to note that the DNA content in 50% Ch-MA was significantly 
greater than in 50% CS-MA and PEG controls by approximately two-fold on days 1 and 
21, based on PicoGreen assay results. Though later time points may be explained by 
improved viability in Ch-MA materials, the difference in DNA on day 1 indicated a 
difference in encapsulation density, which could potentially confound results. However, 
based on the large differences in gene expression in Ch-MA hydrogels, along with similar 
trends of upregulation observed at early time points (days 7, 14, 21) in hydrogels with 
more similar DNA contents (Figure A.1-2), it appears that the cellular response in Ch-
MA materials was primarily influenced by material interactions with Ch-MA in the 
presence of soluble chondrogenic factors, rather than simply increased cell density.  
Together, these results have demonstrated that nonsulfated chondroitin hydrogels 
promote gene expression of chondrogenic markers by MSCs in a TGF-β1-dependent 
manner, and in Chapter 5, desulfation of CS was shown to reduce sequestration of TGF-
β1, suggesting that electrostatic interactions with GAGs may play a role regulating TGF-
β1 signaling to promote differentiation. However, it is important to consider that sulfation 
and charge may also alter the extracellular microenvironment through related differences 
in osmotic swelling pressure or through various interactions with the ECM, cell surface 
receptors, or other signaling molecules to influence MSC gene expression in response to 
soluble chondrogenic cues, independent of biomaterial sequestration of TGF-β1. 
Therefore, to fully elucidate the role of GAG-based materials in promoting chondrogenic 
differentiation, further investigation would be required to determine the cellular 
interactions with CS and downstream signals that result in an enhanced chondrogenic 
response. Controlled systems of study may clarify the importance of electrostatic growth 
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factor interactions in promoting differentiation. TGF-β3 would offer a closely related 
molecule with similar signaling mechanism and chondrogenic response to TGF-β1 (pI 
~9.5), but TGF-β3 (isoelectric point, pI ~6.8) would not be expected to electrostatically 
interact with sulfated GAGs at physiological pH due to its difference in charge [274-276], 
providing a closely related comparison to examine the role of electrostatic growth factor 
interactions in differentiation.  
CS and nonsulfated chondroitin may be combined in varying ratios to develop 
materials with a range of negative charge densities, and the results presented here suggest 
that these materials may be valuable tools to examine the role of charge in directing 
differentiation of MSCs in a highly controlled manner. The combined roles of sulfation in 
modulating TGF-β1 sequestration in Chapter 5 and chondrogenic gene expression by 
MSCs in nonsulfated materials in the presence of soluble chondrogenic cues in these 
studies suggested that an intermediate degree of sulfation may be advantageous to 
enhance TGF-β1 signaling and MSC response for greater chondrogenic differentiation. 
Alternatively, altering the presentation of TGF-β1 through a dose response may examine 
the ability of CS-based materials to regulate signaling in response to low TGF-β1 
concentration environments, or temporal control of TGF-β1 presentation by withdrawing 
exogenously supplemented TGF-β1 after a period of pre-culture may examine the 
persistence of these signals in CS-based hydrogels.  
Sulfated and nonsulfated GAG materials provide a highly controlled system to 
examine the interactions between charged GAGs and MSCs to promote chondrogenic 
differentiation, possibly through sequestration of growth factors, and these materials 
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possess tremendous potential as tissue engineering constructs for controlled tissue 
regeneration and patterning. 
 
6.5 Conclusions 
These studies have demonstrated that encapsulation in CS and chondroitin hydrogels 
enhanced gene expression of chondrogenic markers by MSCs in 50% Ch-MA materials 
in the presence of TGF-β1, compared to 50% CS-MA and PEG-only hydrogels, 
suggesting that chondroitin materials may be better suited for supporting chondrogenic 
differentiation than CS, due to their reduced sulfation and negative charge density. 
However, differences in production of cartilaginous ECM were not apparent in between 
Ch-MA and CS-MA hydrogels, as MSCs may lack sufficient space for significant matrix 
deposition in these tightly crosslinked hydrogel scaffolds. Greater degradation of the 
hydrogel network, either through hydrolytic or enzymatic means, may be required to 
facilitate ECM deposition in these GAG-based materials. These results present CS and 
nonsulfated chondroitin materials as valuable tools to alter GAG sulfation in a highly 
controlled manner as a biomaterial approach to differentially regulate MSC response to 
soluble differentiation cues. These concepts represent a first step in the development of 
novel biomaterials for regulating chondrogenic cues to regenerate the complex ECM 





CONCLUSIONS AND RECOMMENDATIONS 
 
7.1 Summary 
Tissue engineering strategies offer exciting and innovative approaches to treat 
cartilage injuries for long-term regeneration and repair; however, difficulty regenerating 
the complex extracellular matrix (ECM) composition and organization of native cartilage 
remains a significant challenge. Mesenchymal stem cells (MSCs) are multipotent 
progenitor cells that are capable of forming cartilaginous tissues, making them a 
promising cell source for tissue repair [6]. In cartilage tissue, cells are expected to 
synthesize, maintain, and remodel the ECM to maintain function and integrity; however, 
the complex cues necessary to promote cartilage formation are not fully understood [5]. 
Recent research has begun to investigate the ability of cartilaginous ECM molecules to 
promote and direct MSC differentiation down a chondrogenic lineage.  
Chondroitin sulfate (CS), a cartilaginous glycosaminoglycan (GAG) that is 
expressed both during cartilage development and in adult cartilage associated with 
proteoglycans, has been shown to promote production of cartilaginous ECM by MSCs [8-
9]; therefore, CS appears to play a role in altering stem cell microenvironments to direct 
differentiation down a chondrogenic lineage. The overall goal of this dissertation was to 
develop versatile biomaterial platforms to control CS presentation to MSCs in order to 
improve understanding of the role of CS in promoting chondrogenic differentiation. To 
investigate chondrogenic response to a diverse set of CS materials, progenitor cells were 
cultured in the presence of CS proteoglycans and CS GAG chains in a variety of 2D and 
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3D material systems, including surfaces coated with aggrecan proteoglycan, CS-based 
nanospheres and microspheres, and desulfated chondroitin hydrogels. Together these 
studies provided valuable insight into the unique ability of CS materials to alter cell 
morphology and growth factor sequestration to promote chondrogenic differentiation as 
part of tissue engineering strategies to promote cartilage regeneration and repair.  
In Chapter 3, cellular interactions with 2D aggrecan-coated surfaces were 
examined for morphology and production of cartilaginous ECM. Aggrecan was passively 
adsorbed onto tissue culture-treated surfaces, and bovine bone marrow stromal cells 
(BMSCs) and anterior cruciate ligament (ACL) fibroblasts were cultured on aggrecan-
coated 2D surfaces, compared to tissue culture-treated control surfaces and nonadhesive 
surfaces that promoted cell aggregation. Culture on aggrecan surfaces promoted cell 
aggregation, and BMSC and ACL fibroblast aggregates significantly upregulated 
aggrecan gene expression and production over 14 days of culture in the absence of 
chondrogenic media supplements, regardless of how cell clustering was induced. These 
findings support the use of aggregate-inducing materials, including CS-modified 
surfaces, to encourage production of aggrecan and emphasize the role of high-density 
culture in promoting production of chondrocytic ECM.  
In Chapter 4, small particle carriers were developed to study CS interactions with 
charged growth factors. CS-derived nanoscale micelles and microscale particles were 
fabricated as potential growth factor carriers to enhance stem cell differentiation, and 
particles were characterized for size, surface charge, cytocompatibility, as well as growth 
factor release. Conjugation with a hydrophobic methacrylamide group induced spherical 
CS micelles to self-assemble in an aqueous environment, and micelles were negatively 
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charged with a bimodal distribution of ~320 and ~73 nm diameters. Larger CS 
microspheres, synthesized from crosslinking of methacrylated CS in a water-in-oil 
emulsion, possessed a rounded morphology and a diameter of ~4.3 µm. Positively 
charged transforming growth factor-β1 (TGF-β1) demonstrated minimal release from CS 
microspheres over 5 days, while negatively charged tumor necrosis factor-α (TNF-α) 
exhibited substantial burst release, suggesting that TGF-β1 electrostatically complexed 
with negatively charged CS. These studies suggested that CS-based carriers can be 
fabricated over a variety of nano- and microscale sizes, as potential ECM-derived carriers 
of positively charged growth factors to direct stem cell differentiation.  
In Chapters 5 and 6, desulfated chondroitin materials were synthesized to study 
sulfation-dependent CS interactions in growth factor sequestration and chondrogenic 
differentiation. CS was chemically desulfated by acidic methanol treatment, and 
desulfated chondroitin materials were thoroughly characterized to ensure desulfation and 
decreased charge density without significant modification of the CS chemical structure. 
Desulfated chondroitin demonstrated ~98.5% desulfation after 7 days of chemical 
treatment. Crosslinked CS hydrogels consistently demonstrated greater sequestration of 
TGF-β1 as indicated by greater depletion from solution and less release after loading, 
than desulfated chondroitin; however, human MSCs encapsulated in nonsulfated 
chondroitin hydrogels experienced significantly greater gene expression of cartilaginous 
markers when cultured for 6 weeks in chondrogenic medium containing TGF-β1. These 
results suggested that controlled desulfation of GAG-based materials modulated growth 
factor interactions, and less sulfated chondroitin materials may support greater 
chondrogenic differentiation of human MSCs in the presence of chondrogenic medium.  
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Together, these findings presented in this dissertation suggested that CS plays an 
important role in directing chondrogenic differentiation via morphological and 
electrostatic interactions, and CS and chondroitin materials are promising tools to control 
GAG presentation within a variety of stem cell microenvironments to promote 
differentiation for cartilage repair.  
 
7.2 Conclusions 
The research presented in this dissertation advances understanding of how diverse 
CS-based biomaterials can control the presentation of GAGs within a variety of stem cell 
microenvironments to promote differentiation. Due to the abundance of CS in 
cartilaginous tissues, both during development and in adult tissues, highly controlled 
GAG presentation may have important implications in the engineering of novel strategies 
for cartilage repair. 2D surfaces, small scale particle carriers, and 3D bulk hydrogels were 
developed from CS-based materials to investigate stem cell interactions with sulfated 
GAGs, and the results of these studies suggested that highly negatively charged CS-based 
materials can 1) present morphological cues to promote cell aggregation and 2) regulate 
biomaterial interactions with charged growth factors to promote differentiation. The 
sulfation and resulting negative charge density of CS appears to play a critical role in 
morphological and growth factor signaling cues that may direct the chondrogenic 
differentiation of MSCs. Together, these results suggested that CS-based materials may 
possess the unique ability to deliver and modulate growth factor interactions through 
delivery and sequestration within stem cell aggregates.  
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Adsorption of the cartilaginous CS proteoglycan aggrecan onto 2D surfaces, as 
described in Chapter 3, promoted cellular aggregation of bovine BMSCs and ACL 
fibroblasts. The presence of aggrecan appeared to resist cell attachment and spreading on 
tissue culture surfaces, forcing adherent cells to cluster in close contact with one another. 
Formation of these dense BMSC and ACL fibroblast aggregates was accompanied by 
upregulation of aggrecan gene expression; however, upregulation was found to be a 
response to morphological cues rather than a response to the aggrecan-coated surfaces. 
Cell aggregates on nonadhesive culture surfaces that encouraged clustering in the absence 
of aggrecan also promoted upregulation of aggrecan gene expression, as well as aggrecan 
production within the cell spheroids. Aggregation may enhance ECM production through 
changes in cell shape, cell-cell contact, or intercellular signaling. These results 
demonstrated that CS-based materials could be used as a naturally-derived material to 
promote cell clustering and emphasized the importance of high density culture in 
promoting and supporting expression and production of cartilaginous ECM.  
Pellet culture and micromass culture are established methods to delay the 
dedifferentiation of chondrocytes or to promote chondrogenic differentiation of MSCs [6, 
98, 304-305]; therefore, it is not surprising that aggregation promoted a more 
cartilaginous phenotype in these studies. High-density culture supports close cell-cell 
contact and appears to mimic the cell environment of mesenchymal condensation that 
occurs during early cartilage development [24, 308]. Within the condensing 
mesenchyme, neural-cadherin (N-cadherin), neural cell adhesion molecule (N-CAM), 
and gap junctions form cell-cell contacts that facilitate intercellular communication and 
play a critical role in regulating the deposition of cartilaginous ECM [24]. As increasing 
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amounts of ECM are produced, the cells are pushed apart until individual chondrocytes 
become embedded in cartilaginous matrix [13, 27]. In this dissertation, aggrecan-coated 
surfaces used a native cartilage proteoglycan to control cell morphology by promoting 
self-assembly into dense cell aggregates, possibly due to the anti-adhesive properties of 
negatively charged CS [402-404]. Subsequent production of aggrecan proteoglycan by 
bovine BMSC and ACL fibroblast aggregates in the absence of exogenous chondrogenic 
factors suggested that aggrecan-mediated clustering may be especially advantageous to 
promote stem cell differentiation toward more cartilaginous or fibrocartilaginous 
phenotypes. CS-containing 3D hydrogels have also been demonstrated to support cell 
aggregation and subsequent production of chondrocytic ECM by encapsulated MSCs in 
the presence of chondrogenic medium [8]. Together, these data suggested that GAG-
based materials could potentially be used as ECM-derived cell carriers to promote cell 
clustering and production of chondrocytic ECM in the development of tissue engineering 
strategies for cartilage repair.  
The importance of high-density culture in chondrogenesis suggested that the 
development of biomaterial platforms to control presentation of CS within dense cell 
aggregates may be advantageous to promote chondrogenic differentiation. A significant 
challenge that accompanies micromass culture of stem cells involves transport properties 
within cell pellets. These dense, multicellular spheroids present numerous barriers to 
diffusion, in particular limited transport of soluble growth factors from the culture 
medium [322]. Insufficient transport may result in heterogeneous or disorganized 
differentiation within MSC pellets or embryonic stem cell (ESC) embryoid bodies; 
therefore, micromass culture presented a need to enhance growth factor signaling within 
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dense cell aggregates. CS-based materials may possess the unique ability to enhance 
growth factor signaling through sequestration, delivery, and release of growth factors to 
promote stem cell differentiation; therefore, CS-based biomaterial platforms were 
developed to examine electrostatic interactions between sulfated GAGs and positively 
charged growth factors.  
Negatively charged GAGs have been shown bind and sequester a variety of 
charged growth factors [263, 272, 319], and these interactions can be exploited for 
controlled growth factor retention and release by GAG-based carriers [262, 264]. CS is a 
naturally occurring ECM component that is abundant in cartilaginous tissues, and TGF-
β1 plays critical roles in promoting chondrogenesis in vivo and in vitro [340-342]; 
therefore, electrostatic interactions between CS and TGF-β1 may be particularly 
advantageous to promote chondrogenic differentiation of stem cells. Sulfated GAGs 
appear to interact with TGF-β1 via basic amino acid residues at the tips of its β-strand 
loops [272, 274], and highly sulfated GAGs may potentiate TGF-β1 activity, suggesting 
that GAG interactions may have a synergistic effect in TGF-β1 signaling [251, 272, 278]. 
CS proteoglycans are highly regulated during mesenchymal condensation during early 
cartilage development [14-18], and culture in CS-containing hydrogels has demonstrated 
upregulated expression and production of chondrocytic ECM by encapsulated 
mesenchymal stem cells in the presence of chondrogenic medium [8-9], suggesting that 
CS may play a unique role in directing growth factor signaling to promote chondrogenic 
differentiation of progenitor cells [14-15].  
Because the high negative charge density of CS is largely attributable to the 
abundance of sulfate groups along its repeating GAG backbone, sulfation was expected 
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to play a significant role in modulating interactions with charged growth factors; 
therefore, in Chapter 5, the role of sulfation in growth factor sequestration was examined 
through chemical desulfation of the primary CS backbone. CS was chemically desulfated 
by acidic methanol treatment for 7 days, and desulfation yielded a nonsulfated 
chondroitin product, resulting in a significant reduction in negative charge density, with 
little modification of the native CS chemical structure. Subsequent methacrylation of 
these chains allowed CS and chondroitin to be covalently crosslinked to form bulk 3D 
hydrogels; therefore, CS and desulfated chondroitin materials provided a highly 
controlled system to study the role of sulfation and resulting negative charge in 
electrostatic sequestration of growth factors, specifically TGF-β1.  
Desulfation of CS was found to alter the sequestration and release of TGF-β1 in a 
sulfation-dependent manner in vitro. In release studies, in which PEG hydrogels 
containing varying amounts of CS and chondroitin were loaded with TGF-β1, 50% CS 
materials demonstrated the greatest retention and the least cumulative release of TGF-β1 
over 7 days, while decreasing the CS content to 10% CS-MA resulted in significantly 
more release, suggesting that CS retained TGF-β1 in a concentration-dependent manner. 
Additionally, 50% chondroitin hydrogels, which maintained an identical total GAG 
content to 50% CS hydrogels but with reduced sulfation, exhibited significantly greater 
release of TGF-β1 than 50% CS-MA, and these results suggested that sulfation and 
corresponding negative charge were critical in facilitating electrostatic interaction with 
growth factors. The ability of CS to retain growth factors, sequestering them from 
release, proposed that CS-based biomaterials may have potential applications in 
sequestering growth factors for enhanced stem cell differentiation.  
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To examine an alternate system of sequestration, rather than release from CS 
materials, hydrogels containing varying ratios of CS and nonsulfated chondroitin while 
maintaining a 50% total GAG content were examined for their ability to deplete soluble 
TGF-β1 by “pulling” it out of solution and trapping it with their hydrogel networks. After 
incubation in a 2 ng/mL TGF-β1 solution, 50% CS hydrogels demonstrated significant 
depletion of soluble TGF-β1 out of solution, while decreasing the sulfation of the GAG 
matrix reduced the observed interaction with TGF-β1 in a sulfation-dependent manner. 
Nonsulfated 50% chondroitin gels exhibited significantly less pull-down of TGF-β1, 
while 10% CS/40% chondroitin hydrogels sequestered an intermediate degree of TGF-
β1. In addition, incubation in 0.5 M NaCl or 10 mg/mL soluble CS significantly inhibited 
the amount of depletion by 50% Ch-MA hydrogels; however, a similar decrease in 
depletion was not observed in 50% CS-MA hydrogels. These results suggested that while 
chondroitin materials retain some ability to electrostatically sequester TGF-β1, likely due 
the presence of negatively charged carboxylates along its repeating backbone, binding 
with chondroitin appeared to be much weaker than with CS. The inability of soluble CS 
to competitively inhibit binding to 50% CS-MA also suggested that TGF-β1 may 
specifically possess a stronger ability to bind to crosslinked CS hydrogels over soluble 
CS. Together these results suggested that CS-MA hydrogels possessed a relatively strong 
ability to sequester soluble TGF-β1 out of solution, and that binding of TGF-β1 can be 
controlled in a sulfation-dependent manner through chemical desulfation of CS.  
Desulfation of CS provides a well-controlled biomaterial system to alter the 
electrostatic interactions between CS and charged growth factors, and these materials 
could therefore be used to control presentation of growth factors to stem cells for 
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differentiation. The ability of CS and chondroitin to differentially “pull-down” soluble 
TGF-β1 out of solution provided rationale to examine the effect of differentially sulfated 
materials on the chondrogenic differentiation of MSCs, as CS may similarly sequester 
TGF-β1 from chondrogenic media for controlled presentation to encapsulated MSCs. To 
characterize the cellular response while entrapped in CS and nonsulfated chondroitin 
matrix, human MSCs were encapsulated in PEG hydrogels containing either 50% CS or 
50% chondroitin and cultured for 6 weeks in chondrogenic medium containing TGF-β1, 
as discussed in Chapter 6. Encapsulation in PEG-based hydrogels provided an established 
model for chondrogenic differentiation of MSCs in vitro [136, 199, 206-208], and PEG-
based materials, in particular, have been used in the past as systems to investigate the 
effects CS matrix on chondrogenic differentiation of MSCs [8-9, 252].  
CS- and chondroitin-containing materials were shown to differentially modulate 
the chondrogenic response of encapsulated MSCs in response to chondrogenic growth 
factor, suggesting that sulfation may play a role in regulating chondrogenic 
differentiation; however, MSCs in 50% chondroitin hydrogels displayed significantly 
greater upregulation of chondrogenic markers than 50% CS gels after 6 weeks of culture 
in chondrogenic medium. Chondrogenic gene expression in chondroitin hydrogels was 
dependent on the presence of exogenously supplemented TGF-β1 in the medium, 
suggesting that chondroitin materials alone were not sufficient to upregulate expression 
and that desulfation of the CS matrix enhanced the chondrogenic response to TGF-β1. 
Despite a higher degree of TGF-β1 sequestration, as shown in Chapter 5, the high 
negative charge density of CS in these materials could possibly decrease TGF-β1 
signaling activity or inhibit transport within the hydrogel network. The highly charged 
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CS matrix may also prevent transport of other cell-secreted signals within the hydrogel, 
effectively inhibiting intercellular communication, which plays an important role in 
supporting chondrogenic differentiation and maintaining a chondrocytic phenotype [24, 
38, 394-395]. Removal of sulfate groups from CS, however, appeared to promote MSC 
differentiation, possibly through enhanced growth factor signaling. Desulfated 
chondroitin materials remained moderately negatively charged at physiological pH, due 
to the presence of carboxylates in the chondroitin structure, and chondroitin may still 
possess electrostatic interactions with TGF-β1, though binding appeared to be weaker 
than with CS. These results suggested that decreasing the degree of sulfation in GAG-
based hydrogels may be better suited for supporting chondrogenic differentiation than 
highly sulfated CS, despite stronger electrostatic interaction with CS, and that CS and 
chondroitin materials possess potential as biomaterials to alter stem cell 
microenvironments to differentially regulate chondrogenic differentiation of MSCs.  
Unfortunately, despite large differences in gene expression after 42 days of 
culture in vitro, relatively little ECM deposition was observed within the hydrogel 
constructs with no noticeable difference between CS and chondroitin hydrogels. This is 
likely due to the small mesh size of these highly-crosslinked hydrogel constructs, as 
MSCs may have lacked sufficient extracellular space for significant matrix production. 
Controlled degradation of the hydrogel network may play a key role in facilitating ECM 
deposition by encapsulated MSCs, either by hydrolytic or cell-mediated enzymatic 
means. Hydrolytic degradation of crosslinked hydrogel scaffolds is dependent on the 
number of ester moieties within the polymer backbone; however, the degradation rate of 
these esters can be systematically controlled by altering the hydrophilicity of the 
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surrounding environment. Cell-mediated degradation through the incorporation of matrix 
metalloproteinase (MMP)-cleavable peptide sequences can encourage controlled 
degradation localized to the extracellular environment, and degradation rate can be 
customized through these peptides for susceptibility to cleavage, as well as specificity to 
a single MMP type that is expressed by specific cell populations [169, 185-187, 396]. 
Controlled degradation of CS-MA and Ch-MA hydrogel networks may facilitate greater 
ECM deposition and enhanced chondrogenic differentiation by encapsulated MSCs.  
Despite significant upregulation of chondrogenic markers, collagen X, an ECM 
marker of hypertrophic chondrocytes, was also significantly upregulated in 50% 
chondroitin hydrogels; however, 50% CS gels exhibited visibly greater deposition of 
pericellular collagen X after 42 days than 50% chondroitin. Hypertrophy of chondrogenic 
MSCs remains a key challenge to in vitro differentiation [97, 103-104]; however, just as 
specific signals may promote chondrogenic differentiation of MSCs, it is also likely that 
additional signals may be required to maintain a mature chondrocyte phenotype, while 
inhibiting progression toward hypertrophy. Indian hedgehog (Ihh) and parathyroid 
hormone-related protein (PTHrP) signaling appear to interact in vivo through paracrine 
signaling from the perichondrium to regulate chondrocyte maturation and hypertrophy 
[38]. Basic fibroblast growth factor (bFGF) and PTHrP have also been investigated for 
their ability to delay hypertrophy and maintain chondrocytic phenotype in vitro with 
some success [106-109]. Additionally, collagen type I gene expression and production 
did not appear to decrease in 50% chondroitin materials, representative of a more 
fibrocartilaginous response. Collagen type I is normally produced in high amounts by 
undifferentiated MSCs; however, during cartilaginous condensation in early 
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development, collagen I expression is turned off and replaced with production of collagen 
type II and aggrecan proteoglycan in the formation of articular cartilage [24]. Together 
these results suggested that a variety of diverse signals may be required, along with both 
spatial and temporal control of these signals, to properly support chondrogenic 
differentiation and maintenance of a chondrocytic phenotype.  
The desulfation of CS provided a highly controlled biomaterial system to alter 
both the sulfation and charge of CS-based materials, with minimal modification of the 
GAG chemical structure, to examine sequestration of soluble signals for MSC 
differentiation toward a chondrogenic phenotype. The combined roles of sulfation in 
modulating TGF-β1 sequestration and chondrogenic gene expression by MSCs in the 
presence of soluble chondrogenic cues in these studies suggested that an intermediate 
degree of sulfation may be advantageous to enhance TGF-β1 signaling and MSC 
response for greater chondrogenic differentiation. The ability of desulfation to promote 
chondrogenic gene expression in these studies suggested that an optimal amount a charge 
may exist to facilitate growth factor interaction, while possibly permitting intercellular 
communication. As demonstrated in Chapters 5, CS materials can be either be partially 
desulfated by time-dependent acidic methanol treatment or CS and nonsulfated 
chondroitin can be combined in varying ratios to develop materials with a range of 
negative charge densities without altering the total GAG content or composition within 
the bulk material. Additionally these materials may possess the unique ability to 
potentiate signaling in low TGF-β1 concentration environments or to retain growth factor 
for sustained signaling after removal of soluble TGF-β1 from the medium. This 
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demonstrates that CS and chondroitin are versatile systems for highly controlled 
interaction with stem cells and growth factors.  
Due to the low degree of total ECM deposition observed in these tightly 
crosslinked hydrogel systems, ECM production may be enhanced by increasing the ratio 
of cells to matrix, thus allowing the encapsulated cells to further remodel the GAG 
network. While this model system involved encapsulation of MSCs in a large amount of 
crosslinked GAG matrix to examine its role in promoting a chondrogenic response, at the 
other extreme, lesser amounts of CS-based materials could be incorporated into a 
multicellular mass to allow unrestricted ECM deposition in response to cues from the 
incorporated CS matrix. Specifically, CS-based small particle carriers could potentially 
be incorporated to MSC aggregates to permit close cell-cell contact and used to deliver 
various growth factors throughout the cell aggregates for enhanced differentiation, 
compared to diffusion of soluble factors from the medium [322].  
As described in Chapter 4, CS-based small particle carriers were developed for 
controlled delivery of charged growth factors. As a first step, CS-based nanoscale 
micelles and microscale particles were fabricated and characterized as small particle 
carriers for growth factor delivery. With low degrees of modification, methacrylamide-
conjugated CS (CSMAm) self-assembled into ~73 nm and ~320 nm diameter micelles in 
aqueous solution. These micelle particles were found to possess a highly negative surface 
charge, suggesting that they may electrostatically interact with positively charged growth 
factors. Crosslinking of methacrylated CS (CSMA) in a water-in-oil, single-emulsion 
resulted in the formation of larger CS microspheres with an average diameter of 4.3 µm. 
CSMA microspheres were shown to retain positively charged TGF-β1 with little release 
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over 5 days, while negatively charged TNF-α exhibited substantial burst release within 15 
hours at physiological pH. These results suggested that negatively charged CSMA 
microspheres electrostatically interacted with TGF-β1, sequestering it from release. 
CSMA microspheres were successfully incorporated into ESC embryoid bodies with 
good cytocompatibility, suggesting that CSMA microspheres may possess unique 
application as carriers for controlled delivery and presentation of growth factors within 
dense multicellular aggregates. Together with techniques for desulfation of CS to control 
electrostatic interactions and the ability of CS matrix to differentially modulate 
chondrogenic response in the presence of TGF-β1, this work represents a first step in the 
development of novel biomaterials to control presentation of CS in high-density 
micromass culture to promote chondrogenic differentiation of MSCs.  
While traditional tissue engineering paradigms involve the culture of dispersed 
cells within a biomaterials scaffold and supplementation of exogenous differentiation 
cues through the culture medium, this work presents an alternative approach in which 
small scale biomaterials are entrapped throughout a cellular mass with delivery of 
differentiation factors from the embedded biomaterial carriers. This is a novel idea for 
tissue engineering of cartilaginous tissues in which high-density culture and formation of 
cell-cell contacts play important roles in differentiation. The ability of CS to 
electrostatically sequester TGF-β1 also may resolve transport limitations associated with 
traditional micromass culture. GAG-based materials have been shown to possess 
electrostatic interactions with a number of other chondrogenic growth factors including 
bone morphogenetic protein-4 (BMP-4), insulin-like growth factor-1 (IGF-1), and bFGF, 
some of which have demonstrated additive effects when supplemented in combination or 
 
164 
sequentially with TGF-β [25, 256, 264, 273]. These results suggest that CS-based carriers 
could be used as an ECM-derived carrier to deliver a variety of signals within a spatially 
and temporally controlled environment to promote differentiation of stem cell aggregates.  
The CS-based biomaterials presented in this dissertation provide highly controlled 
systems to alter a variety of signals within stem cell microenvironments. CS-based 
materials were shown to regulate cell aggregation, presentation of sulfation and charge, 
growth factor interactions, and MSC response to soluble chondrogenic cues, and these 
materials possess tremendous potential to control growth factor signaling within stem cell 
microenvironments. Therefore, CS-based materials are valuable tools to investigate the 
role of a diverse array of soluble, physical, and morphological cues in stem cell 
differentiation, and additional spatial and temporal control can be engineered into this 
unique biomaterial system to modulate the stem cell environment to promote 
differentiation.  
 
7.3 Future Directions 
The findings presented in this dissertation provide significant insights into the 
potential interactions of sulfated GAGs that alter stem cell microenvironments to promote 
chondrogenic differentiation, including cell aggregation and electrostatic interactions 
with growth factors. A variety of CS-based materials, including 2D surfaces, small scale 
particles, and bulk hydrogels with varying degrees of sulfation, were developed as novel 
tools to control CS presentation to stem cells to investigate the role of CS in 
chondrogenic differentiation; however, future work can expand on the insights gained 
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from this dissertation to examine mechanisms through which GAG-based materials 
control stem cell differentiation.  
The results of these experiments suggested that careful control of GAG structure 
may present a unique opportunity to further investigate the control of charge and 
sulfation in supporting chondrogenic differentiation. The studies in this dissertation 
represent a broad examination of how sulfated CS and nonsulfated chondroitin 
independently influence chondrogenic differentiation; however, significant differences in 
gene expression in chondroitin materials suggested that an intermediate level of sulfation 
and negative charge may be more optimal for chondrogenic differentiation, as greater 
degree of TGF-β1 sequestration in CS materials did not translate to a stronger 
chondrogenic response. An intermediate charge density may facilitate moderate 
interaction with growth factors while still permitting transport of soluble factors and 
potential intercellular communication.  
For a thorough investigation of charge, CS materials can either be partially 
desulfated by time-dependent acidic methanol treatment or CS and nonsulfated 
chondroitin can be combined in varying ratios to develop materials with a range of 
negative charge densities without altering the total GAG content or composition within 
the bulk material; however, the distribution of sulfation would differ in these two 
approaches, as the former would contain a homogenous undersulfated CS variant, while 
the latter would include primarily monosulfated CS chains in a mixture of completely 
desulfated chondroitin. Differences in these two approaches may be able to address the 
role of sulfation patterning and density, compared to the role of bulk charge, in CS-based 
materials for growth factor sequestration and chondrogenic differentiation. In addition, 
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greater charge than the primarily monosulfated CS used in this dissertation can be 
achieved through a variety of chemical techniques to oversulfate CS [25-26], and 
desulfated chondroitin, which remains negatively charged at physiological pH due to the 
presence of carboxylates in the chondroitin structure, could be chemically modified to 
possess a neutral charge. A neutrally charged chondroitin material may be especially 
valuable to examine the effects of uncharged GAG variants, and such a material could be 
easily obtained in the methyl ester intermediate as a part of the acid methanol treatment, 
as described in Chapter 5, in which the carboxylates of chondroitin are methylated, 
resulting in a neutral charge. This versatility to control charge over a wide range from 
uncharged to oversulfated CS chains offers a highly controlled system to investigate the 
various roles of sulfation and charge in growth factor interactions and differentiation, 
without modification of the primary CS backbone.  
Besides total degree of sulfation or total charge density, sulfation pattern may also 
play important roles in modulating GAG interactions with cells, signaling molecules, and 
the ECM. It has been documented that 2-O-sulfation is especially critical for growth 
factor interactions in heparin [266-267, 270, 358], and CS sulfation pattern has been 
shown to alter electrostatic interactions with Co(NH3)6
+3
 cations, in which monosfulated 
chondroitin-4-sulfate possessed greater affinity than equally sulfated chondroitin-6-
sulfate [405]. In Chapters 5 and 6 of this dissertation, the chondroitin sulfate used 
contained a mixture of 58% chondroitin-6-sulfate and 27% chondroitin-4-sulfate 
disaccharides, along with a 15% mixture of other nonsulfated and disulfated 
disaccharides, as determined in Chapter 5. This CS composition was chosen both as a 
result of its increased susceptibility to desulfation as described in Chapter 5, as well as 
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chondroitin-6-sulfate’s relative prevalence in adult human articular cartilage; however, 
chondroin-4-sulfate is more highly expressed during growth and development of human 
cartilage before decreasing expression in the mature tissues [20, 231], suggesting that 4-
sulfation may potentially play an increased role in differentiation and development. 
Differences in sulfation pattern, specifically increased chondroitin-4-sulfate composition, 
may exhibit important differences in growth factor interaction and stem cell 
differentiation that were not observed in this examination of a single CS mixture that was 
a majority chondroitin-6-sulfate.  
It is also important to recall that CS is predominantly associated as part of 
proteoglycans in vivo in which GAGs are bound to a core protein. In cartilage 
specifically, versican is expressed in cartilaginous condensations during development 
[218-219], while aggrecan is the predominant proteoglycan in mature cartilage [31]; 
therefore, presentation of GAGs in conjunction with the full proteoglycan structure may 
further alter GAG presentation to control ECM interactions and cellular presentation. To 
fully understand the role of GAGs in cartilaginous tissues, a thorough investigation of 
cellular response in the presence of CS proteoglycans would be necessary to elucidate the 
roles of the protein core, GAG presentation, and interplay between GAGs and their 
protein cores in signaling and tissue formation.  
Although these studies demonstrated that sulfation of CS influenced growth factor 
interactions and that differential sulfation also altered the chondrogenic response, the 
cellular response was not conclusively linked to growth factor signaling, as differences in 
charge also could potentially alter osmotic swelling pressure or other various ECM 
interactions that influence the extracellular microenvironment [20-21, 250]. Therefore, to 
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fully understand the role of CS in promoting chondrogenic differentiation, further 
investigation is also required to determine the cellular interactions with CS that result in 
an enhanced chondrogenic response. While it is difficult to completely separate the 
independent effects of sulfation, fixed charge, osmotic pressure, swelling, and 
electrostatic interactions with a variety of molecules without significant modification of 
these materials, due to their high interdependency, controlled systems of study may begin 
to start clarifying the importance of these factors in promoting differentiation.  
Specifically, regarding growth factor interactions with TGF-β1 as presented in 
this dissertation, use of TGF-β3 would offer a closely related molecule with similar 
signaling mechanism and chondrogenic response to TGF-β1; however, TGF-β3 is not 
expected to electrostatically interact with sulfated GAGs at physiological pH [274-275]. 
The isoelectric point of TGF-β3 is ~6.8, compared to ~9.5 in TGF-β1, suggesting that 
TGF-β3 is slightly negatively charged at physiological pH [275-276]. Additionally, a 
basic amino acid at position 26 in TGF-β1, a central part of the hypothesized GAG-
binding site, appears to be replaced with a neutral amino acid in TGF-β3, suggesting that 
it may be less likely to interact with CS [274].  
To fully implicate TGF-β1 in the chondrogenic response observed in chondroitin 
hydrogels, a comprehensive investigation of the downstream receptors and signaling 
molecules, such as SMAD and ERK/MAPK pathways, would be required to determine 
the differential effects of growth factor signaling in these materials [406-408]. 
Subsequent receptor blocking and inhibition of these pathways could begin to answer 
these questions; however, signaling from chondrogenic growth factors appeared to play 
an important role in these interactions, as culture of MSCs in chondroitin materials in the 
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absence of chondrogenic medium did not observe comparable effects from the material 
alone.  
It is, however, important to note that MSCs encapsulated in CS-MA hydrogels did 
significantly upregulate collagen II gene expression, and to a lesser extent aggrecan, in 
the absence of TGF-β1 and dexamethasone on day 21, while chondroitin materials did 
not, in an investigation of these materials at earlier time points and lower cell density 
(Figure A.2). Investigation of CS and chondroitin materials in low TGF-β1 environments 
warrants further examination to determine the corresponding roles of TGF-β1 signaling 
in these two materials. The effects of a TGF-β1 dose response on MSC expression in the 
presence of CS and chondroitin materials may clarify these patterns, particularly at low 
and intermediate TGF-β1 concentrations. Chondrogenic medium commonly uses 10 
ng/mL TGF-β1 to promote chondrogenic response [6]; however, this concentration is 
quite high, in order to promote a strong signaling response and encourage chondrogenic 
differentiation. CS-based materials, however, may potentiate chondrogenic response by 
sequestering TGF-β1 and increasing the local concentration of growth factor in close 
proximity to cells or enhancing signaling efficiency within a GAG-based scaffold. CS 
and chondroitin materials may be uniquely capable of capturing and potentiating signals 
in low TGF-β1 concentrations, while overwhelming TGF-β1 concentrations may 
negatively impact the additional signals necessary to promote chondrogenic 
differentiation.  
As the goal of tissue engineering is to develop replacement tissues for tissue 
repair, it remains critically important that chondrogenic MSCs in these CS-based systems 
produce cartilaginous ECM in a controlled fashion. The hydrogel materials discussed in 
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Chapter 6, however, supported relatively little ECM production, and all matrix 
production was restricted to the pericellular domains. It is likely that enhanced 
degradation of the hydrogel network may be required to support deposition of 
cartilaginous ECM, and because human MSCs do not appear to produce sufficient 
amounts of chondroitinase enzyme to encourage substantial degradation of the GAG 
matrix, additional mechanisms of degradation may be required to support ECM 
production. Hydrolytically degradable and cell-mediated enzymatically cleavable 
functionality have been investigated in similarly crosslinked PEG-based system [169, 
185-187, 396]; therefore, similar functionality could be incorporated in GAG-based 
systems to examine the role of degradation on enhanced ECM deposition. 
The unique ability of CS-based materials to selectively sequester soluble signals 
from solution suggests that CS-based materials may also possess considerable potential in 
spatial patterning of scaffolds to control differential effects of signaling. CS and 
chondroitin materials may be used to either trap soluble signals to potentiate signaling, or 
alternatively to sequester cell-secreted signals and restrict paracrine signaling in a 
spatially-defined fashion. These principles can be applied to spatially patterned hydrogel 
materials through photolithographic techniques to promote differential signaling from a 
single cell type within a single media formulation, by differentially trapping soluble cues 
from the medium in the CS matrix [192, 195, 197]. Spatially controlled GAG-based 
scaffolds may represent novel biomaterial systems to regenerate tissue interfaces through 
co-culture of multiple cell types through differential signaling, as well as promoting 
formation of various properties within a single tissue, such as the depth-dependent zones 
of cartilage.  
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Due the importance of cell-cell contact in production of cartilaginous ECM 
exhibited in Chapter 3, CS-based microparticles demonstrate a versatile delivery system 
to examine the effects of CS within chondrogenic MSC spheroids. The use of CS 
microparticles within MSC micromass cultures offers an innovative system to control 
growth factor presentation for “inside-out” delivery, as opposed out “outside-in” 
signaling via diffusion from the medium, through the use of naturally-derived GAG 
materials that may potentiate signaling and support further interaction with surrounding 
cells. While microparticle carriers were developed for growth factor delivery within MSC 
and ESC spheroids, as described in Chapter 4, a thorough examination is required to 
characterize their role in promoting chondrogenic differentiation. A few studies have 
begun to investigate the role of adhesion peptides and TGF-β delivery in MSC pellets to 
promote chondrogenic differentiation [409-410], and these experiments can be used as 
guiding principles in the optimization of this CS-based delivery system as an ECM-
derived growth factor carrier for cartilage regeneration. Additional incorporation of 
desulfated chondroitin materials into this microparticle carrier system may offer further 
control of growth factor affinity, release kinetics, and signaling activity to control 
differentiation, as has been suggested in Chapters 5 and 6 of this dissertation.  
Aside from being a system to promote differentiation through growth factor 
interactions, GAG-based materials may possess significant application as an analytical 
tool to study stem cell signaling. GAG-based materials may be capable of “trapping” 
specific cell-secreted signals for characterization and potential future delivery. 
Microparticles may be incorporated into stem cell aggregates, such as ESC embryoid 
bodies, to sequester cell-secreted signals involved in the maintenance and self-renewal of 
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differentiation potential. Dissociation of the cell spheroids and retrieval of the 
microparticles for molecular analysis may be able to clarify the complex array of secreted 
signals that are involved in stem cell signaling. Use of GAG-based materials as an 
analytical tool to identify molecular players in stem cell signaling may be a novel 
paradigm for stem cell engineering and development of regenerative therapies for tissue 
repair.  
Future work can expand on the various principles presented in this dissertation to 
develop precisely controlled temporal, spatial, and physical cues to enhance 
chondrogenic differentiation for tissue engineering repair, such as controlled release and 
presentation of numerous signaling molecules, inclusion of biomimetic peptides or 
adhesive cues, and application of mechanical strain. Additionally, while this dissertation 
chose to focus on CS and chondrogenic differentiation, due to the prevalence of CS 
matrix in cartilaginous tissues, numerous GAGs are found throughout the body for a 
variety of functions. GAGs such as heparin, heparan sulfate, dermatan sulfate, keratan 
sulfate, and hyaluronan may support similar roles, including interaction with a variety of 
signaling molecules, and these materials may possess significant application in strategies 
to promote tissue repair. The research presented in this thesis provided valuable insights 
into the contributions of GAG matrix in the development, maintenance, and repair of 
cartilaginous tissues, and these findings improve understanding of the role of local 
chemical, biomolecular, and overall physical environments in the development of 






A.1 Viability in CS-MA and Ch-MA hydrogels at 10x106 cells/mL 
A.1.1 Materials and Methods 
Materials and methods were performed as described in Chapter 6, with the lone 
exceptions being that MSCs were incorporated at 10x10
6
 cells/mL, hydrogels were 
cultured both in the presence and absence of 10 ng/mL TGF-β1 and 100 nM 
dexamethasone, and time points for analysis were performed on days 1, 7, 14, and 21. 
A.1.1.1 Encapsulation of Human MSCs 
Human mesenchymal stem cells (MSCs) were encapsulated in hydrogels 
containing a 1:1 ratio of OPF 10K:PEG-DA and 50% chondroitin sulfate methacrylate 
(CS-MA) or 50% chondroitin methacrylate (Ch-MA) by dry mass at a final cell 
concentration of 10x10
6
 cells/mL. PEG controls containing 60% PEG-DA:40% OPF 
were used as swelling controls for 50% Ch-MA materials. Hydrogels were cultured for 3 
weeks in basal medium composed of high glucose DMEM containing 1% ITS+ culture 
supplement, 1% nonessential amino acids, 50 μg/mL ascorbate-2-phosphate, and 1% 
antibiotic/antimycotic, or in chondrogenic medium supplemented with 10 ng/mL TGF-β1 
and 100 nM dexamethasone. 
A.1.1.2 LIVE/DEAD Staining for Viability 
On days 1, 7, 14, and 21, hydrogels were stained for 60 minutes in LIVE/DEAD 




A.1.1.3 PicoGreen DNA Assay 
PicoGreen assay was used to evaluate the total DNA content in each sample on 
days 1, 7, 14, and 21. Within each hydrogel formulation, DNA content of each gel was 
normalized to wet mass to correct for small differences in gel size (n=4). 
A.1.1.4 Statistical Analysis 
A two-factor analysis of variance (ANOVA) was used to determine statistical 
significance of groups, and Tukey's post hoc multiple comparison test with significance 
set at p≤0.05 indicated significance between individual samples. For DNA analysis, the 
factors were hydrogel type and time.  
A.1.2 Results 
LIVE/DEAD staining of human MSCs in 50% CS-MA and 50% Ch-MA 
hydrogels indicated that visible MSCs remained mostly viable over 3 weeks of culture 
(Figure A.1a). Cells remained dispersed evenly throughout the hydrogel scaffolds with a 
spherical shape, and no cell aggregation or spreading was observed. Total DNA content, 
as a measure of cell number, suggested that cellularity decreased over time in all 
hydrogel formulations (Figure A.1b). DNA content significantly decreased from day 1 to 
day 7 in CS-MA and Ch-MA hydrogels and by day 14 in PEG controls. DNA content 
was fairly consistent across hydrogel types from day 1 until day 14; however, PEG 
control hydrogels experienced a significant decrease in DNA content on day 21, 





Figure A.1. Viability and cellularity of human MSCs encapsulated in 50% CS-MA 
and 50% Ch-MA hydrogels at 10x10
6
 cells/mL in chondrogenic medium. (a) Human 
MSCs appeared largely viable in all hydrogel formulations over 21 days of culture. 
Cells remained dispersed with a rounded morphology. Scale bars = 100 μm. (b) 
DNA content, as a measure of cellularity, decreased over time with a significant 
decrease observed between day 1 and day 7 in CS-MA and Ch-MA hydrogels and 
by day 14 in PEG controls. Additionally, a significant decrease in DNA content was 
measured in PEG control hydrogels on day 21. * indicates significantly less DNA 
than day 1 (p≤0.05). # indicates significantly less DNA than 50% Ch-MA at the same 
time point (p≤0.05). + indicates significantly less DNA than 50% CS-MA at the same 
time point (p≤0.05). 
 
 
A.2 Gene expression in the presence and absence of TGF-β1 at 10x106 cells/ml 
A.2.1 Materials and Methods 
Materials and methods were performed as described in Chapter 6, with the lone 
exceptions being that MSCs were incorporated at 10x10
6
 cells/mL, hydrogels were 
cultured both in the presence and absence of 10 ng/mL TGF-β1 and 100 nM 
dexamethasone, and time points for analysis were performed on days 1, 7, 14, and 21. 
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These differences in cell encapsulation and culture conditions are described in detail in 
Section A.1.1.1.  
A.2.1.1 Reverse transcription polymerase chain reaction 
Gene expression of encapsulated MSCs was analyzed after 1, 7, 14, and 21 days 
by reverse transcription polymerase chain reaction (RT-PCR). RNA was extracted and 
reverse transcribed, and quantitative PCR amplification for each gene target was 
performed for gene expression of human mRNA for collagen II, aggrecan, and SOX9 
(chondrocytic markers), and for collagen X (hypertrophic chondrocyte marker). To 
determine fold regulation over 50% Ch-MA hydrogels in the absence of TGF-β1 on day 
1, the raw fluorescence data was processed using LinRegPCR with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as an endogenous control (n=6).  
A.2.1.2 Statistical Analysis 
PCR amplification data for each gene were first transformed using a Box-Cox 
transformation to obtain a normal distribution for analysis. A three-factor analysis of 
variance (ANOVA) was used to determine statistical significance of groups, and 
Tukey's post hoc multiple comparison test with significance set at p≤0.05 indicated 
significance between individual samples. For gene expression analysis, the factors were 
hydrogel type, media type, and time.  
A.2.2 Results 
In the presence of chondrogenic medium, human MSCs encapsulated in 
nonsulfated 50% Ch-MA hydrogels significantly upregulated gene expression of the 
cartilaginous ECM molecules collagen II and aggrecan on days 7, 14, and 21, over 50% 
CS-MA hydrogels (Figure A.2a-b). MSCs in 50% Ch-MA expressed 186 ± 162 fold 
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upregulation of collagen II expression on day 21, compared to only 0.022 ± 0.015 in 50% 
CS-MA and 9.9 ± 19.2 fold in PEG controls (Figure A.2a). Similarly, aggrecan 
expression in Ch-MA gels was upregulated 27.6 ± 9.5 fold on day 21 in the presence of 
TGF-β1, compared to 10.8 ± 3.7 in CS-MA and 7.8 ± 1.5 in PEG (Figure A.2b). 
Cartilaginous transcription factor SOX9 experienced slight upregulation on day 7 only in 
50% Ch-MA with 1.57 ± 0.29 fold regulation, while CS-MA only expressed 0.51 ± 0.41 
fold regulation (Figure A.2c). Collagen X, an ECM marker of hypertrophic chondrocytes, 
was also significantly upregulated in Ch-MA hydrogels over CS-MA controls in 
chondrogenic medium on days 7, 14, and 21 (Figure A.2d). MSCs in 50% Ch-MA 
exhibited large upregulation of collagen X of 4,350 ± 1390 fold on day 21, compared to 
655 ± 371 in CS-MA.  
In the absence of chondrogenic medium, MSCs encapsulated in 50% Ch-MA 
hydrogels did not upregulate any of the chondrogenic markers analyzed here. 50% CS-
MA hydrogels, on the other hand, significantly upregulated collagen II gene expression 
compared to both Ch-MA hydrogels in basal medium and CS-MA gels in chondrogenic 
medium on days 14 and 21. MSCs in CS-MA hydrogels expressed 69.9 ± 19.2 fold 
upregulation of collagen II on day 21 in basal medium, compared to 1.28 ± 1.66 fold in 
Ch-MA. Aggrecan and collagen X were also upregulated on day 21 in 50% CS-MA in 






Figure A.2. Gene expression of chondrocytic markers by MSCs in 50% CS-MA and 
50% Ch-MA hydrogels at 10x10
6
 cells/mL in chondrogenic and basal medium. 
MSCs in 50% Ch-MA hydrogels significantly upregulated gene expression of (a) 
collagen II and (b) aggrecan on days 7, 14, and 21 in chondrogenic medium, and (c) 
SOX9 on day 7 only, compared to 50% CS-MA. 50% CS-MA hydrogels in basal 
medium, however, upregulated expression of (a) collagen II and (b) aggrecan after 
21 days, compared to 50% Ch-MA. (d) Hypertrophic chondrocyte marker collagen 
X was also significantly upregulated in 50% Ch-MA gels on days 7, 14, and 21 in 
chondrogenic medium over 50% CS-MA, while 50% CS-MA in basal medium 
upregulated collagen X expression only on day 21, compared to 50% Ch-MA. * 
indicates significantly greater than 50% CS-MA in same medium and at same time 
point (p≤0.05). # indicates significantly greater than PEG controls in same medium 
and at same time point (p≤0.05). + indicates significantly greater than 50% Ch-MA 
in same medium and at same time point (p≤0.05). § indicates significantly greater 







A.3 Immunostaining for ECM in CS-MA and Ch-MA hydrogels at 10x106 
cells/mL 
A.3.1 Materials and Methods 
Materials and methods were performed as described in Chapter 6, with the lone 
exceptions being that MSCs were incorporated at 10x10
6
 cells/mL, hydrogels were 
cultured both in the presence and absence of 10 ng/mL TGF-β1 and 100 nM 
dexamethasone, and time points for analysis were performed on days 1, 7, 14, and 21. 
These differences in cell encapsulation and culture conditions are described in detail in 
Section A.1.1.1.  
A.3.1.1 Histological staining 
ECM production by encapsulated MSCs was determined by immunostaining on 
days 1, 7, 14, and 21. For aggrecan staining, samples were deglycosylated with 30 µl of 
0.75 U/ml chondroitinase ABC for 1.5 hours. For primary antibody binding, sections 
were incubated in monoclonal mouse anti-human collagen I, collagen II, or aggrecan. 
Sections were then incubated with highly cross-adsorbed Alexa Fluor 488-conjugated 
goat polyclonal anti-mouse immunoglobulin G (IgG), and counterstained with 0.1 μg/mL 
4',6-diamidino-2-phenylindole (DAPI) (n=2). Negative controls were stained as 
described, but using a monoclonal mouse IgG1 isotype control with no known reactivity 
with human antigens as the primary antibody at 10 μg/mL. 
A.3.2 Results 
Immunostaining for ECM production demonstrated that while some accumulation 
of cartilaginous ECM collagen II and aggrecan was observed pericellularly over 21 days, 
staining was generally weak and clear differences were not apparent between CS-MA and 
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Ch-MA formulations (Figure A.3a-b). Deposition of collagen I appeared to persist over 
time, but few differences were observed between CS-MA and Ch-MA hydrogels (Figure 
A.3c). Isotype controls demonstrated little non-specific staining (Figure A.3d).  
 
 
Figure A.3. Immunostaining for ECM deposition by MSCs in 50% CS-MA and 
50% Ch-MA hydrogels at 10x10
6
 cells/mL in chondrogenic medium. (a) Collagen II, 
(b) aggrecan, and (c) collagen I were produced in relatively small quantities by 
MSCs in CS-MA and Ch-MA hydrogels, and there were no distinguishable 
differences across gel types. (d) Isotype controls demonstrated little non-specific 







B.1 OPF Synthesis 
Fumaryl Chloride (FuCl) Distillation (if necessary) 
Warning: Fumaryl chloride has a very pungent odor. Work only in the fume hood with 
the sash down as far as possible. Double glove, and leave jars, glassware, used gloves in 
the hood overnight to air out.  
1) Wash and dry:  
2 x 500 ml round-bottom flasks, 1 x joint for thermometer, 1 x thermometer to fit 
joint (~160°C), 1 x large condenser, 1 x glass elbow, 1 x joint for desiccators,  
1 x glass stopper, 1 x glass funnel, 1 x egg-shaped FuCl stir bar.  
2) Set up the distillation apparatus as shown, without the FuCl flask and collection flask: 
 
3) Replace the 500 ml collection flask with a 100 ml round bottom flask to collect the 
first 30 ml of distillate.  
 
182 
4) Clamp the apparatus to the scaffolding in the back of the fume hood.  
5) Vacuum grease and clamp all connections.  
6) Run cold, ice water UP the condenser tube using the circulation pump. This allows 
any bubbles to flow up and out of the condenser. Make sure that the circulation pump 
is not actively heating the water by turning the temperature control all the way down 
to -20°C. 
7) Tie a KimWipe around the bottom of the condenser to catch external condensation.  
8) Use the funnel to pour 150 ml (100 g) of FuCl into a 500 ml round-bottom flask.  
9) Add the FuCl stir bar into the FuCl flask.  
10) Vacuum grease the FuCl flask, and connect the flask to apparatus.  
11) Place the flask in heating mantle with magnetic stirring at ~3.  
12) Insulate the flask and neck with glass wool all the way up to the condensing tube to 
promote boiling and prevent condensation.  
13) Start the transformer at 40 units.  
14) Increase the transformer by 10 units, every 5 minutes.  
15) Increase the transformer until the vapor temperature is 160°C (~80 units on 
transformer).  
16) Dispose of the first ~30 ml of distillate by turning the neck up, removing the 1st 100 
ml collection flask, and quickly replacing it with a clean 500 ml round-bottom flask.  
17) FuCl distillate should be a light amber color.  
18) The solution in the heated FuCl flask will become darker and more viscous.  
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19) When ~50-75 ml remains the heated FuCl flask and the solution is dark brown, turn 
off the transformer, remove the glass wool, turn the condenser off, and replace the 
heating mantle with a cork ring.  
20) Stopper the FuCl distillate, parafilm the stopper, cover the flask with aluminum foil, 
and label it.  
21) Store the distillate in the 4°C explosion-proof refrigerator.  
22) Dilute the FuCl waste with tap water, and leave it in the hood overnight. Be careful of 
HCl production in the reaction with water, and pour the water in SLOWLY.  
23) On the next day, use a spatula to break up the FuCl waste, retrieve the stir bar, and 
disposed of the waste in the aqueous waste container.  
24) Glassware can be cleaned with acetone and the base bath.  
Methylene Chloride (MeCl) Distillation 
Warning: Use nitrile or silver-shield gloves when handling MeCl. 
1) Wash and dry:  
1 x 1000 ml round-bottom flask, 1 x joint for thermometer, 1 x thermometer to fit 
joint (~40°C), 1 x large condenser, 1 x glass elbow, 1 x joint for desiccators,  
1 x glass stopper, 1 x glass funnel.  





3) Replace the 500 ml collection flask with a 100 ml round bottom flask to collect the 
first 30 ml of distillate. Clamp the apparatus to the scaffolding in the back of the fume 
hood.  
4) Vacuum grease and clamp all connections.  
5) Run cold, ice water UP the condenser tube using the circulation pump. This allows 
any bubbles to flow up and out of the condenser. Make sure that the circulation pump 
is not actively heating the water by turning the temperature control all the way down 
to -20°C. 
6) Tie a KimWipe around the bottom of the condenser to catch external condensation.  
7) Use funnel to add 750 ml of MeCl and calcium hydride (CaH2, if needed) into the 
existing MeCl + CaH2 flask.  
8) Vacuum grease the MeCl flask, and connect the flask to apparatus.  
9) The MeCl + CaH2 flask already contains a stir bar. Place the flask in heating mantle 
with magnetic stirring at ~4.  
10) Insulate the flask and neck with glass wool all the way up to the condensing tube to 
promote boiling and prevent condensation.  
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11) Set the transformer to 35 units.  
12) Vapor temperature should increase to ~40°C.  
13) Dispose of the first ~30 ml of distillate by turning the neck up, removing the 1st 
collection flask, and quickly replacing it with a clean 1000 ml round-bottom flask.  
14) When ~150-200 ml remains in the heated MeCl flask, turn off the transformer, 
remove the glass wool, turn the condenser off, and replace the heating mantle with a 
cork ring. You should have ~500 ml MeCl distillate in your collection flask (need 
340-380 ml for remaining steps).  
15) Vacuum grease the glass stopper, and stopper the MeCl distillate, and label it.  
16) Store the anhydrous MeCl distillate in the hood overnight. Do not parafilm the 
stopper.  
17) Vacuum grease the original MeCl + CaH2 stopper, stopper the undistilled MeCl + 
CaH2, and store it in the back of the hood.  
18) Dispose of the MeCl waste in the chlorinated organic solvents waste container.  
19) Glassware can be dried in the hood, and then cleaned normally.  
Azeotropic Distillation of PEG 
Warning: Use nitrile or silver-shield gloves when handling toluene.  
1) Wash and dry:  
1 x 500 ml or 1000 ml round-bottom flask, 1 x Dean stalk, 1 x condenser,  
1 x glass stopper, 1 x Kontes #2 glass valve with LARGE hole,  
1 x egg-shaped stir bar, 1 x glass funnel, 1 x 250 ml glass graduated cylinder.  




3) Clamp the apparatus to the scaffolding in the back of the fume hood.  
4) Vacuum grease and clamp all connections.  
5) Run cold, ice water UP the condenser tube using the circulation pump. This allows 
any bubbles to flow up and out of the condenser. Make sure that the circulation pump 
is not actively heating the water by turning the temperature control all the way down 
to -20°C. 
6) Tie a KimWipe around the bottom of the condenser to catch external condensation.  
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7) Weigh 50 g PEG 3.4K or 10K in the 500 ml round-bottom flask.  
8) Use the graduated cylinder and funnel to add 200 ml of toluene to the PEG in the 500 
ml flask.  
9) Add the stir bar to the flask, vacuum grease the flask, and connect the flask to 
apparatus.  
10) Place the flask in heating mantle with magnetic stirring at ~5. The PEG will dissolve 
with stirring and heating.  
11) Insulate the flask and neck with glass wool all the way up to the condensing tube to 
promote boiling and prevent condensation.  
12) Set the transformer to 65 units.  
13) When the Dean stalk fills to 20 ml, dispose of the toluene by draining the solution 
from the Dean stalk into a 250 ml waste beaker. The first few batches of waste may 
be partially cloudy, while others should be clear.  
14) Repeat step 13 seven more times, removing 20 ml toluene at a time until ~160-180 ml 
toluene has been removed.  
15) Turn off the transformer, remove the glass wool, turn the condenser off, and replace 
the heating mantle with a cork ring. 2-5 ml extra toluene waste may condense as you 
do this.  
16) Allow the distilled PEG and toluene to cool, and then vacuum grease the glass 
stopper and stopper the distilled PEG. Parafilm the stopper, and label the flask.  
17) Store the distilled PEG in the hood overnight. The PEG will solidify as it cools.  
18) Dispose of the toluene waste in the nonchlorinated organic solvent waste container.  








PEG MW = 3,400 Da 
50 g PEG = 0.01471 mol PEG 
1 PEG : 0.9 FuCl  10% molar excess for PEG addition to ends of FuCl 
(0.9 mol FuCl / mol PEG) * (0.01471 mol PEG) = 0.01324 mol FuCl 
FuCl MW = 153 g/mol 
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(0.01324 mol) * (153 g/mol) = 2.025 g FuCl 
FuCl density = 1.415 g/ml 
(2.0235 g) / (1.415 g/ml) = 1.431 ml FuCl 
1 FuCl : 2 TEA  TEA removes Cl from ends of FuCl, 2 Cl per FuCl  Twice as much 
TEA as FuCl 
(2 mol TEA / mol FuCl) * (0.01324 mol FuCl) = 0.02648 mol TEA 
TEA MW = 101.2 g/mol 
(0.02648 mol) * (101.2 g/mol) = 2.6798 g TEA 
TEA density = 0.726 g/ml 
(2.6798 g) / ( 0.726 g/ml) = 3.6912 ml TEA 
10K Calculations: 
PEG MW = 10,000 Da 
50 g PEG = 0.005 mol PEG 
1 PEG : 0.9 FuCl  10% molar excess for PEG addition to ends of FuCl 
(0.9 mol FuCl / mol PEG) * (0.005 mol PEG) = 0.0045 mol FuCl 
FuCl MW = 153 g/mol 
(0.01324 mol) * (153 g/mol) = 0.6885 g FuCl 
Density FuCl = 1.415 g/ml 
(0.6885 g) / (1.415 g/ml) = 0.4866 ml FuCl 
1 FuCl : 2 TEA  TEA removes Cl from ends of FuCl, 2 Cl per FuCl  Twice as much 
TEA as FuCl 
(2 mol TEA / mol FuCl) * (0.0045 mol FuCl) = 0.009 mol TEA 
TEA MW = 101.2 g/mol 
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(0.009 mol) * (101.2 g/mol) = 0.9108 g TEA 
TEA density = 0.726 g/ml 
(0.9108 g) / ( 0.726 g/ml) = 1.2545 ml TEA 
Reaction 
1) Wash and dry:  
1 x 1000 ml 3-arm round-bottom flask, 2 x 60 ml dropping funnels,  
1 x joint for the N2 balloon, 1 x PTFE valve for the N2 balloon,  
2 x Kontes #2 glass valves with LARGE holes, 2 x glass stoppers, 
1 x 250 ml or 1000 ml glass graduated cylinder. 
2) Use the funnel and graduated cylinder to add 320 ml MeCl to the distilled 
PEG/toluene. Dissolve PEG with stirring.  
3) Use the funnel to pour the PEG/MeCl into the 3-arm flask. The PEG distillation stir 
bar can be reused in this step.  




5) Clamp the apparatus to the scaffolding in the back of the fume hood.  
6) Vacuum grease and clamp all connections. Be careful not to vacuum grease over the 
holes in the valves, or else the FuCl and TEA will not flow through. Also the PTFE 
valve for the N2 balloon does not require vacuum grease.  
7) Place the 3-arm flask in a small autoclave bin, filled with ice on a large stir plate. 
Optional: Add salt to the ice to keep the ice from melting.  
8) For PEG 3.4K, use glass pipettes to add 30 ml MeCl to volumes of FuCl and TEA 
calculated above (3.4K: 1.431 ml FuCl and 3.6912 ml TEA). Add MeCl to dropping 
funnels first, then FuCl and TEA. MeCl removes the markings from glass pipettes, so 
exercise care when transferring MeCl.  
9) For PEG 10K, use glass pipettes to add 10 ml MeCl to volumes of FuCl and TEA 
calculated above (10K: 0.4866 ml FuCl and 1.2545 ml TEA). Add MeCl to dropping 
funnels first, then FuCl and TEA. MeCl removes the markings from glass pipettes, so 
exercise care when transferring MeCl. 
10) Flush system with N2 gas, using the N2 tank and hose and the N2 filled balloon. Lift 
the glass stoppers from the dropping funnels slightly to purge excess air. Make sure 
the N2 valve remains open.  
11) Stir PEG solution on the stir plate at ~5.  
12) Start reaction by dropping the FuCl and TEA at the same rate of 1 drop per ~3-4 
seconds. A slower drop rate will result in a more efficient reaction.  
13) Reaction will turn dark brown.  
14) When necessary, siphon melted water from the ice bin, and replace the ice.  
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15) When dropping is complete, allow the reaction to continue on ice for the rest of the 
day.  
16) When necessary, siphon melted water from the ice bin, and replace the ice.  
17) At the end of the day, remove the ice bin, remove the dropping funnels, and replace 
the funnels with glass stoppers.  
18) Allow the reaction to continue at room temperature with stirring on a cork ring for at 
least 2 days.  
19) Check the N2 balloon over the next 2 days, and refill the balloon if necessary (close 
valve when refilling the balloon).  
20) Glassware can be dried in the hood, and cleaned with acetone and the base bath.  
Rotovaporing of MeCl 
Warning: Use nitrile or silver-shield gloves when handling MeCl. 
1) Wash and dry:  
1 x 1000 ml round-bottom flask,  
1 x glass funnel.  
2) Turn on Rotovapor by switching Vacuum Controller V-800, Rotovapor R-200, and 
Vacuum V-500 on.  
3) Fill the water bath with distilled H2O, and heat to 40°C.  
4) Use the circulating pump to flow cold, ice water through the condensing tube.  
5) Use the funnel to pour the OPF solution into a 1000 ml round-bottom flask.  
6) Clamp and vacuum grease the flask to the Rotovapor.  




8) Slowly rotate the flask in the water bath.  
9) Turn on the vacuum on at 850 mbar (“Set”  Up or down  “Run”).  
10) Gradually decrease the vacuum as necessary to maintain a steady drip of 
condensation into the collecting flask. Vacuum can be decreased as low as 700 mbar.  
11) When OPF/MeCl solution is thick and “stew-like” consistency, remove OPF from 
Rotovapor.  
12) Dispose of the MeCl waste in the chlorinated organic solvents waste container.  
13) Glassware can be dried in the hood, and cleaned normally.  
Wash in Ethyl Acetate 
Warning: Use nitrile or silver-shield gloves when handling ethyl acetate. 
1) Wash and dry: 
2 x 2 L aspiration flasks, 1-2 x 2 L Erlenmeyer flasks, 1-2 x 2 L beakers,  
2 x Buchner funnels, 1-2 x glass funnels, 1 x stir bar, 2 x spatulas.  
2) Add ethyl acetate (EA) to the OPF solution until the flask is ~2/3 full.  
3) Stir the solution while heating with the heatgun (low speed, med heat) for 15-20 min, 
rotating every 5 minutes.  
4) Solution will become less viscous and salts become visible at the surface. Ethyl 
acetate is a solvent for the OPF, but not for the salts produced in the TEA reaction.  
5) Connect the vacuum and filter the solution through a Buchner funnel with #1 
Whatman filter paper (11 µm pores) into a 2 L aspiration flask.  
6) The salts will be filtered out of the solution by the filter paper. Discard these salts.  
7) Add EA to the OPF to a total volume of 1500-1700 ml.  
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8) Stopper the flask with a #9 rubber stopper and parafilm the stopper and aspiration 
neck, and place the flask into the -20°C explosion-proof freezer for at least 2 hours or 
overnight if necessary.  
9) If necessary, clean glassware for the next step.  
10) After cooling, remove the OPF/EA from the freezer. The decreased temperature alters 
the solubility of the OPF, causing the OPF to precipitate out.  
11) Connect the vacuum and filter the solution through a Buchner funnel with #1 
Whatman filter paper, capturing the OPF in the filter paper and pulling the EA into an 
aspiration flask.  
12) While filtering, stir the solution, allowing the EA to be pulled through the filter paper. 
Discard the EA.  
13) When nearly dry, transfer the OPF from the filter paper to a beaker.  
14) Add 1 L ethyl acetate to the solution.  
15) Stir the solution while heating with the heat gun to redissolve the OPF in the EA. 
Solution goes from light brown to dark brown and becomes less viscous.  
16) Use a clean glass funnel to transfer the OPF and EA to a 2 L Erlenmeyer flask and 
add EA to a total volume of 1500-1700 ml.  
17) Stopper the flask with a #10 rubber stopper, and recrystallize the OPF/EA solution in 
a 2 L aspiration flask at -20°C for 1.5 hours or overnight.  
18) Dispose of the EA waste in the nonchlorinated organic solvent waste container.  
19) After cooling, filter the solution through a clean Buchner funnel with #4 Whatman 
filter paper (20-25 µm pores), capturing the OPF in the filter paper and pulling the 
EA into an aspiration flask.  
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20) The second filtering step may proceed much more slowly than the first. If EA/OPF is 
solid after removing from the freezer, add more EA to the solution. Tape 2 spatulas 
together to scoop product from the bottom of the flask.  
21) Dispose of the EA waste in the nonchlorinated organic solvent waste container.  
22) Optional: Repeat steps 13-19 for a third filtering step. This may be necessary if OPF 
appears too dark.  
23) Dispose of the EA waste in the nonchlorinated organic solvent waste container.  
24) Glassware can be dried in the hood, and cleaned normally.  
Wash in Ethyl Ether 
Warning: Use nitrile or silver-shield gloves when handling ethyl acetate and/or ethyl 
ether. 
1) Wash and dry: 
1 x 2 L beaker, 1 x stir bar, 1 x Buchner funnel, 2 x PTFE coated jars. 
2) When OPF is nearly dry and EA is mostly gone, add 1 L ethyl ether (EE) directly to 
the funnel to remove the EA. 
3) Once mostly dry, transfer the OPF from the funnel and filter paper to a 2 L beaker.  
4) Add 1 L ethyl ether (EE) to the OPF for a second wash with stirring.  
5) Filter the solution through a Buchner funnel with #4 Whatman filter paper (20-25 µm 
pores), capturing the OPF in the filter paper and pulling the EE into an aspiration 
flask.  
6) Optional: Add EE to the OPF for a third wash.  




8) By the end, you should have a fine powder that is mostly dry.  
9) Scoop the OPF powder evenly into 2 Teflon-coated jars with the spatula.  
10) Leave the OPF in the hood overnight with the lid on loosely.  
11) Dispose of the EE waste in the nonchlorinated organic solvent waste container.  
12) Glassware can be dried in the hood, and cleaned normally.  
Vacuum Dry OPF 
1) Clamp a lyophilizer tube to the scaffolding in the back of the fume hood as shown: 
 
 
2) Tape aluminum foil to the top of the OPF jars and poke holes in the foil with a small 
gauge needle.  
3) Add liquid nitrogen to the solvent trap.  
4) Connect the vacuum to the solvent trap.  
5) Close the valves to the samples (3rd and 4th from the top). Open the valve to the 
manometer (bottom).  
6) The top 2 valves are open to the atmosphere and should remain closed.  
7) Turn on manometer, and then the vacuum pump.  
8) Once a vacuum is established, gradually open the valves to the samples. Open the 
valve to the first sample until a vacuum is established, then close that valve. Then 
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open the valve to the second sample until a vacuum is established. Now you can 
reopen the first sample.  
9) Pressure should be less than 10 mbar (preferably 1-2 mbar).  
10) Check the pressure and the liquid nitrogen level every 30-45 minutes.  
11) Refill the liquid nitrogen if necessary.  
12) When OPF is dry and you cannot smell any EE in the powder, open the valve to break 
the vacuum and turn off the pump.  
13) Dispose of solvent from the solvent trap.  
14) Parafilm OPF and store it at -20°C.  
Verify Product 
1) A lighter brown color is preferred.  
2) Polymerize a 100% OPF hydrogel with thermal and photo-initiation to test 
crosslinking.  
3) Run GPC on the OPF in chloroform to verify molecular weight.  
 
B.2 PEG-DA Synthesis 
Reaction Calculations 
1) Begin with 24 g PEG, MW 3400. 
2) React with 100% excess acryloyl chloride (AcCl; 2 AcCl:1 PEG). 
3) 24 g PEG / (3400 g/mol PEG) = 7.06 mmol PEG 
4) 7.06 mmol PEG * 2 end groups * 2 (100% excess) = 28.24 mmol AcCl 
5) 0.02824 mol AcCl * 90.51 g/mol / (1.114 g/mL) = 2.294 mL AcCl 
6) React with 1:1 AcCl:triethylamine (TEA) 
7) 0.00706 mmol PEG * 2 end groups = 0.0141 mol TEA 
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8) 0.0141 mol TEA * 101.9 g/mol / (.726 g/mL) = 1.982 mL TEA 
9) Workup with anhydrous potassium carbonate (K2CO3) 
10) 0.02824 mol AcCl * 2 mol K2CO3/mol AcCl / 2 M K2CO3 = 28.2 mL 2M K2CO3 (aq) 
11) 138.205 g/mol = 276.41 g in 1L = 27.641 g in 100 mL = 8.2923 g K2CO3 in 30 mL ddH2O 
Day 1 – Methylene Chloride Distillation 
Distill MeCl following the instructions in the OPF synthesis protocol. Keep in mind that 
you only need approximately 100 mL. Distillation is necessary to remove aqueous 
contamination (make MeCl anhydrous) that might generate unwanted side reactions in 
Day 2.  
Day 2 – Reaction 
What’s going on? PEG is being acrylated. TEA acts as a catalyst by sequestering HCl to 
allow the reaction to proceed to completion. MeCl is the solvent used for this reaction. 
Caution: AcCl doesn’t smell as bad as FuCl, but it is worse for you (eye, throat irritant)! 
1) Set up 3-arm round bottom flask in the 
fume hood on a stir plate. Weigh and 
add PEG to the flask. Add stirbar. 
2) Attach one dropping funnel, with a 
glass stopper, and a PTFE valve for N2 
gas flow. Vacuum grease glass-glass 
connections for the dropping funnel 
(excluding glass stopper) and the PTFE 
valve. Do not grease the PTFE valve itself. 
3) Hook up N2 tubing to the valve. Continually purge the whole system as you add 40 mL MeCl 
to the round bottom flask through the ungreased arm using a glass funnel. Stir. Gently float a 
glass stopper in the arm on the air being pushed out. 
Equipment: 
1x 500 mL 3-arm round 
bottom flask 
1x dropping funnel 
1x PTFE gas valve 
3x glass stoppers 
1x glass stopcock 
1x PTFE stopcock 
 
1x stirbar 
1x glass funnel 
1x graduated cylinder 
1x balloon 
Glass pipettes 
1x stir plate 
1x clamp 











4) When dissolved, use a glass pipette to add TEA. Vacuum grease a glass stopper and gently 
float the dropping funnel’s glass stopper as before. Let stir for 5 min. 
5) Use a glass pipette to add 20 mL MeCl and the appropriate amount of AcCl to the dropping 
funnel. Be aware that MeCl (and its fumes) will remove markings from glass pipettes. 
Vacuum grease and stopper the funnel while you are adding and turn off N2 flow. 
6) Remove the N2 hose and attach an N2 balloon. 
7) Drip the AcCl/MeCl mixture into the round bottom flask (about 1 drop every 3-4 seconds). 
Drip AcCl in MeCl very slowly (about 1 drop every 4 seconds). 
8) After dripping is complete, you can replace the funnels with stopcocks. 
9) Let stir overnight. 
Day 3 – Workup 
What’s going on? To remove TEA-HCl, we first react the 
mixture with potassium carbonate to produce KCl, which 
will transfer to the aqueous phase. Some TEA will remain 
in the organic phase for Day 3 filtration. 
1) Use a glass funnel to transfer the mixture from the round 
bottom flask to a separatory funnel with a greased stopcock. 
(Don’t forget to close the stopcock prior to transfer. Also, remember to wipe vacuum grease 
from connections before pouring.) 
2) Add appropriate amount of 2M K2CO3 to the separatory funnel. 
3) Stopper funnel, hold vertically, and give it a quick shake or two. Immediately open the 
stopper to release CO2. Repeat a few times. 
4) Hold the separatory funnel horizontally, but with the tip tilted higher. One hand should hold 
the glass stopper, the other holding the stopcock knob up. Rotate vigorously, and open the 
Equipment: 
1x 250 mL separatory 
funnel 
1x glass stopper 
1x glass funnel 
1x glass stopcock 







stopcock periodically to release CO2. Repeat until all gas is released. Solution should have 
the consistency of a milky-white emulsion. 
5) Leave overnight. Place a beaker underneath to capture any leaked product. 
Day 4 – Filtration and Drying 
What’s going on? We isolate the mixture from KCl in the aqueous phase, add MgSO4 to 
remove any additional aqueous solution, and precipitate PEG-DA in ethyl ether. TEA 
should remain in solution. 
1) Drain the two organic phases into a 250 mL beaker on a stir plate with stir bar. 
2) While stirring, add MgSO4 until the mixture goes from a lumpy consistency to a well 
dispersed mixture of powder and organic solvent. It should appear as opaque milk – if it 
doesn’t look like milk, add more MgSO4. Add ~20-40 mL MeCl to keep the PEG-DA in 
solution (may help to have a smaller bottle or beaker with MeCl). The goal here is to add as 
little MeCl as possible to keep the solution saturated with 
PEG-DA. But, if you add too much, no sweat. 
3) Prepare a Buchner funnel with aspiration flask and filter 
paper and pre-wet the filter paper with MeCl. 
4) Pour the mixture into the filter and a clear liquid should be 
collected (containing PEG-DA). If the liquid is cloudy, 
filtration should be performed again. The vacuum will also 
begin to evaporate MeCl. Thus, you can elect to evaporate 
MeCl if necessary. 
5) Prepare a 2L beaker with 1.7L ethyl ether and a stir bar. Pour in the PEG-DA solution and 
wait 10 min to precipitate PEG-DA. 
6) Prepare another Buchner funnel with two filter paper sheets, and pre-wet with ethyl ether. 
Equipment: 
2x 250 mL beakers 
1x 1L aspiration beaker 
1x 2-3L beaker 
2x stir bars 
2x Buchner funnels 











7) Filter to separate PEG-DA. If the filtrate is not clear, re-filter. Pound into bits. See an older 
grad student to measure your performance. 
8) Dry under vacuum until no ether can be smelled (at least 5 hours). At least some of this 
vacuum drying must be performed immediately after filtration. 
9) Store at -20ºC. Expected recovery is approximately 75%. 
Note: If necessary, you may need to dialyze the resulting product to remove impurities. 
Use a 1000 MWCO dialysis membrane at 0.2 g/mL and lyophilize after dialysis. 
 
B.3 Desulfation of Chondroitin Sulfate with Acidic Methanol to Form Chondroitin 
Adapted from: Schubert M. Chondroitin From Chondroitin Sulfate. Methods Carbohyd 
Chem. 1965;5:109-10. 
Materials: 
Chondroitin-6-sulfate – Wako 032-14612, 25 g 
Acetyl chloride – Fisher AC21947-2500, 250 ml 
Can scale quantities/volumes accordingly. 
Desulfation of Chondroitin Sulfate to Form Methyl Ester of Chondroitin 
1) Slowly add 5 ml acetyl chloride in 1000 mL methanol (very acidic, pH 0.0) 
2) Let the solution stir for a few hours 
3) Add 5.0 g chondroitin sulfate in 1000 ml of acidic methanol 
4) Stir for 1 day at room temperature 
5) Centrifuge (4000 RPM for 5 min) and discard clear solution 
6) Repeat on days 3 and 7 
7) Dissolve white residue in 100 mL water 
8) Precipitate in 600 mL 95% ethanol 
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9) Separate by centrifugation 
10) Wash with ethanol and separate by centrifugation at least twice 
11) Wash with ether and separate by centrifugation at least twice 
12) Vacuum dry 
13) Yields ~2.8 g methyl ester of chondroitin 
14) Store product at 4°C 
Demethylation to Form Chondroitin 
1) 2.5 g methyl ester of chondroitin in 100 mL 0.1M aqueous KOH 
2) Keep 1 day at room temperature on shaker plate 
3) Add to 1 mL glacial acetic acid, 1 g potassium acetate in 10 ml water 
4) Precipitate product with 400 ml ethanol 
5) Separate by centrifugation (4000 RPM for 5 min) 
6) Wash with ethanol and separate by centrifugation at least twice 
7) Wash with ether and separate by centrifugation at least twice 
8) Vacuum dry 
9) Yields ~2.3 g chondroitin 
10) Store product at 4°C 
 
B.4 Chondroitin Sulfate Methacrylamide Synthesis with EDC/NHS 
Purpose: To add methacrylamide group to chondroitin sulfate chains. 
Materials: 
Small glass vial and small stir bar 
Chondroitin sulfate A, 1 mg (Sigma) 
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1) Add 1.14 mg chondroitin sulfate (~0.0025 mmol by -mer MW, 457.4 Da) per mL of 
distilled water.  
2) Add 0.96 mg (0.005 mmol) of EDC and 0.89 mg (0.005 mmol) of N-3-aminopropyl 
methacrylamide for every 1 mL of solution.  
Optional: Add 1.09 mg (0.005 mmol) of Sulfo-NHS. 
3) Incubate the mixture for 2 hrs at pH 5.0 with stirring at room temperature.  
4) Add another 0.96 mg (0.005 mmol) of EDC and 0.89 mg (0.005 mmol) of N-3-
aminopropyl methacrylamide for every 1 mL of solution.  
5) Incubate the mixture for 2 more hrs at pH 5.0.  
Dialysis 
1) Dialyze (1,000 MW cutoff) solution against 10 mM NaCl solution for 1 day.  
2) Cut the dialysis tubing into strips a little shorter than the beaker that will be used for 
dialysis. 
3) Since the dialysis tubing is stored in sodium azide it needs to be rinsed. To do this put 
the dialysis tubing in a beaker with about 1L of dH2O and mix. Refresh the dH2O 
every 15 minutes (3x) in order to thoroughly rinse the tubing. 
4) After the tubing is thoroughly rinsed remove it from the beaker and close one end of 
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the dialysis tubing with a weighted closure. After the reaction in step 5 is complete, 
use a transfer pipette to add the mixture to the tubing until the tubing is about half 
full. Close the open end of the tubing with a non-weighted closure. 
5) Use teflon tape to hold the tubing high in the water as it stirs. 
6) Dialyze (1,000 MW cutoff) solution against distilled water for another 2 days.  
7) If starting on the morning of the first day change the water the morning and night of 
the second day. 
8) Lyophilize product for 4 days.  
 
B.5 Chondroitin Sulfate Methacrylate Synthesis with Methacrylic Anhydride 
Purpose: 
To conjugate methacrylate groups onto a chondroitin sulfate polymer that enable 
photopolymerization into a cohesive CS-MA hydrogel that maintains degradative 
properties. The goal of this experiment is to create CS-MA with various degrees of 
methacrylate (MA) substitution by reacting chondroitin sulfate with methacrylic 
anhydride (MAA) in the presence of sodium hydroxide (NaOH). 
References: 
Bryant SJ et al. Synthesis and characterization of photopolymerized multifunctional 
hydrogels: water-soluble poly(vinyl alcohol) and chondroitin sulfate macromers for 
chondrocyte encapsulation. Macromolecules. (2004). 37:6726-6733. 
Wang L-F et al. Synthesis and characterization of chondroitin sulfate-methacrylate 
hydrogels. Carbohydrate Polymers. (2003). 52:389-396. 
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Huang S-J et al. Controlled immobilization of chondroitin sulfate in polyacrylic acid 
networks. Journal of Biomaterials Science. Polymer Edition. (2007). 18(1):17-34. 
Tsai M-F et al. Characterization of hydrogels prepared from copolymerization of the 
different degrees of methacrylate-grafted chondroitin sulfate macromers and acrylic 
acid. Journal of Biomedical Materials Research. Part A. (2008). 84A:727-739. 
Reaction Chemistry: 
 
The synthesis of CS-MA is shown above. Any of 3 hydroxyl groups in each disaccharide 
unit of CS may under nucleophilic acyl substitution via a carbonyl group in methacrylic 
anhydride to form an ester bond, producing a methacrylic acid by-product. The reaction 
is driven forward by the addition of excess strong base (NaOH) to neutralize the 
methacrylic acid (pKa = 4.58) that is formed (Le-Châtelier’s principle). Since the 
solubility of highly charged CS is limited in organic solvents, this methacrylation scheme 
is carried out in an aqueous environment MAA. To compensate for the tendency of MAA 
to react with water and form methacrylic acid, an excess of MAA is used in all cases. 
Reagents: 
 chondroitin sulfate A (Chondroitin 4-sulfate, C 9819, Sigma) 
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 Storage temperature 2-8°C 
 Approximate MW 48,700 Da and PI 1.49 per Bryant et al, MW of 
disaccharide unit = 458.37 Da 
 ddH2O 
 methacrylic anhydride (Product # 276685-500mL, Aldrich) 
 Stored liquid at RT, acids cabinet 
 Use respiratory and contact precautions, wear eye protection 
 Must be added dropwise to aqueous solutions 
 Assay 94%; MW 154.16; density 1.042 g/mL at 25 °C; FP 84°C, BP 87°C 
 5N NaOH 
 Stored solid pellets at RT, bases cabinet 
 Methanol 
 Stored 4°C, explosion-proof refrigerator 
 D2O 
Equipment: 
 100mL beaker and stir bar for dissolving CS 
 500mL, 3-neck round-bottom flask for reaction, thermometer fitted into glass 
stopper for flask, 125mL dropping funnels (2), glass valves and clips (2), glass 
stoppers and clips (3)  
 Heating mantle, magnetic stir plate and stir bar 
 Pipette pump and glass serological pipettes 
 Silicone vacuum grease 
 Cork ring 
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 2L Erlenmeyer flask 
 Large Buchner funnel and 125mm diameter #42 Whatman quantitative cellulose 
filter membranes, 1L filtration flask 
 High vacuum system, lyophilizer tube (1), liquid nitrogen, scintillation vials (1), 




1) Clean stir bars and any glassware. For glassware, begin with soap and water, followed 
by dH2O, and then acetone. For plastics, use ethanol in lieu of acetone. Dry in oven or 
at room temp. 
2) Make solution (>150mL) of 5N NaOH (NaOH MW: 40.00). 
3) Prepare scintillation vials that will contain solution for pH readings. 
4) Bring CS to room temperature (~20min). 
5) Place small heating mantle on stir plate inside the fume hood and connect power to 
nearby transformer. Plug in transformer and stir plate into hood outlet. 
Conjugation 
6) Dissolve 15g chondroitin sulfate in 60mL ddH2O (yields a volume of ~100mL) using 
a beaker. This will take ~30-45 min at moderate stir velocity. Transfer to 3-neck 
round bottom flask and place on heating mantle on stir plate inside fume hood, setting 
at speed 7. Begin stirring. The flask now contains a 25% w/v solution of chondroitin 
sulfate, which has 19.062x10
-3




7) Cap the flask with a rubber stopper fitted with a thermometer that is submerged in the 
reaction solution (left-most neck of the flask). Switch on the transformer at setting 0 
and raise the temperature to 60°C (~ transformer setting of 30). 
8) Assemble dropping funnels. Place an extremely thin layer of silicone vacuum grease 
on either side of the hole on the glass valve, being careful to avoid getting any in the 
hole. Place the valve in its corresponding slot on the dropping funnel and fix in place 
with a metal clip on the other side. Mount a dropping funnel on the middle neck of 
the flask after coating the male end with a very thin layer of vacuum grease. For now, 
cap the right-most neck with a glass stopper that has also been coated with a very thin 
layer of vacuum grease. 
9) Using a manual pipette pump and glass serological pipette, slowly add specified 
volume of methacrylic anhydride via the top end of the dropping funnel, making sure 
the valve is in the closed position first. Cap the dropping funnel with a glass stopper 
(coated with vacuum grease) until intended time of addition. 
10) Once the temperature of the reaction vessel has stabilized, add methacrylic anhydride 
in specified amount in the table below to the flask in a dropwise fashion via the 
dropping funnel, making sure that the rate of dropping is slow and consistent over 
time until all MAA has been added. To enable a slow addition, partially open the 
valve. 
11) Replace the MAA dropping funnel with one containing 5N NaOH. [Note: This is a 
highly corrosive base! Wear silver nitrate gloves and face shield!] Add 5N NaOH 
dropwise (consistent rate) into the flask to reach a pH ~10. Measure and record the 
pH of the reaction vessel by drawing 10mL of solution after mixing from the 
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rightmost neck of the flask. Once the appropriate pH is reached, cap the dropping 





















60 405.6 x 10
-3




12) Stir reaction vigorously at 60°C for 24h under fume hood. Extract 10mL of reaction 




13) Prior to setting up equipment, make sure all glassware and related equipment is 
washed and dried. For glassware, begin with soap and water, followed by dH2O, and 
then acetone. For plastics, use ethanol in lieu of acetone. Dry in oven or at room 
temp. Weigh scintillation vials that will be used to later store CSMA (will be used to 
calculate an approximate percent yield). 
14) Set up filtration apparatus: a) Place filter membrane in Buchner funnel and mount in 
neck of 1L filtration flask; b) Attach plastic tubing to connection in neck of flask and 
secure to vacuum nozzle in hood; c) secure to mounted clamp in back of hood to 
stabilize flask. 
Precipitation, Filtration, Washing, and Drying 
15) Turn off transformer, cap all necks of flask with glass stoppers, and (using thermal 
gloves) place reaction flask on cork ring to allow reaction to cool to room 
temperature. Carefully pour reaction through a single neck (wipe vacuum grease off 
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with a Kimwipe first) into a 2L Erlenmeyer flask. Add ~500mL of methanol to flask 
to precipitate CS-MA and remaining CS. Following complete precipitation, 
thoroughly mix the solution and pour into filtration funnel in increments. Wash the 
resulting filtrate 5x with 50mL methanol (10mL methanol:1g CS reacted). Transfer 
filtrate to scintillation vial, cover with aluminum foil secured with tape, and poke 
several small holes in foil with small gage needle. 
16) Place vial inside glass lyophilizer tube and connect tube to a vacuum pump via a 
liquid N2 condenser trap. 
17) Establish vacuum and dry for ~12h or until no methanol is detected by wafting. 
[Note: Vacuum must be monitored every 30min while running and cannot be left 
unattended longer than 1h, thus cannot be left on overnight. Doing so presents a 
significant explosion hazard.] 




19) Rinse NMR glass tubes with acetone and dry in oven. 
20) Prepare 10mg/mL sample of CS-MA in D2O in microcentrifuge tube and transfer to 
NMR tubes (~1mL). Cap and number tubes with sample identifier. In addition, 
prepare a D2O blank, a CS control, and a MAA control in NMR tubes. 
21) Perform 1H NMR and analyze data for the following peaks: 
a) Residual MAA or MA acid: Integrate peak corresponding to methyl groups on 
MAA is observed at 1.6ppm 
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b) Confirmation of MA substitution: Integrate peaks corresponding to methylene 
portion of conjugated methacrylate moiety at 5.65 and 6.10ppm. Peak 
corresponding to methyl portion of conjugated methacrylate moiety at 1.89ppm. 
c) Determination of degree of substitution: Expand region from 1.6 to 2.1ppm, 
then deconvolute and integrate peaks at 1.89 (see above) and 1.99ppm (methyl 
group of native CS). Calculate ratio of peak intensity at 1.89ppm to that at 
1.99ppm to calculate degree of MA substitution on CS. [Since there are 3 
hydroxyl groups that could be substituted by methacrylate, maximum DS is 3. 
According to Bryant et al, a heteronuclear shift correlation through multiple bond 
connectivities (HMBC) experiment (analyzes relationship between protons and 
carbons in structure) did not reveal a preferred substitution site.] 
 
B.6 Chondroitin Sulfate Methacrylate Synthesis with Glycidyl Methacrylate 
1) Dissolve 1 g of chondroitin sulfate (CS) per 50 mL dH2O 
CS disaccharide: 457.4 Da (Chondroitin disaccharide: 378.35 Da) 
1 g = 2.19 mmol = 1 equivalent 
2) Add 50 mL acetone, resulting in a 1% w/v solution of CS in 50:50 mixture of 
acetone:water 
3) Stir overnight at room temperature 
4) Add 20 molar equivalents of triethylamine (TEA) 
TEA: 101.19 Da, 0.726 g/mL 
20 equivalents = 43.7 mmol = 4.42 g = 6.09 mL 
5) Slowly drip in 20 molar equivalents of glycidyl methacrylate (GMA) 
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GMA: 142.15 Da, 1.042 g/mL 
20 equivalents = 43.7 mmol = 6.22 g = 5.97 mL 
6) Stir for 24 hr at room temperature 
7) Rotovap to concentrate if necessary 
8) Dialyze in 50:50 acetone:water for 1 day using 1,000 Da MWCO regenerated 
cellulose membrane 
9) Dialyze in dH2O for 2 days 
10) Lyophilize product for 4 days 
11) Store product at -20°C 
  
B.7 CSMA Microparticle Formation 
Remove CSMA from -20°C and allow to sit at room temperature for 30 minutes. Keep 
ALL ingredients on ice. 
1) Place 60 mL of corn oil in the 4°C refrigerator. 
2) Make APS solution in 1.5 mL tube: 34.2 mg APS in 500 µL PBS 
3) Make TEMED solution in 1.5 mL tube: 22.5 µL in 500 µL PBS 
4) Weigh out 55.6 mg Chondroitin Sulfate Methacrylate (CSMA) in a scintillation vial 
and add 440uL of PBS. 
5) Homogenize corn oil at 3900 rpm for 5 minutes. 
6) Add 30 uL of APS and 30 uL of TEMED to the CSMA solution, mix, and add 
solution dropwise to corn oil. Make sure everything is on ice to prevent crosslinking. 
Homogenize for 5 minutes. 
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*DO NOT MIX APS AND TEMED TOGETHER BEFORE ADDING TO CSMA 
SOLUTION-ALWAYS ADD SEPERATELY 
7) Place corn oil mixture on a hot plate (set to 100°C) with the largest stir bar that will 
fit in the container (to keep particles moving so as not to crosslink with one another) 
and a thermometer (to monitor temperature-I usually let it go up to 50-60°C). Allow 
to crosslink for 30 minutes.  
8) Separate mixture into two 50 mL conical tubes and centrifuge at 1500 rpm for 5 
minutes at 4°C. 
9) Remove oil from microparticles and resuspend pellet in ddH2O and transfer to 1.5 
mL tube (if possible). Wash 3 times to remove oil. Store at 4°C. 
 
B.8 Passive Adsorption of Aggrecan to TCPS Sufrfaces 
Materials: 
Aggrecan (Sigma) 





24-well tissue culture-treated polystyrene plates 
Protocol: 
Aggrecan pre-treatment 
1) Sterile filter a 0.05 mg/mL aggrecan solution in PBS.  
2) Warm up the aggrecan solution to 37°C. 
3) Dispense 100 µL of aggrecan solution into each well of a 24-well tissue culture-
treated polystyrene plate. This gives each well 5 µg of aggrecan. 
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4) Leave plates, with the lids askew, in the sterile hood overnight (with the blower 
running, UV lights off) to allow the D-PBS to evaporate and aggrecan to adsorb. 
 
B.9 Bovine BMSC Harvest 
Purpose: Isolation of bMSCs from a bovine tibia and femur bone. 
Materials: 
Saw + saw blade 
Tweezers, Spatulas 
MSC media - Low glucose DMEM, FBS, Antibiotic/Antimicotic, bFGF 




Isopropyl alcohol (for Mr. Frostys) 
** Contact Kim x51547 in IBB to make sure there’s enough room for our bag in the meat 
freezer** 
Protocol: 
1) Make sure to autoclave all appropriate tools (saw blade, tweezers, spatulas, PBS+ 
bottle). 
2) Make up MSC media. 
500 ml Low glucose DMEM 
56.18 ml FBS 
5.62 ml Antibiotic/Antimycotic 
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562 ul Fungizone 
56.2 μl bFGF 
3) Make up PBS+ 
500 ml Sterile PBS 
5 ml Antibiotic/Antimicotic 
4) Prepare the hood area by laying down sterile drapes and taping them down. 
5) Cut away all tissue from the leg. This can be done non-sterilely outside of the hood. 
6) Bring the bone into the tissue culture hood. Using a bone saw cut the bone into two 
roughly equal pieces. Squirt the cut with PBS+. 
7) Remove bone marrow using tweezers and spatulas and transfer into a 50 ml tube. 
8) Squirt PBS+ solution into the tube. 
9) Pippette up and down in a 50 ml pipette until the solution starts to flow smoothy. 
Tapping the pipette on the bottom of the tube as pipetting will help to break up 
clumps faster. 
10) Repeat using a 10 ml pipette. 
11) Run the solution through needles of 16 G, 18 G, 20 G. If the needle becomes clogged 
try pulling back on the plunger and then adding pressure again. If there is still an 
obstruction remove the needle and replace. 
12) Repeat previous step. 
13) Spin down at 1200 rpm for 15 min. 
14) Aspirate supernatant, not blood. 
15) Pool remainder and spin down if needed. 
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16) Add PBS+ to bring the solution up to a desired level. Take a 1 ml sample for counting 
and spin down. 
17) Make a 4% acetic acid soln. by mixing 80 uL acetic acid in 2 mL sterile PBS. 
18) Add 100 uL 4% acetic acid solution to 100 uL cell suspension to lyse RBCs 
19) Add 175 μl media, 100 μl trypan blue, and 25 μl of the cell solution/acetic acid to a 
tube for counting. This creates a 1:12 dilution. The cells can be spun down in the 
centrifuge while the counting process in taking place. 
20) Inject approximately 10-15 μl of the cell solution into the groove of the 
hemocytometer. 
21) Look at the hemocytometer under the microscope and count the cells in the 4 sections 
at the corners of the grid. 
22) Resuspend in DMEM for a concentration of 40e6 cells/25 ml of media (1.6e6 
cells/ml). 
Calculations 
 (Total number of cells in the 4 grids) x (2500) = Concentration of solution in 
cells/ml. Multiply this number by 12 to get the concentration of the full solution. 
 Multiply the concentration by the volume in the tube to get the total number of 
cells. 
23) Add 40e6 cells in 25 ml of media to a 150x25 mm dish and leave in incubator for 30 
min. Neutrophils and fast adhering cells will stick to the plate. MSCs won’t. 
24) Add 12.5 ml of fluid from the plate and 12.5 ml of media to a T-150 flask. Tilt the 




25) Incubate overnight x2 (for two days). 
26) Aspirate media from the T-150s. 
27) Wash in 10 ml PBS. 
28) Aspirate the PBS. 
29) Repeat the previous two steps. 
30) Add 20-25 ml of media to the flasks. 
31) Grow till confluency (~10 days). 
32) Freeze down cells (use Mr. Frosty!). Note: You will probably have less than the 20e6 
cells/plate that were first plated. 
Dispose of leg as appropriate. Double bag the remains in biohazard bags and take it to 
IBB 0230 (basement) before 4 pm and ring the doorbell for assistance. 
 
B.10 Bovine Tendon/Ligament Fibroblast Harvest 
Purpose: Tendon and ligament will be digested to remove matrix (i.e. collagen) and 
isolate the fibroblasts for use in experiments. Approximately 10g of tendon and ligament 
tissue can be obtained with each harvest, resulting in around 100e6 cells. 
Materials Needed: 
Tissue: 
Mammal legs (intact joint capsule) 
Solutions: 












70% ETOH or IPA solution 
DMEM 
Collagenase type II, Gibco, 17101-015 
Supplies: 
#4 blade handles 
#22 blades 
Sterilized razor blades 
Autoclaved Forceps 
Autoclaved Nalgene squirt bottle 
Hemostats 
For cell isolation: 
Autoclaved cell strainer (with 74 µm mesh) 
60 ml syringes and 0.2 µm filters 
T-75 flasks 
Shaker plate 




a. Use undiluted 1x bottle of Dulbecco’s PBS w/o Ca++ and Mg++. 
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b. Add 10ml/L antibiotic/antimycotic (stock @ 100x). 
2. DMEM+ a.k.a. Arnold (overnight antiobiotics for tissue samples) 
a. Use sterile high glucose DMEM. Add 10 ml/L PSN (stock @ 100x), 10 ml/L 
kanamycin (stock @ 100x), 1 ml/L gentamicin (stock @ 1000x), and 1 ml/L 
fungizone (stock @ 1000x). 
Cell isolation 
1. 0.4% collagenase digest solution 
a. In DMEM+ (see above) add 0.4% collagenase. Make enough for 10 ml digest 
solution per 1 gram tissue + extra volume. 
b. CALCULATION: [total mass of tissue]*10 ml/g tissue * 0.004 = ___ g of 
collagenase. 
c. Sterile filter collagenase solution using 60 ml syringe and 0.2 µm filter. 
Procedure for Tissue Isolation 
1) Prepare sterile PBS and place in a sterile 500ml Nalgene squirt bottle. 
2) Cut the majority of the meat away from around the joint capsule, but do not penetrate 
the capsule. Make sure to cut enough meat away from around the capsule in order for 
someone to hold the bones comfortably. 
3) Transfer the leg to the hood. 
4) Wash the capsule surface with EtOH and then PBS+. 
5) Articulate the joint to identify the femoral heads and patella. 
6) Using a #4 scalpel with a #22 blade, take light slices on the outside of the joint 
capsule along the imaginary line immediately below the femoral condyles. These 
slices will expose the lateral and medial collateral ligaments. 
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7) Penetrate the joint capsule on the anterior side exposing the patellar ligament (inferior 
to the patella) and the fat pads. Squirt the inside of the capsule with PBS+. 
8) Use a second scalpel and blade to transect the collateral ligaments and the patellar 
ligament. 
9) Transect the anterior and posterior cruciate ligaments (between the two femoral 
condyles) without damaging the menisci or the cartilage on the condyles. 
10) At this point the femur and the tibia should be easy to separate, if not, go back and see 
which ligaments have not been fully transected. 
11) Cut through the meat on the posterior side of the leg to fully separate the tibia and 
femur. 
12) Detach the tendons and ligaments from bone. 
13) Transfer ligaments and tendon to Petri dishes and squirt with PBS+. 
14) Dispose of leg as appropriate. Double bag the remains in biohazard bags and take it to 
IBB 0230 (basement) before 4 pm and ring the doorbell for assistance. 
Procedure for Cell Isolation 
1) With a new scalpel blade, attempt to remove any excess soft tissue and fibrous tissue. 
2) Dice the tissue into roughly 1-3 mm3 cubes. 
3) Record weight of empty Petri dish. Aspirate excess PBS and weigh tissue in Petri 
dish to get tissue only weight. 
4) Place tissue into T-75 flasks so that there is about 2-3 grams of tissue per flask. 
5) Add 10 ml of 0.4% collagenase digest solution per 1 gram of tissue to each T-flask. 
T-flasks should be placed on their sides and secured firmly to the shaker plate. The 
whole assembly is then placed into the incubator for 12-48 hours. Agitate at 3-5 Hz. 
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After digestion (~48 hr) 
6) When fully digested, filter cell suspension by pipetting suspension into a 60 ml 
syringe attached to a metal cell strainer with 74μm mesh. Strain cell solution into a 50 
ml conical. Dilute the suspension 1:1 with warm PBS to decrease the viscosity of the 
collagenase solution. 
7) Centrifuge all samples at 1300 rpm for 10 minutes. For ligament and tendon the 
solution above the pellet may appear murky due to cells that did not completely 
separate out during the centrifugation. If this occurs leave at least 5 ml of solution 
above the pellet when aspirating. Then, dilute and repeat centrifugation to get the 
maximum number of cells to pellet down. 
8) Aspirate off collagenase solution and resuspend cells in 10 ml sterile PBS w/o IONS 
or DMEM. Recombine and repeat if necessary. 
9) Count cells to determine how much media to later add for the desired cell density. 
10) Spin the cells at 1300 rpm for 7 min. Aspirate off the PBS. 
11) Add an appropriate amount of media with 10% FBS and 10% DMSO. Use the auto to 
pipette up and down to mix cells thoroughly throughout the solution. 
12) Add 1 ml of cell solution to each tube you will be freezing down. 
13) Place the cell vials in the appropriate cooling container and place them in a -80°C 
freezer. 





B.11 Cell Encapsulation 
Purpose: Gels will be created with cells incorporated in them. 
Materials: 
Media (prepared day before) 
Sterile PBS 
15 and 50 mL conicals as needed 
3 and 10 mL syringes, with one 18G needle for each. 
1 mL syringe 
Sterile filters 
12-well plates 
Sterile containers for your gels (Teflon molds, or other molds) 
Spatulas, sterilized 
The day before your encapsulation 
1) Combine the polymers desired in a scintillation vial. You can freeze this vial down 
until the day of encapsulation. Note: You will lose about 200-300 µL due to sterile 
filtration, so adjust accordingly by making a gel that requires 300 µL more than the 
PBS you would have added to your polymers. 
2) Sterilize Teflon molds and spatulas as required. Always a good idea to have extra. 
3) Make sure you have enough sterile filters and other items for your encapsulation. 
Day of encapsulation 
Polymer side 
4) Warm up your polymer powders, trypsin, and your media. 
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5) If doing a thermal encapsulation, create 0.3 M stock solutions of APS and TEMED in 
scintillation vials as you would normally. 
a. APS: 684.6 mg in 10 mL PBS 
b. TEMED: 0.348 g (~350 µL) in 10 mL PBS 
6) Add sterile PBS to each vial according to your calculations and vortex. 
7) Let the solutions sit at 37 °C for at least 30 min in order to remove bubbles. 
8) Filter sterilize APS and TEMED solutions (if you’re using them) into 15 mL tubes. 
Make sure to cover the tubes with aluminum foil to prevent photoinitiation. 
a. Open the packaging of a syringe filter, but leave the filter in its container. 
b. Attach a needle to a 10 mL syringe, and draw up the contents of a scintillation 
vial. 
c. Invert the syringe and remove the needle. 
d. Grip the sides of the filter container, and screw the syringe onto the filter. 
e. Filter into an open 15 mL tube. 
9) Prepare the UV lamp and warm it up if you’re doing a photo encapsulation. 
10) Place sterile, autoclaved molds into petri dishes (one mold per dish). 
11) Filter sterilize your prepolymer mixtures. Tip: For a gel less than 1 mL, use a 3 mL 
syringe, then after pulling up the gel, pull up additional air. The air helps with sterile 
filtering. 
12) Transfer the correct amount of gel to a separate 15 mL tube. 
13) Place your sterile spatulas. 
14) Prepare and label your 12-well plates. 
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Important note: At minimum, steps 4-11 must be completed before the actual 
encapsulation itself. 
Cell side 
15) Rinse your flasks twice with PBS, and trypsinize your flasks as normal. 
16) While you count your cells, spin down the cells in the centrifuge. Caution: Before 
you spin down the cells in this step, make sure steps 4-11 are done. 
17) Aspirate the media off the cells, then resuspend the pellet in sterile media, typically at 
a concentration of 50x10
6 
cells/mL. 
 Amount of media to resuspend in µL = # of cells/desired concentration x 1000 
 e.g., with 10,000,000 cells total, then 10e6 / 50e6 x 1000 = resuspend my cell 
pellet in 200 µL of media. 
Crosslinking/encapsulation 
18) Add cell solution according to your calculations and quickly mix with the pipette (do 
not vortex). If the cell solution has a concentration of 50x10
6
 cells/mL and you used 
the standard gel calculator, this will give a final solution of 10x10
6
 cells/mL. 
19) If doing a thermal encapsulation, add APS according to your calculations and mix 
with pipette. Then, add TEMED according to your calculations and mix with pipette. 
20) If doing a photo encapsulation, add sterile D2959 to your solution and mix with 
pipette. 
21) Deposit the appropriate amount of the resulting solution in your molds. The standard 
is 30 µL of gel in a 1.0-mm Teflon mold well. 
22) Cover petri dish and place it in the incubator for 10 min for thermal polymerization; 
leave under lamp for photo polymerization. 
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23) Aliquot 2 mL media into each well of a 12-well plate, depending on how many gels 
you have. 
24) Remove from the heat and carefully move the gels into the 12-well plate using a 
sterile spatula. Put the 12-well plate into the incubator. 
25) Repeat steps 18-24 as necessary with other polymer solutions. 
26) Recommended: Change media one hour after encapsulation. 
 
B.12 Dimethylmethylene Blue (DMMB) Assay 
Materials: 
Chondroitin sulfate A or B (B = Dermatan sulphate) Sigma Aldrich C-4384 
9-dimethylmethylene blue chloride (DMMB) Sigma Aldrich 341088 
Na2HPO4 Fisher Sci BP332-500 
Di-sodium-EDTA Fisher Sci S311-100 
NaCl Fisher Sci S640-500 
Glycine Fisher Sci G46-500 
Cysteine-HCl Sigma Aldrich C7477 
0.1 M stock HCl solution 
Regular flat-bottom 96-well plates (clear) 
Reagent Preparation: 
PBE buffer, pH 6.5: Dissolve 7.1 g Na2HPO4 and 1.86 g Na2EDTA in 495 mL of ddH2O. 
Calibrate pH meter, then read and adjust pH to 6.5 +/- 0.1 with concentrated HCl (~3 
mL 12 M stock HCl and ~8 mL 1 M HCl), using a glass pipette. Adjust volume to 
500 mL and filter sterilize (buffer can be stored for 1-2 months under refrigeration).  
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GAG standard: Dissolve 17.5 mg of cysteine-HCl in 10 mL of PBE buffer. Make a stock 
GAG soln of 20 mg/mL in PBE/cysteine, aliquot, and store at -20C. For the GAG 
standard, a working solution of 200 ug/mL is needed (100 X dilution of stock – 10 
uL stock in 990 uL PBE) 
DMMB solution: Add 95 mL of 0.1 M HCl solution (792 uL of 12 M HCl in 94.2 mL 
ddH2O) to 905 mL ddH2O and dissolve 3.04 g glycine and 2.37 g NaCl. Verify the 
pH = 3 (correct if necessary) and, while stirring, add 16 mg DMMB to the buffer. 
When stored in the dark at RT, the solution is stable for 3 months – may have to 
filter before use.  
NaCl solution, 2.3 M: Dissolve 13.4 g of NaCl in 100 mL ddH2O.  
GAG Assay: 
1) Pipette standards into wells of a clear bottom 96-well assay plate. 
Standard Curve: Should be linear from 0-2 μg/well.  
 
μg GAG/well μL GAG stock (200 μg/mL) μL PBE 
2 10 μL 15 μL 
1.5 7.5 17.5 
1.25 6.25 18.75 
1 5 20 
0.75 3.75 21.25 
0.5 2.5 22.5 
0.25 1.25 23.75 
0 0 25 
 
2)  Add 25 μL of sample to empty wells. 
Samples: Often need 2-3X dilution to get in linear range.  
3) Add 5 μL of 2.3 M NaCl to each well. 
4) Add 200 μL of DMMB solution to each well (can use multichannel pipette). 




B.13 PicoGreen Assay 
Purpose: The Pico Green assay quantifies the amount of DNA present which is an 
indirect measure of the number of cells. 
Materials: 




96 well plates 
For Gels 
1) Remove media. 
2) Add 2ml iPBS. 
3) Remove iPBS. 
4) Add 3-4ml iPBS 
5) Place in incubator for at least 30 min. Leave in incubator until gels are no longer the 
color of the media and have become clear. 
6) Transfer the gels between pieces of weigh paper to remove excess water and weigh 
the gels. Then put the gels in 1.7 ml eppendorf tubes. 
7) Homogenize the gels with a pellet grinder in the tubes. Be careful not to lose any of 
the gel. 
8) When the gel is well ground add ddH2O to the tube depending on the size of the gel 
(500 μl for 30 μl gels from 1.0 mm Teflon molds). Some of the ddH2O can be used to 
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wash the pellet grinder tip into the tube and to wash the side of the tube. This will 
maximize the amount of gel that is available for the bioassay. 
9) Let sit at room temperature for 30 min. 
10) Store at -80 °C if needed. 
For Plated Cells in a well plate 
1) Aspirate liquid from the wells of the plate 
2) Add 2 ml PBS to rinse. 
3) Repeat steps 1-2. 
4) Add 1 ml distilled, deionized water (ddH2O). 
5) Let sit at room temperature for 30 min. 
6) Store at -20 °C if needed. 
Lysing the cells 
1) Freeze the cells at -80 °C for a minimum of 1 hour. 
2) Thaw at room temperature for 30 minutes. 
3) Sonicate for 30 min. to lyse the cells. 
Note: The sonicator will heat up after each usage. Ice should be added to the water in 
order to cool the sonicator down. If this is not done the DNA in the sample could 
break down. 
Safety note: The sonicator is meant to lyse the cells. Do not put fingers into the water 
bath while the sonicator is on or cells in your fingers will be lysed. 
4) Repeat steps 1-3 two additional times. 




Making the plates 
Standards 
1) Make sure to thaw out samples and PicoGreen reagents for about 20 minutes before 
doing the assay. 
2) Make up buffer solution and PicoGreen according to the PicoGreen calculator. Vortex 
both solutions to make sure they are mixed thoroughly. 
 Note: When creating the buffer solution make sure to take the volume in the DNA 
standards into account. Also, cover the PicoGreen solution in aluminum foil to protect 
it from light. 
3)  Make up DNA standards according to the table below. 
 
4) Add 43 μl of your sample solutions into the appropriate wells of a 96 well plate. 
Make sure to change tips between samples. 
5) Add 107 μl of the buffer solution into the wells. 
6) Add 150 of the PicoGreen Solution to the wells. 
7) Read in a plate reader: ex 485, em 528. 
 
  




0.5 50 of 5 ug/ml 450
0.3 50 of 3 ug/ml 450
0.1 50 of 1 ug/ml 450
0.05 50 of 0.5 ug/ml 450
0.03 50 of 0.3 ug/ml 450




B.14 Confocal Microscopy 
Notes 
 You must be trained to use the confocal microscopes. Email 
steve.woodard@ibb.gatech.edu for the next training session. 
 There are three scopes that you can use: 
o LSM 510 UV, in room 1328.  
o LSM 510 NLO, in room 1326. This is “the multi-photon” confocal microscope. 
o LSM 510 VIS, in room 1326. This is currently the preferred scope. 
 Make sure to reserve a spot on the confocal microscope up to one week in advance at 
http://my.ilabsolutions.com/account/login/. You will need to make an account there if 
you haven’t already. 
 These instructions are for the LSM 510 VIS. 
Materials Needed 
 Bring a box containing gloves and your samples. 
 When working with gels, bring additional equipment: 
o Attofluor cell chamber and round glass coverslips 
o PBS squirt bottle (Complete PBS with Ca2+, Mg2+) 
o Spatulas and tweezers as necessary, plus Kimwipes for any spills. 
Setting Up 
1) Turn on the two switches to the left of the microscope – turn these on if needed, plus 
the computer. 
2) At the login screen, login with your Georgia Tech AD username and password. 
3) Click on ZEN 2008, in the middle of the screen, and click Start System.  
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4) Adjust the workspace zoom using the slider on the upper right side of the screen. Use 
an existing preset or make your own, clicking the “open folder” or “save” icons to 
save or apply changes. 
5) Turn the first two lasers on (488 must go to “standby” first, 543 is simply on/off). No 
need for 633. 
6) Below the laser controls, open the Temenoff Lab setting. This is specially configured 
for Live/Dead imaging.  
7) At the top of the second column, note the current objective being used. 
a) On the LSM 510 VIS, there are 10x, 20x and 40x air objectives. 10x is the most 
commonly used. 20x and 40x objectives give better magnification, but have less 
light exposure (and thus produce less bright images as a result). 
b) Two objectives, 40x and 63x objectives are oil-based. 
i) Select the objective using the software and place one drop of oil on the objective. 
ii) Mount your sample and raise the objective until it just touches and oil spreads out. 
iii) When you are done, wipe off the oil with lens paper, not kimwipes. 
8) Note other settings for averaging images (usually 1, with more for 20x/40x 
objectives), the resolution of your images (preferred is 1024x1024), and make sure 
scan speed is set to “Max” (9). 
9) Note your physical controls. To the right of the microscope is an X-Y controller. 
Below your monitor is a touchscreen with a coarse and fine control for controlling Z 
direction. 
Preparing Samples 
1) Prepare a sample for viewing. 
a) If you’ve got a plate, just place the plate on top and you are all set. 
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b) To prepare for viewing a gel, place a glass cover slip on the bottom piece of the 
cell chamber. Screw both pieces together and squirt some PBSi into the chamber 
to keep the gel hydrated. Then load your sample into the circular grooves on the 
microscope platform. 
2) Control your imaging using the Channels area in the 2nd column. 
a) Pinhole size refers to how much light is let through. Higher pinholes let through 
more light but will increase the amount of light captured in the Z-direction (that 
is, above and below your image). A preferred pinhole size is 1 AU (Airy unit, 
showing the lowest Z distance that will be captured). You can increase this if 
necessary. 
b) Detector Gain amplifies light received by the detector. Higher gain, brighter 
images, but also more noise. You should settle for a max of around 800 on both 
channels; sometimes you may even go below 700. 
c) Digital Offset eliminates light below a certain threshold. Use this to eliminate 
stray bright pixels. 
3) Click Fast on the upper left hand of the screen to begin continuously scanning. 
4) How to make images clear 
a) Something important is that imaging is highly subjective and depends on what 
you are looking for. Microscopy experts don’t like saturating images, but our lab 
usually tends towards that. Use your experience and be consistent in how you 
image, and things’ll turn out fine. 




c) To the left of the image, choose Split to separate the red and green signals. 
d) Scan to where you can find cells. This can be done by moving up and down 
(using the focus knob on the side) or by xy translation. Look at where the laser 
hits the gel to determine where you are. For Z location, check the Z Stack section 
(lower right, 2
nd
 column) for your height. 
e) Below the image, there are colors indicating what is being shown. Click the colors 
below the “Merged” button to change the display to Range Indicator mode. Red 
mean oversaturation, blue means undersaturation, and black/gray is somewhere in 
between.  
f) For each channel, you can use the Detector Gain and Offset controls to change 
how things look. You want just a tiny amount of red, and any spots NOT of 
interest should be totally blue. Eliminate as much noise as possible without losing 
areas of interest. 
g) Exit Range Indicator mode and see how your images look. You may want to 
retweak as necessary.  
h) Your calibration should be good for the rest of your wells/gels. 
Taking Pictures 
1) Taking single pictures 
a) Use Fast to assist as you scan for areas of interest. When you find one, click 
Single in the upper left, then save the current image. 
b) Images should be saved in D:\[your name] in .lsm format. 
2) Taking Z stacks 
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a) The Z Stack section is below Channels. Check the box to the right of the title to 
activate it (without it, the Start button in the upper left will be grayed out). 
b) Use Fast to select your bottom image (if imaging whole gel, start with a 
completely black image) and click Set First. 
c) Use Fast to select your top image and click Set Last, then click Stop. 
d) Make sure Keep Interval is selected. This will keep the z slice size constant, even 
if you later decide to change the # of slices or the upper and lower limits in your 
stack. Typically the slice size in our lab is set to 10 µm. 
e) Click Start. A scan will automatically begin. To view the images as they are being 
generated, click Gallery to the left of the image. 
f) Don’t forget to save your Z stack (also in .lsm format). 
Saving Data 
Note: Do not expect your data to be backed up. It usually is, but there’s no guarantee. We 
make it easy for you to save your data to the Temenoff lab drive. 
1) Click Start > Run: \\zoe.bme.gatech.edu\temenoff-lab 
2) When it asks for a username and password, give it your BME credentials. 




a) Shut down the Argon laser (or put it on Standby if you know someone else will 
use it). 
b) Shut down the HeNe laser (or leave it on). 
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2) If you need to shut down the system, give the lasers a few minutes to finish cooling 
(you should hear a noise stop in 2-3 minutes). Shut down the computer first, then flip 
both switches (the ones to the left of the scope) off. 
3) If working with gels, rinse out the cell chamber and throw away the glass cover slip 
in biohazard glass trash. Wash the cell chamber with soap and distilled water and 
leave the individual pieces on the rack in the cell culture room to dry. Do not use 
ethanol; it dries out the rubber O-ring. 
Working with Pictures 
1) The free LSM 510 Image Browser (downloadable from Zeiss) can be used to view 
images. Pretty much the only reason you’d really need to use it, other than viewing 
pictures and exporting them to various formats, is the Projection feature. 
a) Select your Z stack and open it. 
b) Select Projection. Rotate around the Y axis, and choose the most projection 
images (64/panorama) to generate to ensure a smooth 3D projection. 
c) The created projection can be slowed and manipulated, as well as stored along 
with the database. 
d) This can also be exported to a movie file. 
2) You can also use the image browser to create your own databases with custom 
images. Use the Copy and Paste functions in the toolbar. 
3) You can also use the Zeiss ZEN LE software (essentially, ZEN without the 
microscope controls). 




Confocal Microscope Settings 
You can use the FITC/CY3 as an initial setting. 
Below the imaging buttons, check Z-Stack. 
Turn on the Argon and HeNe543 lasers. (Argon must go to standby first, and after a 
while you can set it to On. This is very important - don't forget to turn it off of Standby.) 
Imaging Setup 
Mode Switch track every 
Channel Mode Frame 
 
First channel name: Fluorescein 488-517 (FITC) 
Second channel name: Rhodamine 543-600 
Select the fluorescein channel. 
Light path: To the left of laser, select HFT 488/543. 
Above HFT 488/543, select NFT 545. 
To the right of NFT 545, select BP 505-530, and check Ch2. Select green for Ch2. 
Above NFT 545, select Plate. 
Next on the path, select LP 560. Check Ch1 and select Red. 
 
Select the rhodamine channel and perform the exact same steps. 
 
Acquisition mode: 
Objective Scan mode Frame size Line step Speed Averaging 
10x Frame Click X*Y 
1024 x 1024 






Averaging isn’t important unless you want to fiddle around with how it averages images. 
Useful for poor visibility. 
Channels: Fluorescein 
Laser power Pinhole Gain Digital offset Digital gain 
3.0 1 AU 1100-1200 set; 
700-750 operating 




Channels: Rhodamine  
Laser power Pinhole Gain Digital offset Digital gain 
35.0 1 AU 1100-1200 set; 
800 operating 




Z Stack: Rhodamine  
Interval Keep 
10 microns Interval 
  
Use "Set First" and "Set Last" to specify the beginning and end of a stack. 
Once all of this has been set up, click the Save icon near the Configuration name near the 
upper left corner, and save it under your own custom preferences. 
 
B.15 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
RNA Extraction 
Extract RNA using Qiagen RNeasy Mini Kit  
(Consult the RNeasy kit manual for more specific protocols depending on your 
cell/tissue source) 
Materials 
Molecular BioProducts RNase Away Spray (VWR 17810-491; 475 ml) 
Aerosol Filter Pipette Tips for Rainin LTS, 20 μl (VWR 83009-688; pack of 960) 
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Aerosol Filter Pipette Tips for Rainin LTS, 200 μl (VWR 82003-196; pack of 960) 
Aerosol Filter Pipette Tips for Rainin LTS, 1000 μl (VWR 82003-198; pack of 576) 
QIAshredder (Qiagen 79654 or 79656; 50 or 250 runs) 
RNeasy Mini Kit (Qiagen 74104 or 74106; 50 or 250 runs) 
Optional Alternative: RNeasy Protect Mini Kit (Qiagen 74124 or 74126; 50 or 
250 runs) 
EMD 2-Mercaptoethanol (VWR EM-6010; 100 ml) 
RNAse-free DNase Set (Qiagen 79254; 50 runs) 
Protocol 
For plated cells 
I) Trypsinize cells and centrifuge (10 min, 1000 rpm). 
II) Aspirate supernatant, resuspend pellet in media, and centrifuge (10 min, 1000 
rpm). 
III) Aspirate supernatant, rinse pellet with PBS, and centrifuge again (10 min, 1000 
rpm), aspirate PBS. 
For gels 
I) Soak gels in PBS for ~ 1h to remove media. 
II) Transfer the gel to an RNase free, DNase free microcentrifuge tube. 
III) Break the gel into small pieces using a pellet grinder. 
1) Lyse cell pellet or cells in gel in 350 µl Buffer RLT with β-mercaptoethanol (add 10 
µl BME per 1 ml Buffer RLT). 
2) Put solution in purple QIAshredder column and centrifuge (2 min, 14000 rpm). 
3) Discard filter and add 350 µl 70% ethanol to eluted substance.  
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4) Transfer suspension to pink RNeasy column and centrifuge (15 sec, 14000 rpm). 
5) Discard eluted substance and put filter back on. (Do NOT mix Buffer RLT or RW1 
with bleach when discarding. Contact with acids forms highly reactive guanidine salts 
and liberates very toxic gas) 
6) Add 350 µl Buffer RW1 to column and centrifuge (15 sec, 14000 rpm).  
7) Discard eluted substance and put filter back on. 
8) Add 10 µl DNase I (lyophilized DNase I is resuspended in 550 µl RNase-free water) 
to 70 µl Buffer RDD for each sample. 
9) Add 80 µl of DNase/RDD solution directly onto RNeasy membrane and incubate at 
room temperature for 15 min. 
10) Add 350 µl Buffer RW1 to column and centrifuge (15 sec, 14000 rpm). 
11) Discard eluted substance and put filter back on. 
12) Add 500 µl Buffer RPE (add 44 ml of 96-100% ethanol to starting 11 ml of Buffer 
RPE concentrate before first time use) to column and centrifuge (15 sec, 14000 rpm). 
13) Discard eluted substance and put filter back on. 
14) Add 500 µl Buffer RPE to column and centrifuge (2 min, 14000 rpm). 
15) Discard eluted substance and transfer column to new 2 ml collection tube. 
16) Centrifuge (1 min, 14000 rpm).  
17) Discard 2 ml collection tube, and transfer column to new 1.5 ml collection tube with 
cap. 
18) Add 30 µl RNase-free water and centrifuge (1 min, 14000 rpm). 




Quantify and check purity of RNA 
Materials 
MP Biomedicals RNase, DNase-free water (VWR IC821739; 500 ml) 
Protocol 
1) Take absorbance readings of 2 μl of undiluted RNA at 260 nm and 280 nm light in 
NanoDrop. 
2) Quantity of RNA can be calculated using the following equations: 
 Corrected A260 = average sample A260 – average blank A260 
 Concentation in µg/ml = (corrected A260) * (44 µg/ml) * (dilution factor) 
(using above protocol, dilution factor = 50) 
 Total mass in µg = (µg/ml concentration value) * (µl volume) / 1000 
(volume of RNA extraction sample; using above extraction protocol, volume = 
30-50 µl) 
 Volume in µl needed for 1 µg RNA = (1 µg RNA) * 1000 / (µg/ml concentration 
value) 
(1 ng to 5 µg RNA can be used for Reverse Transcription) 
 Volume of water in µl needed = 10 µl total volume – RNA volume determined 
above 
3) Purity of RNA can be calculated using the following equation: 
 Purity = A260 / A280 







Reverse Transcription with SuperScript III Reverse Transcriptase 
Materials 
Oligo(dT)15 Primer (Promega C1101; 20 µg) 
PCR Nucleotide Mix, 10 mM (Promega C1141; 200 µl) 
SuperScript III Reverse Transcriptase (Invitrogen 18080-093 or 18080-044; 2000 or 
10000 units) 
Invitrogen RNaseOUT RNase Inhibitor, 40 units/ml (Invitrogen 10777-019; 5000 
units) 
Protocol 
1) Add the following components to a nuclease-free PCR tube: 
 1 ng to 5 µg total RNA: 10 µl 
 Oligo(dT)15 (500 µg/ml): 1 µl 
 dNTP Mix (10 mM each): 1 µl 
 RNase, DNase-free water: to 12 µl final volume 
2) Heat mixture to 65˚C for 5 min and chill on ice for at least 1 min. Collect the contents 
of the tube by brief centrifugation and add: 
 5X First-Strand Buffer (250 mM Tris-HCl, 375 mM KCl, 15 mM MgCl2): 4 
µl 
 0.1 M DTT: 1 µl 
 RNaseOUT (40 units/µl): 1 µl 
3) Mix contents of the tube gently. Incubate at 42˚C for 2 min.  
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4) Add 1 µl (200 units) of SuperScript III RT and mix by pipetting gently up and 
down.  
5) Incubate at 50˚C for 30-60 min. 
6) Inactivate the reaction by heating at 70˚C for 15 min. 
7) Store cDNA at -20˚C. 
8) Amplification of PCR targets (>1 kb) may require the removal of RNA 
complementary to the cDNA. To remove RNA complementary to the cDNA, add 1 µl 
(2 units) of E. coli RNase H and incubate at 37˚C for 20 min. 
Primer Preparation 
Reconstitute primers (100 μM) 
Materials 
Custom Primers/Oligonucleotides, desalted (Invitrogen; 25 nmol) 
Protocol 
1) Find the total nmoles from the information sheet that came with the primer. 
2) The volume of DNase-free water needed to create a 100 μM stock can be calculated 
using the following equation:  
 Volume of DNase-free water in μl = (nmoles of primer) *1000 / (100 μM) 
Make 10 μM aliquots 
Protocol 
1) Briefly spin the primers and add the needed amount of water for a 10-fold dilution. 






Polymerase Chain Reaction 
Run PCR 
Materials 
SYBR Green Master Mix (Applied Biosystems 4309155; 5 ml) 
Applied Biosystems StepOnePlus Real-Time PCR System and Materials 
 MicroAmp Fast 96-Well Reaction Plates, 0.1 ml (Applied Biosystems 4346906; 
20 plates) 
 MicroAmp Optical Adhesive Films (Applied Biosystems 4360954; 25 films) 
OR  
 MicroAmp Fast 8-Tube Strips, 0.1 ml (Applied Biosystems 4358293; 125 strips) 
 MicroAmp Optical 8-Cap Strips (Applied Biosystems 4323032; 300 strips) 
 MicroAmp 96-Well Trays for Veriflex Blocks (Applied Biosystems 4379983; 10 
trays) 
Protocol 
1) Thaw the following components on ice: 
 SYBR Green mix 
 10 µM forward primer of interest 
 10 µM reverse primer of interest 
 Sample cDNA 
2) To make Master Mix, count the number of wells needed for each primer, add 2, and 




 12.5 µl SYBR Green mix 
 10.5 µl DNase-free water 
 0.5 µl 10 µM forward primer 
 0.5 µl 10 µM reverse primer 
3) Load PCR wells: 
 Load 24 µl of Master Mix into each well for that primer (target sequence of 
interest). 
 Add 1 µl of sample cDNA into the well with Master Mix and mix by pipetting up 
and down (change pipette tips between each well). 
4) After all wells are loaded, cover with optical tape or caps, and put entire plate on ice 
until ready to run PCR.  
5) Load plate into StepOnePlus system: 
 Load plate into machine (A1 in upper-left, H12 in lower-right). 
 Open “StepOne Software v2.0” program.  
 Click “Advanced Setup” button.  
 Under “Experiment Properties,” enter an Experiment Name, select “StepOnePlus 
Instrument (96 Wells)” for the instrument, select “Quantitation – Comparative CT 
(ΔΔCT)” for the experiment, select “SYBR Green Reagents” for the reagent (melt 
curve is optional), and select “Standard” for the ramp speed.  
 Under “Plate Setup,” add your targets and samples under “Define Targets and 
Samples,” changing the Reporter to “SYBR” and the Quencher to “None.” Under 
“Assign Targets and Samples,” assign the appropriate targets and samples to each 
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well, selecting your control sample as the reference sample, GAPDH as the 
endogenous control, and “ROX” as the “dye to use as a passive reference.”  
 Under “Run Method,” change the reaction volume to 25 μl and set the method to 
the following: 
- Hold at 95˚C for 10 min (100% ramp). 
- Cycle 40 times at 95˚C for 15 sec and 60˚C for 1 min, collecting data at 60˚C.  
- Optional melt curve: 95˚C for 15 sec, 60˚C for 1 min, and +0.3˚C ramp, 
ending at 95˚C for 15 sec and collecting data during the +0.3˚C ramp.  
 Save the file.  
(Templates can be saved to reduce setup time.) 
 Select “Start Run.”  
 After the run, click “Analyze” (settings can be modified under “Analysis 
Settings”) and resave the file.  
 Export results to Excel by clicking “Export…” and export “Results” as “One File” 
with “.xls” file type.  
 
B.16 Quantitative PCR Analysis 
Adapted from: 
Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den Hoff MJB, and 
Moorman AFM. Amplification efficiency: linking baseline and bias in the analysis of 






Let’s review the basics of PCR amplification and detection. We start with a few basic 
equations: 
      
      
    
  
      
  
   
 
where N = concentration of amplicon, E is the efficiency of the PCR reaction (where 1 
means no amplification, and 2 is 100% amplification), and C is a cycle threshold of 
interest. If you want to compare a gene’s amplification to its target gene,  
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assuming the concentrations of the two genes are the same (given, say, a fluorescence 
threshold). If you then make the next assumption that the efficiencies are the same (say, 
100%), then 
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These calculations are contingent on a few assumptions: 
 Baseline fluorescence is something that can be eliminated. 




 Cycle to cycle efficiency does not vary throughout amplification. 
Typical PCR analysis errors 
If there is baseline fluorescence in your sample, you will introduce error into your 
estimation of efficiency: 
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which for even a 5% difference in efficiency can be                       times 
different. 
What LinRegPCR does 
 Estimates individual well baseline by reconstructing the log-linear portion of the 
amplification curve: 
 Discards any samples where low amplification is detected. 
 Calculates the second derivative maximum (SDM) to find the plateau. 
 Subtracts baseline, then fits both the upper and bottom portions of log-linear region. 
 When the lower and upper sections’ slopes match, the baseline has been found. 
 Calculates individual PCR efficiencies for every well 
 Calculates mean efficiency and starting amount (N0) for a given amplicon. 
 Mean efficiencies are adequate for calculating fold regulation values 
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 Differences are more a result of statistical error than true differences in efficiency. 
 What about running multiple plates for the same gene? 
 Individual efficiencies can vary significantly 
How to use LinRegPCR 
1) Process your data in StepOne first. 
a) Do a quick quality control check on your samples and remove samples that didn’t 
amplify well, that have a high standard deviation, etc. 
b) Disable the auto baseline feature in StepOne for each target. 
c) Export the data to Excel – check Sample Setup and Amplification Data. 
2) Open the spreadsheet and then open LinRegPCR. 
Note: LinRegPCR will not work correctly unless Excel is opened beforehand. 
3) In LinRegPCR: 
a) Read in your data. 
i) Check the drop-down boxes to make sure Amplification Data is selected. 
ii) Select Step-One Plus (ABI) and DNA binding dye (SYBR Green). 
iii) Select columns A through D, rows 8 through 3848 (that is, a 40-cycle run. A 50-cycle 
run would go to row 4808.) 
iv) Make sure ss cDNA is checked, and select No for “Data are baseline-corrected.” 
b) Click the red button labeled determine baselines. 
c) Check each sample to examine efficiencies and tweak if necessary. 
d) If necessary, use the Amplicon Groups tab to set amplicon groups. The boxes there can 
help you auto-select amplicon groups quickly for each gene. 
e) Set the log(fluorescence) value on the left. 
i) Note: Make sure to keep this consistent between all plates with the same gene. 
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ii) Note: In StepOne, the threshold fluorescence is usually less than 1, which is why the 
log(fluorescence) value in LinRegPCR is negative. 
f) Save this data to Excel. 
4) Back in Excel: 
a) Use the sample setup tab to help re-label your samples and rearrange your data to your 
liking. You may want to pick up some Excel-fu to summarize and put all of your wells 
together, do any extra quality control, etc. 
i) Note: Remember to use geometric means when averaging data. (Taking the 
geometric mean is the same as taking the arithmetic mean of the cycle thresholds.) 
b) To calculate fold regulation, use the starting concentration of your gene, or N0. The value 
of N0 has already been calculated by LinRegPCR using the mean efficiency for the 
amplicon group. 
i) If many of your wells did not use the mean efficiency to be calculated, it may be a 
good idea to calculate a new N0 based on each individual well’s PCR efficiency. 






c) Calculate a manual ∆∆ method; that is, divide a sample’s gene’s N0 by the sample’s 
GAPDH N0 value, then divide by the geometric mean of your day 1 sample. 
d) Perform statistical analysis on the divided-by-GAPDH values. 
 
B.17 Immunostaining 
Rules to remember: 
 Do not let your sample dry out. This will encourage non-specific binding (and 
staining) from anything floating around in the air, etc. If you need to stop, make sure 
samples are wet or otherwise sitting in PBS. 
 Store samples at -80°C prior to staining to maintain maximum antigenicity. 
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 Rinsing with PBS can be done using a slide rack. Place slides into the stain rack, then 
gently lower into the stain holder with PBS. After two minutes, raise and lower the 
rack gently, then remove the rack completely. Do this twice, discarding PBS between 
washes. You’ll need ~1000-1200 mL PBS for 12 slides. 
Day 1 
For Fixed Paraffin Sections 
1) Deparaffinize 
a) Deparaffinize slides in xylene and alcohol (Program 4 in autostainer). 
2) Antigen retrieval 
For heat-induced: 
a) Citrate Buffer (10 mM, pH 6.0) 
i) Citric acid (anhydrous) – 1.92 g 
ii) Distilled water – 1000 ml 
iii) Mix to dissolve. Adjust pH to 6.0 with 1 N NaOH, and then add 0.5 ml Tween 
20 and mix well. 
iv) Store this solution at room temperature for 3 months or at 4°C for longer 
storage. 
b) Place slides in 10 mM citrate buffer.  
c) Perform heat-induced antigen retrieval in pressure cooker (high setting) in citrate 
buffer for 15 min. 
d) Allow slides to cool to room temperature before rinsing.  





a) TE-CaCl2 Buffer (50 mM Tris Base, 1 mM EDTA, 5 mM CaCl2, 0.5% Triton X-
100, pH 8.0) 
i) Tris Base – 6.10 g  
ii) EDTA – 0.37 g 
iii) CaCl2 – 0.56 g 
iv) Triton X-100 – 5 ml 
v) Distilled Water – 1000 ml 
vi) Mix to dissolve. Adjust to pH 8.0 using concentrated HCl (10 N).  
vii) Store this buffer at room temperature. 
b) Proteinase K Stock Solution (20X, 400 μg/ml)  
i) Proteinase K (30 units/mg) – 8 mg 
ii) TE/CaCl2 Buffer – 10 ml 
iii) Glycerol – 10 ml 
iv) Add proteinase K to TE-CaCl2 buffer until dissolved. Then add glycerol and 
mix well.  
v) Aliquot and store at -20°C for 2-3 years. 
c) Proteinase K Working Solution (1X, 20 μg/ml) 
i) Proteinase K Stock Solution – 1 ml 
ii) TE-CaCl2 Buffer – 19 ml 
iii) Mix well.  
iv) This solution is stable for 6 months at 4°C. 
d) Circle samples with PAP pen to create hydrophobic barrier around your samples. 
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e) Cover sections with Proteinase K working solution, and incubate for 10-20 min at 
37°C in humidified chamber. 
f) Allow sections to cool at room temperature for 10 min. 
g) Rinse twice in PBS. 
For Unfixed Frozen Sections 
1) Fixation 
a) Warm up slides at room temperature for 30-60 minutes. 
b) Lightly fix in ice cold acetone for 10 minutes. Place a stain holder containing 
acetone into an ice bucket, then lower the slide rack inside. Change acetone 
between slide racks if you’re doing more than 12 slides at a time. 
c) Let slides air dry for 30 minutes.  
2) Wash off OCT 
a) Rinse twice in PBS.  
b) At this point, samples should be completely free of OCT and other trash. Circle 
each sample with a PAP pen to isolate future liquids to the sample. 
Deglycosylation with Chondroitinase Digestion for Aggrecan Staining 
1) Chondroitinase Digestion 
a) Activate chondroitinase ABC in buffer of 50mM Tris, 60 mM sodium acetate, 
0.02% BSA, pH 8.0. Dilute 1 U/ml chondroitinase 3:4 with 4X activating buffer 
(eg. 0.75 ml chondroitinase, plus 0.25 ml buffer).  
b) Apply 30 µl of 0.75 U/ml of chondroitinase ABC to each sample, and incubate in 




Staining for Immunohistochemistry 
1) Preparation (while slides dry) 
a) 1% BSA solution (make 1 g BSA / 100 mL PBS; store at 4°C) 
b) Serum from species of secondary Ab (goat, horse, or rabbit) 
c) Make a humidified chamber using a 150 mm petri dish with a wet paper towel in 
the bottom, plus 4-5 small petri dishes with water inside. Each chamber can hold 
4 or 5 slides. 
2) Peroxidase Blocking (For frozen sections only) 
a) Use a slide rack/stain holder to immerse slides in 0.3% peroxide/methanol 
solution (1 mL 30% H2O2 in 100 mL methanol; store in foil < 1 week at 4°C) for 
10 minutes at room temperature. You can reuse the peroxide/methanol solution 
between racks. 
3) Serum Blocking 
a) Normal Serum Block Solution (60 µL/sample, mix in 10 mL and store at 4°C):  
i) 1% BSA solution in PBS (stabilizer) – 9.7 mL 
ii) 2% serum (blocking) – 200 µL 
iii) 0.1% Triton X-100 (penetration enhancer) – 100 µL 
b) Incubate sections for 20 min in blocking solution – serum should be same species 
as secondary antibody. Tap the slide on a kimwipe to remove the solution. Don’t 
do a PBS wash afterwards. 




a) Make a humidified chamber using a 150 mm petri dish with a wet paper towel in 
the bottom, plus 4-5 small petri dishes with water inside. Each chamber can hold 
4 or 5 slides. 
2) Image-iT Signal Enhancer Blocking 
a) Cover section in Image-iT Signal Enhancer (for AlexaFluor488-conjugated IgG) 
b) Incubate sections for 30 min in blocking solution, then PBS wash. 
Primary Antibody 
1) Primary Antibody 
a) Prepare the working dilution of the primary antibody in 1% BSA. If using an 
antibody for the first time, you’ll need to run a series of dilutions to determine the 
optimal working concentration). With our antibodies, 1:10, 1:100, 1:500, 1:1000 
is a good start. 
b) Use a 10 µL pipette to carefully apply 8 µL primary antibody to each sample. 




1) Peroxidase Blocking (For paraffin sections only) 
a) Use a slide rack/stain holder to immerse slides in 0.3% peroxide/methanol 
solution (1 mL 30% H2O2 in 100 mL methanol; store in foil < 1 week at 4°C) for 
10 minutes at room temperature. You can reuse the peroxide/methanol solution 
between racks. 
2) Secondary Antibody 
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a) Remove slides from the humidified chamber and PBS wash. 
b) Incubate sections in 1:200 goat biotin conjugated secondary antibody in PBS for 
30 minutes at room temperature, then PBS wash. 
3) Signal Amplification 
a) Solution: Vectastain ABC Elite Standard kit 
i) 5 mL PBS + 2 drops of solution A + 2 drops of solution B, added into the 
provided bottle.  
ii) Allow solution to sit for 30 min before use. 
b) Drop solution onto slides. Incubate for 30 min, then PBS wash. 
4) Chromagen/Substrate Stain 
a) Immediately after rinsing, make the peroxidase substrate solution using 1 mL 
substrate buffer and 20 µL chromogen. There should be no delay between making 
the solution and adding it to your slides. 
b) Allow color to develop for 5-10 minutes (you will need to experiment with this 
time).  
c) Immediately rinse with PBS twice. All DAB waste should be added into a 
separate waste container and brought to the histology room for disposal. 
For Immunofluorescence 
1) Secondary Antibody 
a) Remove slides from the humidified chamber and PBS wash. 
b) Incubate sections in 1:200 goat anti-mouse Alexa Fluor 488-conjugated secondary 
antibody in PBS for 30 minutes at room temperature, then PBS wash. 
2) Nuclear counterstain 
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a) Incubate sections in 0.1 μg/ml DAPI working solution for 5 min at room 
temperature, then PBS wash.  
Coverslip 
1) Cover slip 
a) The slide should be wet from the PBS wash you just did. Place a drop of 
FluoroGel with Tris buffer on each of your samples within a PAP pen circle. 
FluoroGel should mix with the water already on the slide. 
b) Place additional FluoroGel (can use two drops; may use more if desired) outside 
of the PAP pen circles. 
c) Tilt the bottom edge of the cover slip against the bottom edge of the slide. Tilt the 
slide as necessary so the cover slip catches a consistent edge of liquid along the 
bottom, then gently lower the top edge so the liquid rides over the PAP pen circles 
and catches the entire surface of the slide. 
d) Allow slides to dry overnight. You can view them on a microscope sooner than 
that (a few hours after coverslipping), but sometimes liquid will leak from a slide 
as it dries. Clean liquid that has leaked onto the outside with wet kimwipes. 
e) Seal the edges of the slides with clear nail polish to prevent bubbles from forming 
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